---
document_datetime: 2023-09-21 20:46:40
document_pages: 116
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/equidacent-epar-public-assessment-report_en.pdf
document_name: equidacent-epar-public-assessment-report_en.pdf
version: success
processing_time: 121.4532089
conversion_datetime: 2025-12-20 07:41:22.647845
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

23 July 2020 EMA/427966/2020 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Equidacent International non-proprietary name: bevacizumab Procedure No. EMEA/H/C/005181/0000 Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Administrative information

<!-- image -->

| Name of the medicinal product:                  | Equidacent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant:                                      | Centus Biotherapeutics Europe Limited 6th Floor South Bank House Barrow Street Dublin 4 IRELAND authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Active substance:                               | BEVACIZUMAB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| International Non-proprietary Name/Common Name: | bevacizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Pharmaco-therapeutic group (ATC Code):          | other antineoplastic agents, monoclonal antibodies longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Therapeutic indication(s): Medicinal            | (L01XC07) Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Equidacent in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line product no |

<div style=\"page-break-after: always\"></div>

| Medicinal product           | treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1). Bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). Bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1). no longer authorised   |
|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pharmaceutical form(s):     | Concentrate for solution for infusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Strength(s):                | 25 mg/mL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Route(s) of administration: | Intravenous use                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Packaging:                  | vial (glass)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Package size(s):   | 4 mL solution in a vial, pack of 1 vial 16 mL solution in a vial, pack of 1 vial   |
|--------------------|------------------------------------------------------------------------------------|

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ............................................10                                                               |                                                                                                          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................10                                    |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.......................................................12                                             |                                                                                                          |
| 2. Scientific discussion                                                                                                                                | ..............................................................................14                         |
| 2.1. Problem statement                                                                                                                                  | .............................................................................................14          |
| 2.2. Quality aspects                                                                                                                                    | ..................................................................................................14     |
| 2.2.1. Introduction....................................................................................................14                               |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................14                                  |                                                                                                          |
| 2.2.3. Finished Medicinal Product                                                                                                                       | ................................................................................19                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................26                                                    |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects authorised                                                                    | ......................26                                                                                 |
| 2.2.6. Recommendation(s) for future quality development.............................................26                                                  |                                                                                                          |
| 2.3. Non-clinical aspects                                                                                                                               | ............................................................................................27           |
| 2.3.1. Introduction....................................................................................................27                               |                                                                                                          |
| 2.3.2. Pharmacology                                                                                                                                     | .................................................................................................27      |
| 2.3.3. Pharmacokinetics.............................................................................................29                                  |                                                                                                          |
| 2.3.4. Toxicology                                                                                                                                       | ......................................................................................................31 |
| 2.3.5. Ecotoxicity/environmental risk assessment                                                                                                        | .........................................................32                                              |
| 2.3.6. Discussion on non-clinical aspects......................................................................33                                       |                                                                                                          |
| 2.3.7. Conclusion on the non-clinical aspects................................................................34 no longer                               |                                                                                                          |
| 2.4. Clinical aspects                                                                                                                                   | ..................................................................................................34     |
| 2.4.1. Introduction....................................................................................................34                               |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................34                                  |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................42                                     |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................42                                         |                                                                                                          |
| 2.4.5. Conclusions on clinical pharmacology.................................................................43 product                                  |                                                                                                          |
| 2.5. Clinical efficacy ..................................................................................................43                             |                                                                                                          |
| 2.5.1. Dose response study........................................................................................44                                    |                                                                                                          |
| 2.5.2. Main study......................................................................................................44                               |                                                                                                          |
| 2.5.3. Discussion on clinical efficacy............................................................................69                                    |                                                                                                          |
| 2.5.4. Conclusions on the clinical efficacy.....................................................................72 Medicinal                            |                                                                                                          |
| 2.6. Clinical safety                                                                                                                                    | ....................................................................................................72   |
| 2.6.1. Discussion on clinical safety ............................................................................                                       | 105                                                                                                      |
| 2.6.2. Conclusions on the clinical safety.....................................................................                                          | 108                                                                                                      |
| 2.7. Risk Management Plan......................................................................................                                         | 108                                                                                                      |
| 2.8. Pharmacovigilance............................................................................................                                      | 108                                                                                                      |
| 2.9. Product information ..........................................................................................                                     | 109                                                                                                      |
| 2.9.1. User consultation...........................................................................................                                     | 109                                                                                                      |
| 2.9.2. Additional monitoring.....................................................................................                                       | 109                                                                                                      |
| 3. Biosimilarity assessment.....................................................................109 3.1. Comparability exercise and indications claimed | .................................................... 109                                                 |
| 3.2. Results supporting biosimilarity..........................................................................                                         | 111                                                                                                      |
| 3.3. Uncertainties and limitations about biosimilarity...................................................                                               | 112                                                                                                      |

<div style=\"page-break-after: always\"></div>

| 3.4. Discussion on biosimilarity................................................................................. 112   |
|-------------------------------------------------------------------------------------------------------------------------|
| 3.5. Extrapolation of safety and efficacy .................................................................... 113      |
| 3.6. Additional considerations................................................................................... 113   |
| 3.7. Conclusions on biosimilarity and benefit risk balance ............................................ 113             |

4. Recommendations ...............................................................................  114

<!-- image -->

<div style=\"page-break-after: always\"></div>

## List of abbreviations

%AUCext

The percentage of AUC0- ∞ that is due to extrapolation from Ct to infinity

ADA

Anti-drug antibody

ADCC

Antibody-dependent cell cytotoxicity

ALK

Anaplastic lymphoma kinase

AUC

Area under the concentration-time curve

AUC0- ∞

Area under the concentration-time curve extrapolated to infinity

AUC0-T

Area under the concentration-time curve to last quantifiable sampling time Blinded independent central review Best overall response Circular dichroism Complement dependent cytotoxicity Cation Exchange High Performance Liquid Chromatography Chinese Hamster Ovary Confidence interval Capillary isoelectric focusing Clearance Maximum concentration Critical quality attribute Complete response Clinical study report Last quantifiable sampling time Common Terminology Criteria for Adverse Events Trough concentration Data cut-off Deoxyribonucleic Acid Drug product Drug Substance Differential scanning calorimetry Electrocardiogram Eastern Cooperative Oncology Group Epidermal growth factor receptor Enzyme-linked immunosorbent assay European Medicines Agency European Union European Union-approved Avastin Forced degradation studies Good Clinical Practice Host Cell Protein Medicinal product no longer authorised

BICR

BOR

CD

CDC

CEX-HPLC

CHO

CI

cIEF

CL

Cmax

CQA

CR

CSR

Ct

CTCAE

Ctrough

DCO

DNA

DP

DS

DSC

ECG

ECOG

EGFR

ELISA

EMA

EU

EU-Avastin

FDS

GCP

HCP

HER2

Human Epidermal Growth Factor Receptor 2

HMWS

High molecular weight species detection

HPLC

High Performance Liquid Chromatography

ICH

International Council for Harmonisation

IgG1

Immunoglobulin G1

IP

Investigational product

IPC

In-process Controls

IRR

Infusion-related reactions

ITT

Intent-to-treat

iv

Intravenous

LC

Liquid Chromatography

LC-MS

Liquid chromatography mass spectrometry

LMWS

Low molecular weight species

LS

Least squares

LVEF

Left ventricular ejection fraction

MAA

Marketing Authorisation Application

MCB

Master Cell Bank

MedDRA

Medical Dictionary for Regulatory Activities

MoA

Mechanism of action Mass Spectroscopy Meso Scale Discovery Neutralising antibody Non-squamous, non-small cell lung cancer Optimal density Overall response rate Overall survival Process attributes Progressive disease Progression-free survival Isoelectric point process parameter Per Protocol Set Partial response Preferred term Polyvinylidene difluoride Quality assurance Reference medicinal product Retention time Serious adverse event Standard deviation Size Exclusion Size exclusion high precision liquid chromatography System organ class Surface plasma resonance Single use bioreactor Treatment-emergent adverse drug reaction Treatment-emergent adverse event Treatment-emergent serious adverse event Total ion chromatogram Medicinal product no longer authorised

MS

MSD

NAb

NS-NSCLC

OD

ORR

OS

PA

PD

PFS

PI

PP

PPS

PR

PT

PVDF

QA

RMP

RT

SAE

SD

SE

SE-HPLC

SOC

SPR

SUB

t1/2

Half-life

TEADR

TEAE

TESAE

TIC

tmax

Time to maximum concentration

TSE

Transmitting Animal Spongiform Encephalopathy

US

United States

US-Avastin

United States-licensed Avastin

USP

United States pharmacopeia

VEGF

Vascular endothelial growth factor

VEGFR

Vascular endothelial growth factor receptor

WCB

Working Cell Bank

WoC

Withdrawal of consent

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

λ z Elimination rate constant

<!-- image -->

CHMP assessment report

EMA/427966/2020

Page 9/116

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Centus Biotherapeutics Europe Limited submitted on 13 September 2019 an application for marketing authorisation to the European Medicines Agency (EMA) for Equidacent, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004.

The applicant applied for the following indications:

Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with bevacizumab in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1). Bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). Bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. Medicinal product no longer authorised

Bevacizumab,  in  combination  with  paclitaxel  and  cisplatin  or,  alternatively,  paclitaxel  and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

## The legal basis for this application refers to:

Article 10(4) of Directive 2001/83/EC - relating to applications for a biosimilar medicinal products

The application submitted is composed of administrative information, complete quality data, appropriate non-clinical and clinical data for a similar biological medicinal product.

<div style=\"page-break-after: always\"></div>

The chosen reference product is:

Medicinal product which is or has been authorised in accordance with Union provisions in force for not less than 10 years in the EEA:

- Product name, strength, pharmaceutical form: Avastin 25 mg/ml concentrate for solution for infusion
- Marketing authorisation holder: Roche Registration GmbH
- Date of authorisation: 01/12/2005
- Marketing authorisation granted by:

-Union · Marketing authorisation number: EU/1/04/300/001-002 Medicinal product authorised in the Union/Members State where the application is made or European reference medicinal product: · Product name, strength, pharmaceutical form:  Avastin 25 mg/ml concentrate for solution for infusion · Marketing authorisation holder: Roche Registration GmbH · Date of authorisation: 01/12/2005 · Marketing authorisation granted by: -Union · Marketing authorisation number: EU/1/04/300/001-002 Medicinal product which is or has been authorised in accordance with Union provisions in force and to which bioequivalence has been demonstrated by appropriate bioavailability studies: · Product name, strength, pharmaceutical form: Avastin 25 mg/ml concentrate for solution for infusion · Marketing authorisation holder: Roche Registration GmbH · Date of authorisation: 01/12/2005 · Marketing authorisation granted by: -Union · Union Marketing authorisation numbers: EU/1/04/300/001-002 Information on Paediatric requirements Not applicable Information relating to orphan market exclusivity Medicinal product no longer authorised

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan medicinal products.

## Scientific advice

The applicant received Scientific Advice on 26 March 2015 (EMEA/H/SA/3041/1/2015/III) and 17 December 2015 (EMEA/H/SA/3041/1/FU/1/2015/III) for the development programme supporting the

<div style=\"page-break-after: always\"></div>

indication granted by CHMP.

The Scientific Advice pertained to the following quality, preclinical and clinical aspects of the dossier:

## Quality :

- The strategy to support a demonstration of biosimilarity in terms of physicochemical and biological analyses.
- The strategy to demonstrate the suitability of the biosimilar candidate formulation.
- The comparability exercise to support the DP manufacturing facility change.
- The suitability of HUVEC potency assay versus a cell-based reporter gene bioassay.

| Date       | Reference                      | SAWP Co-ordinators                           |
|------------|--------------------------------|----------------------------------------------|
| 26/03/2015 | EMEA/H/SA/3041/1/2015/III      | Dr Juha Kolehmainen, Mr Christian Gartner no |
| 17/12/2015 | EMEA/H/SA/3041/1/FU/1/2015/III | Dr Walter Janssens, Dr Ira Palminger Hallen  |

| The application was received by the EMA on                                                              | 13 September 2019   |
|---------------------------------------------------------------------------------------------------------|---------------------|
| The procedure started on                                                                                | 3 October 2019      |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on Medicinal                | 19 December 2019    |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on                       | 19 December 2019    |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                     | 20 December 2019    |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on | 30 January 2020     |
| The applicant submitted the responses to the CHMP consolidated List of                                  | 27 March 2020       |

Preclinica l: · The appropriateness and adequacy of the non-clinical comparability studies to demonstrate similarity to the reference medicinal product. The main clinical aspects under consideration were: · The design of the PK study in healthy volunteer to demonstrate similarity in PK profiles of the biosimilar candidate, EU Avastin, and US Avastin. · The design of the efficacy/safety trial in patients with advanced/recurrent non-squamous non-small cell lung cancer and supportive PK assessment to demonstrate biosimilarity of the biosimilar candidate to the reference medicinal product. Aspects pertained the population selected, the primary endpoint, the selected dose/regime of the study drugs and the combination chemotherapy, the proposed equivalence margin, the statistical assumptions, the duration of the trial and the safety and immunogenicity evaluation. · Extrapolation of the clinical results in non-small cell lung cancer to support registration in the other indications approved for the reference medicinal product. SAWP Co-ordinators Dr Walter Janssens, Dr Ira Palminger Hallen 1.2. Steps taken for the assessment of the product The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Ingrid Wang Co-Rapporteur:  Outi Mäki-Ikola Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| Questions on                                                                                                                                                                                                                                  |                       |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| The following GCP inspection(s) were requested by the CHMP and their outcome taken into consideration as part of the Quality/Safety/Efficacy assessment of the product:                                                                       |                       |
| - A GCP inspection at an investigator site in Russia, at an investigator site in Bosnia and Herzegovina and at the sponsor site between 13 January and 14 February 2020. The outcome of the inspection carried out was issued on 1 April 2020 | 14 April 2020         |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                                                                       | 4 May 2020 authorised |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                                                                      | 14 May 2020           |
| The CHMP agreed on a list of outstanding issues in writing and to be sent to the applicant on                                                                                                                                                 | 28 May 2020           |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on longer                                                                                                                                                        | 22 June 2020          |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                                                                              | 08 July 2020          |
| The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on no                                                                                                                    | n/a                   |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Equidacent on product                                            | 23 July 2020          |
| The CHMP adopted a report on similarity of Equidacent with Zejula on (Appendix 1)                                                                                                                                                             | 23 July 2020          |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## About the product

Equidacent (FKB238) has been developed as a biosimilar to the reference product Avastin (bevacizumab).

Equidacent belongs to the pharmacotherapeutic group 'monoclonal antibodies' (ATC code: L01XC07). Bevacizumab selectively binds to human VEGF and inhibits the binding of VEGF to its receptors, Flt-1 and KDR, on the surface of endothelial cells. Neutralizing the biologic activity of VEGF reduces the vascularization of tumours, thereby inhibiting tumour growth. Administration of bevacizumab or its parental murine antibody to xenotransplant models of cancer in nude mice resulted in extensive anti-tumour activity in human cancers, including colon, breast, pancreas and prostate. Metastatic disease progression was also inhibited, and microvascular permeability was reduced. The applicant is seeking all the indications for which Avastin is licensed in the EU, except for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The recommended posology and method of administration correspond to those of Avastin. Equidacent must be administered under the supervision of a physician experienced in the use of antineoplastic medicinal products. 2.2. Quality aspects 2.2.1. Introduction Equidacent is a biosimilar medicinal product (reference product Avastin). It is presented as a sterile concentrate for solution for infusion containing 100 mg of bevacizumab in a 4 mL vial or 400 mg bevacizumab in a 16 mL vial. Each mL of concentrate contains 25 mg of bevacizumab (25 mg/mL). The active substance bevacizumab (also referred to as FKB238) is formulated with commonly used excipients: sodium L-glutamate, sorbitol (E420), polysorbate 80, hydrochloric acid (for pH-adjustment) and water for injections (WFI). Equidacent is provided in a single use Type I glass vial with a butyl rubber stopper and an aluminium sealing cap. Equidacent is supplied in packs of 1 vial of 4 mL or 16 mL. 2.2.2. Active Substance Medicinal product no longer authorised

## General information

Bevacizumab (also referred to as FKB238) is a recombinant humanised IgG1 monoclonal antibody produced by DNA technology in Chinese Hamster Ovary (CHO) cells. It selectively binds to human vascular endothelial growth factor (VEGF).

Bevacizumab is composed of two heavy chains (HC) (453 amino acid residues) and two light chains (LC) (214 amino acid residues) with a total molecular weight of 149 kDa. One N-linked glycosylation site is located at Asn303.

<div style=\"page-break-after: always\"></div>

Figure 1 Primary structure of bevacizumab

<!-- image -->

Manufacture, process controls and characterisation Manufacture The active substance is manufactured at Kyowa Kirin Co., Ltd., Takasaki Plant, 100-1 Hagiwara-machi, Takasaki, Gunma, 370-0013, Japan. The site is EU GMP compliant. The manufacturing process follows a standard monoclonal antibody platform technology. The FKB238 active substance (AS) commercial manufacturing process starts from the Working Cell Bank (WCB) (derived from a CHO cell line) and is performed in two key stages: 1) Upstream cell culture process and 2) Downstream purification process. FKB238 is produced in a CHO cell line by expansion in shake flasks and rocker bags, seed culture expansion in seed bioreactors, before fed-batch production and supernatant harvest. The subsequent downstream purification process consists of Protein A affinity chromatography, low-pH virus inactivation, cation exchange chromatography, multimodal chromatography, virus filtration ultrafiltration/diafiltration (UF/DF), formulation, filtration, bulk filling, and storage. The upstream and downstream processes have been adequately described. Control of materials Raw materials Raw materials used in the active substance manufacturing process are controlled to ensure the quality and safety of the active substance and to maintain the consistency of the manufacturing process. Medicinal product no longer authorised

<!-- image -->

All manufacturing raw materials are accepted for use based on in-house testing to pre-determined specifications and/or the vendor Certificate of Analysis (CoA), according to written procedures, as required by current Good Manufacturing Practices (cGMP). Alternative suppliers or raw materials of the same quality grade may be used following a change control procedure upon completion of vendor qualification.

No raw materials of animal origin are used in the active substance manufacturing process or in the establishment of the master cell bank (MCB) and working cell bank (WCB).

<div style=\"page-break-after: always\"></div>

## Source, history and generation of the cell substrate

The source, the method of construction, and the structure of all expression vectors is included in the dossier, as well as the cDNA sequence and deduced amino acid sequence of heavy chain and light chain. The method of construction of the expression plasmid is adequately described.

A two-tiered cell banking system consisting of an MCB and WCB was utilised. The end-of-production cells (EOP) were collected from the end of fed-batch production culture of an active substance lot and were used to establish the cells at the limit of in vitro cell age used for production (LIVCA). Release tests, including safety and characterisation of the MCB and WCB and qualification of the LIVCA cells, were performed in accordance with the ICH guidelines Q5A, Q5B, and Q5D and are sufficiently described.

The CQAs for the active substance were identified based on the assessment of CQAs for the final finished product to meet the quality target product profile (QTPP). The CQAs are presented, along with a summary of the control strategies for the different categorised CQAs. Each CQA is controlled by critical and key process parameters and material attributes, in addition to the testing plans during the FKB238 active substance manufacturing process. The rationale to set in-process and/or release testing for each CQA is also presented. Manufacturing data from clinical and commercial scale lots was evaluated in order to classify the criticality of the in-process quality attributes (IPQAs), based on the attribute's potential to impact the quality of the active substance.

Control of critical steps and intermediates Process parameters and in-process controls (IPCs) are defined and controlled by acceptable ranges and limits. The operating ranges are themselves the acceptable ranges or are set within the acceptable range of a process parameter, to allow for variance within the normal operating ranges. In summary, the manufacturing process is sufficiently described and the overall control strategy adequately explained. Process validation The lifecycle approach to process validation follows 3 stages: process development and evaluation, process verification and ongoing process verification. A list of the elements of the FKB238 active substance manufacturing process that have been validated and/or evaluated is included, as well as a list of the analytical procedures used for the process validation. The results from process verification activities are acceptable. Cleaning and reuse validation for the chromatography columns used in the active substance purification process was performed at full scale within a maximum acceptable number of reuse cycles determined in the bench-scale process evaluation studies. A summary of the validated number of reuse cycles for each column is presented.  Sufficient details have been provided for the cleaning and reuse validation studies. Validation of the commercial manufacturing process for the active substance is considered satisfactory. Manufacturing process development Risk-based approaches, which included identification of the critical quality attributes (CQAs), assessment of the criticality of the performance attributes and the process parameters, were employed during the establishment of the control strategy. Medicinal product no longer authorised

Process evaluation studies were performed. The results of the process evaluation studies for the upstream cell culture process and the downstream purification process are included. The results were used for identification and classification of process parameters. From the effects observed in the process evaluation studies on performance attributes, the acceptance ranges were identified as ranges for process parameters that can deliver acceptable process performance and consequently, acceptable

<div style=\"page-break-after: always\"></div>

product quality. Operating ranges were established equal to or within the acceptable ranges in order to control the process and product quality.

The only change in the manufacturing process during development has been discussed and justified.

A risk assessment of leachables from in-process product contact materials used in the FKB238 active substance manufacturing process is provided. Based on the vendor's product information or equivalent, it was confirmed that neither biological reactivities nor any safety concerning leachables are anticipated for the components listed as the high-risk components.

## Characterisation

A summary of the process-related impurities is presented, which includes the limit of quantitation, the source of impurity, residual impurity in active substance, and the maximum patient exposure calculated as the maximum adult dose per kg.

Elucidation of structure and other characteristics The active substance was characterised in accordance with ICH Q6B using state-of-the-art analytical procedures for confirming the structural, physicochemical and immunochemical properties and the biological activity of the active substance. All characterisation studies were performed using the FKB238 active substance lot, which is the primary reference standard. Additional FKB238 active substance lots were included to demonstrate manufacturing consistency. The results from the characterisation studies are adequately presented. All characterisation and elucidation studies were conducted on FKB238 manufactured by the commercial manufacturing process. The analytical techniques and methodologies applied to the characterisation of FKB238 are capable of evaluating primary structure, molecular mass, posttranslational modifications, charge and size heterogeneity, extinction coefficient, higher order structure, aggregation and fragmentation, biological activity and degradation pathways. The results demonstrated that FKB238 has the expected structure and functional properties. Assays used for characterisation of product-related variants and physicochemical properties are adequately described. Impurities The characterisation and risk assessment of impurities as presented are in line with ICH Q6B. All characterisations in this section were performed using five active substance lots manufactured by the same commercial process. Product-related impurities are molecular variants of the product arising during manufacture and/or storage, which do not have properties comparable to those of the desired product with respect to activity, efficacy and safety. Characterisation data and the results of the criticality assessment of each of the API/product-related impurities, including its impact on efficacy, PK, safety and immunogenicity is included. The process-related impurities identified in FKB238 active substance are considered part of the AS critical quality attributes (CQA) and are controlled during the manufacturing process, by analytical testing at release and on stability testing. Medicinal product no longer authorised

## Specification

## Specification

The active substance release and shelf-life specifications list the attributes, references to the compendial test methods and the acceptance criteria. The proposed specification tests are adequate and in line with

<div style=\"page-break-after: always\"></div>

relevant guidelines and include appropriate tests for physicochemical characteristics, identity, purity and potency.

## Analytical procedures

Detailed descriptions of all analytical procedures used in routine control of FKB238 active substance, as well as summaries of method validations have been provided.

Limit of quantitation and range are analysed as described in the ICH Q2R1 guideline. The strategies and the data provided to demonstrate specificity, accuracy, limit of quantitation and range are considered appropriate.

Adequate information regarding the containers used for active substance stability studies is provided. The proposed shelf-life for FKB238 active substance is justified by the available data from the long-term stability studies. The long-term stability studies were performed per ICH guidelines. In addition, stability studies were conducted under elevated and stress storage conditions - and photostability storage conditions to evaluate the effect of these conditions on the active substance quality.

The validation characteristics of the methods are sufficient. The Applicant has clarified the approach to calculate intermediate precision and repeatability, and repeatability was adequately demonstrated. The robustness of the methods was evaluated. Batch analyses Batch analysis data for active substance lots produced is included in the dossier. These are the batches used in the non-clinical studies, clinical studies and stability studies. The data was used to assess manufacturing consistency and to establish commercial specification limits. All lots were tested to and complied with the specification in place at the time of product release. Reference standards The reference standard is routinely used in identity and potency tests for both active substance and finished product. The history of the reference standards is provided. Future reference standards will be prepared to ensure sufficient inventory for release and stability testing and will be filled from representative material, qualified for use and monitored on stability. Container closure system FKB238 active substance is stored in single use bags that have been selected and assessed according to the EMA 'Guideline on plastic immediate packaging materials (CPMP/QWP/4359/03)'. The bag meets the criteria stated/indicated in Ph. Eur. 3.2.2.1. Stability A suitable shelf life is proposed for active substance stored at the intended storage conditions. Active substance lots manufactured by the commercial process were used for the stability study. The test methods were selected based on their ability to assess potential changes that may affect product quality, safety, and/or efficacy. Medicinal product no longer authorised

All results are within specifications.

The Applicant will continue the ongoing stability studies through completion. A minimum of one lot of FKB238 active substance manufactured at the commercial site per year will be put on long-term stability studies. Commercial lots will be assessed using the post-approval stability protocol.

Based on the stability results, the proposed shelf-life for the active substance is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Finished Medicinal Product

## Description of the product and Pharmaceutical Development

## Description and composition of the drug product

FKB238 finished product is supplied as a 100 mg or 400 mg sterile, single-use, preservative-free, clear to opalescent, colourless to pale brownish-yellow solution in a glass vial for intravenous administration.

Each vial (10 and 20 mL respectively) contains 4 mL or 16 mL deliverable volume of FKB238 at a concentration of 25 mg/mL. The method of administration is described in the SmPC. Bevacizumab should be withdrawn and diluted to the required administration volume with sodium chloride 9 mg/mL (0.9%) solution. The concentration of the final solution should be kept within the range of 1.4 mg/mL to 16.5 mg/mL and administered as an intravenous infusion. The components and function of the formulation are summarised in Table 1. Sorbitol is an excipient with known effect and each vial of 4 mL of concentrate contains 191 mg sorbitol (E420) and each vial of 16 mL of concentrate contains 764 mg sorbitol (E420).

| Component                 | Function        |
|---------------------------|-----------------|
| FKB238                    | API             |
| Monosodium glutamate      | Buffering agent |
| Sorbitol                  | Tonicity agent  |
| Polysorbate 80            | Stabiliser      |
| Hydrochloric acid, dilute | pH modifier     |
| Water for injection       | Solvent         |

The formulation of FKB238 is not identical to the EU-reference product formulation. Detailed formulation studies were executed to justify the use the new formulation. The description is satisfactory. The formulation is designed to provide the appropriate osmolality and pH and to prevent antibody aggregation, degradation, loss of biological activity and to ensure that the desired product quality is maintained during storage and shipping. Formulation development studies were performed to identify the final formulation. The control strategy for critical formulation parameters is acceptable A control strategy of critical formulation parameters is defined. To minimise formation of aggregates and visible particles during storage and shipping it was instrumental to control protein concentration and polysorbate 80 concentration together with the pH. In order to minimise formations of fragments, oxidised species and the change in charge variants, pH is controlled.

Table 1 - Composition of FKB238 finished product Each vial of FKB238 finished product is filled with an overfill. The excess fill volume is provided to ensure that the labelled volume of the finished product solution can be withdrawn from the vial. There are no overages in the FKB238 finished product formulation. Pharmaceutical development A control strategy was adequately developed. A QTTP with associated CQAs has been defined and justified. Formulation development Medicinal product no longer authorised

## Manufacturing development

The finished product manufacturing process is described in the dossier. The process was characterised and CQAs that are instrumental for achieving the QTTP and to consistently deliver the required product

<div style=\"page-break-after: always\"></div>

quality were identified. Process attributes needed for evaluation of product quality and process performance were identified and assessed with regards to criticality. Further process parameters of each step were identified and their impact on each process attribute was evaluated with a risk assessment. Appropriate range for process attributes and process parameters were set. There are no reprocessing steps in the finished product manufacturing process.

## Comparability

Comparability between the 100 mg and 400 mg presentations were discussed and it was demonstrated that the FKB238 finished product 100 mg/4 mL and 400 mg/16 mL are comparable.

Container closure The container closure system consists of type I, clear borosilicate tubing glass vial (10 mL and 20 mL), f butyl rubber stopper and an aluminium sealing cap with polypropylene top. The container closure has been evaluated for safety, compatibility, functionality and ability to prevent microbiological contamination. Extractables and leachables were also assessed. The level of leachables detected in the study does not compromise the purity, efficacy, and safety of the finished product. FKB238 is a sterile, preservative-free solution for intravenous infusion. Compatibility In-use compatibility studies are performed, investigating the compatibility with the infusion bag and line. The results support the proposed use Impurities Impurities were described in detail. Adequate controls are in place for all impurities. Purity and stability profiles have been compared between active substance and finished product. It is concluded that no further API-related impurities are arising from formulation and manufacture of the finished product. Process/material-related impurities from excipients are considered well-controlled and the contamination risk is low. An assessment and characterisation of visible and sub-visible particles are examined. Stress studies did not lead to generation of new particle species in term of morphology. Lot-to-lot consistency of particle size distribution was shown in the finished product at release. Sub-visible particles are considered adequately controlled. A risk assessment of potential source of elemental impurities found no high-risk sources. From the safety assessment, no elemental impurities of toxicological concern have been identified in the FKB238 finished product. Manufacture of the product and process controls Manufacture The lot release site in Europe/EEA is Geryon Pharma Ireland Ltd., Dublin K67 P6K2, Ireland. The manufacturing sites for the finished product are EU GMP compliant. Medicinal product no longer authorised

The manufacturing process is described in an appropriate level of detail. The finished product presentations of 100 mg/4 mL and 400 mg/16 mL (both 25 mg/mL) are manufactured using the same process steps and controls. The only differences between the presentations are the fill volume and size of vial. All other manufacturing steps and process parameters are the same. A batch formula is defined for maximum and minimum batch size.

Critical steps were identified and controlled adequately.

<div style=\"page-break-after: always\"></div>

## Process validation

The process validation approach was designed to demonstrate that the commercial manufacturing process is controlled and reproducible, consistently yielding finished product with the defined product quality.

Process validation acceptance criteria were established. Process validation was performed using three finished product lots of each presentation (100 mg/4 mL and 400 mg/16 mL) manufactured at the commercial facility and at a minimum and maximum scale. This is considered acceptable.

All validation results met the predetermined acceptance criteria.

Aseptic process validation studies including filter validation and media fills together with equipment performance qualification are presented in sufficient detail and demonstrate that the process is capable of producing a sterile product. Process validation lot data are all within specification. The Applicant will conduct ongoing process verification where monitored data will be collected and evaluated on a lot-by-lot basis. In addition, the results accumulated by continued monitoring will be reviewed annually and the knowledge gained will be used for the manufacturing process and monitoring program improvements, as appropriate. Shipping Shipping and shipping container validation concluded that the finished product quality was not affected by the shipping conditions. The study was designed to mimic actual shipment and temperature was within the range of 2°C to 8°C. To maintain 2°C to 8°C during transport, temperature is controlled via qualified shipping containers. Shipping information and shipping container validation were provided in sufficient detail. Product specification The product specification includes appropriate physicochemical tests and tests for identity, purity and potency. To ensure that the selected panel of methods has stability indicating capabilities, forced degradation studies (FDS) were conducted. A rationale was provided for the QAs not included in the specification. Multiple finished product lots are included to justify the specification. There have been no major process changes for the lots used for this purpose. Different statistical approaches were employed. Justifications for the statistical strategy were provided. The finished product release and shelf-life specifications are acceptable. Analytical procedures The panel of analytical procedures is considered adequate to monitor and control the quality of FKB238 at release and during shelf-life. Several of the analytical procedures are common to the active substance and finished product and only those specific for finished product are described in this section. Medicinal product no longer authorised

The description of all analytical methods is satisfactory. All methods are validated or verified for intended use.

## Batch analysis

Analytical data for multiple FKB238 finished product lots are included. All lots met the acceptance criteria in place at the time of release and end of shelf life at long term storage condition. Overall, the results demonstrate consistency of the manufacturing process capabilities.

<div style=\"page-break-after: always\"></div>

## Reference standards

The reference standard used in the analysis of the FKB238 finished product is the same as that used for the FKB238 active substance.

## Stability of the product

The proposed shelf-life of 100 mg/4 mL and 400 mg/16 mL finished product is 3 years when stored at the recommended temperature of 2-8°C and protected from light.

Stability studies are performed according to ICH guidelines and at the recommended storage temperature to support the expiry period. The lots are of the same formulation and packed in the same container closure system as proposed for marketing. Additionally, photostability (in accordance with ICH Q1B) study is performed and concludes that the finished product is sensitive to light. Stability-indicating parameters/methods are identified by forced degradation studies and justified at an appropriate level.

Chemical and physical in-use stability of diluted finished product in sodium chloride 9 mg/mL (0.9%) solution for injection stored for 48 hours at 2°C to 30°C has been demonstrated. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions. Short term temperature excursions above and below the recommended storage conditions are supported by the forced degradation studies described in the dossier. 'Do not freeze' is stated in the product information under 'Special precautions for storage', which is acceptable. Overall, results of these studies, together with results from the accelerated and stressed stability studies, demonstrate that the finished product is stable in the primary container, protected from light, under conditions that may be encountered during transport, storage, handling, and use. The Applicant will continue the ongoing primary long-term and accelerated stability studies described in the dossier through to completion. In addition, a minimum of one lot per year of each FKB238 finished product, 100 mg/4 mL finished product or 400 mg/16 mL finished product, manufactured at the commercial site, will be added to the post-approval long-term stability studies. A shelf-life for the finished product of 3 years when stored at 2°C - 8°C is supported based on the available stability data . Adventitious agents The microbial control strategy includes control of materials, monitoring of bioburden and bacterial endotoxins levels at critical manufacturing steps, control of active substance and finished product and an adequate container closure system. The MCB, WCB and unprocessed bulk have been tested for viral contamination in accordance with ICH Q5A and the results are acceptable. No substance of animal or human origin are used in manufacture of FKB238. A risk assessment with regards to TSE exposure during early cell line development is provided together with certificates of suitability and is acceptable. Medicinal product no longer authorised

Viral clearance studies were performed with a suitable panel of model viruses on qualified small-scale models. The results showed that the current FKB238 purification process has the capability to reduce retrovirus particles. The approach to ensure viral safety is considered sufficient and supports acceptable viral clearance for the downstream process.

## Biosimilarity

The applicant has conducted a comprehensive biosimilarity exercise, which is in line with the relevant EMA guidelines. The results are summarised in Table 2.

<div style=\"page-break-after: always\"></div>

Table 2 - Results of analytical biosimilarity exercise

<!-- image -->

| Category               | Quality attribute                                                                                                          | Test method                                          | Similarity Assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|------------------------|----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary structure      | N-terminal amino acid                                                                                                      | Edman sequencing                                     | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Primary structure      | Amino acid sequence, C-terminal amino acid                                                                                 | Peptide mapping (LC/MS)                              | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Primary structure      | Disulfide bond                                                                                                             | Reduced/Non-reduced peptide mapping (LC/MS)          | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Primary structure      | N-glycosylation site                                                                                                       | N-glycosydase F-digested/Nondigested peptide mapping | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Primary structure      | Molecular weight                                                                                                           | Intact MS                                            | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Primary structure      | pI                                                                                                                         | cIEF                                                 | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Primary structure      | Extinction coefficient                                                                                                     | AAA and UV spectroscopy                              | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Glycosylation          | Sialic acid, Other Minor Peaks (OMP), High mannose species Afucosylated species (F0), Fucosylated species (F1) and product | (M5), Gal/N N-linked glycan profiling no longer      | Minor differences in glycosylation are considered not significant. Sialic acid, Gal/N: Pass OMP: contents for 3 lots of FKB238 DS were at the higher end than the reference product and other FKB238 DS lots. M5: contents for 3 lots of FKB238 DS were at the higher end than the reference product and other FKB238 DS lots. F0: contents for 3 lots of FKB238 DS were at the higher end than the reference product and other FKB238 DS lots. F1: contents for 3 lots of FKB238 DS were at the lower end than the reference product and other FKB238 DS lots. authorised |
|                        | Galactose, Mannose, Fucose (Neutral sugar), GlcNAc (Amino sugar), Neu5Ac, Neu5Gc (Sialic acid) Medicinal                   | Monosaccharide composition                           | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                        | Glycosylation site occupancy                                                                                               | CE-SDS (R)                                           | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Higher order structure | Secondary structure                                                                                                        | Far-UV CD                                            | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                        | Secondary structure                                                                                                        | FT-IR                                                | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                        | Tertiary structure                                                                                                         | Near-UV CD                                           | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                        | Tertiary structure                                                                                                         | FL                                                   | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                        | Thermo transition properties                                                                                               | DSC                                                  | Pass                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                                    | Main species (HC+LC), MMWS and LMWS (Fragments)                                                                 | CE-SDS (R)                          | Pass                                                                                                                                                                                                                                                                                                                                                                        |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Size heterogeneity                 | Monomer, LMWS (Fragments)                                                                                       | CE-SDS (NR)                         | Minor differences in size heterogeneity are considered not significant. Contents for 2 lots of FKB238 DS were at the higher end than the reference product and other FKB238 DS lots.                                                                                                                                                                                        |
| Size heterogeneity                 | HMWS (Aggregates), Monomer                                                                                      | SE-HPLC                             | Pass                                                                                                                                                                                                                                                                                                                                                                        |
| Size heterogeneity                 | HMWS (Aggregates), Monomer, LMWS (Fragments)                                                                    | FFF                                 | Pass                                                                                                                                                                                                                                                                                                                                                                        |
| Charge heterogeneity               | Acidic variants, Main species, Basic variants                                                                   | CEX-HPLC no longer                  | Minor differences in charge heterogeneity are considered not significant. Basic variants: Pass Acidic variants: contents for 2 lots of FKB238 DS were at the higher end than the reference product and other FKB238 DS lots. Main species: main peak contents for 2 lots of FKB238 DS were at the lower end than the reference product and other FKB238 DS lots. authorised |
| Charge heterogeneity               | Acidic variants, Main species, Basic variants                                                                   | cIEF                                | Pass                                                                                                                                                                                                                                                                                                                                                                        |
| Amino acid modifications Medicinal | C-terminal variants (Lys variants, Amidated proline), N-terminal variants and Deamidation/Isomerisation product | Reduced peptide mapping (LC/MS)     | Pass                                                                                                                                                                                                                                                                                                                                                                        |
| Amino acid modifications Medicinal | Glycation                                                                                                       | BAC                                 | Pass                                                                                                                                                                                                                                                                                                                                                                        |
| Amino acid modifications Medicinal | Oxidation                                                                                                       | Reduced peptide mapping (LC/MS)     | Pass                                                                                                                                                                                                                                                                                                                                                                        |
| Amino acid modifications Medicinal | Glycation                                                                                                       | HI-HPLC                             | Pass                                                                                                                                                                                                                                                                                                                                                                        |
| Amino acid modifications Medicinal | Free thiol                                                                                                      | Colorimetric method                 | Pass                                                                                                                                                                                                                                                                                                                                                                        |
| Amino acid modifications Medicinal | Trisulfide and Tioether                                                                                         | Non-reduced peptide mapping (LC/MS) | Pass                                                                                                                                                                                                                                                                                                                                                                        |
| Amino acid modifications Medicinal | Cysteinylation                                                                                                  | Non-reduced peptide                 | -                                                                                                                                                                                                                                                                                                                                                                           |
| Amino acid modifications Medicinal |                                                                                                                 | mapping (LC/MS)                     |                                                                                                                                                                                                                                                                                                                                                                             |
| Strength                           | Protein concentration                                                                                           | UV spectroscopy                     | Pass                                                                                                                                                                                                                                                                                                                                                                        |
| Binding to target                  | Binding to VEGF A 165 and VEGF A 121                                                                            | ELISA                               | Pass                                                                                                                                                                                                                                                                                                                                                                        |
| antigen(s)                         | Binding to VEGF A121, VEGF A 165 , VEGF A 189 and VEGF B, C, D                                                  | SPR                                 | Pass                                                                                                                                                                                                                                                                                                                                                                        |
| Binding to Fc                      | Binding to FcγRI, FcγRIIa and                                                                                   | SPR                                 | Pass                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| receptors                | FcγRIIb                                            |                                                  |                                                                                                                                                                                                     |
|--------------------------|----------------------------------------------------|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                          | Binding to FcγRIIIa(V) and FcγRIIIa(F)             | SPR                                              | Binding Affinity to FcγRIIIa(V) and FcγRIIIa(F) for 3 lots of FKB238 DS were at the higher end than the reference product and other FKB238 DS lots. Minor differences in binding are considered not |
|                          | Binding to FcγRIIIb -NA1, FcγRIIIb -NA2 and FcRn   | SPR                                              | significant Minor differences in binding are considered not significant authorised                                                                                                                  |
| Fab-associated functions | Neutralisation of VEGF induced biological activity | Cell-based assays: HUVEC and Reporter Gene Assay | Pass                                                                                                                                                                                                |
| Fc-associated functions  | ADCC and CDC                                       | Cell-based assay                                 | Pass                                                                                                                                                                                                |
| Binding to complement    | Binding to C1q                                     | ELISA                                            | Pass                                                                                                                                                                                                |

Binding to FcγRIIIb FcγRIIIb Fab-associated functions Neutralisation of VEGF induced biological  activity Fc-associated functions ADCC and CDC Binding to complement Binding to C1q The Applicant has conducted an extensive, robust, comprehensive physicochemical and functional exercise to develop a similarity program using state-of-the-art techniques capable to assess the analytical similarity of FKB238 with EU-approved Avastin and to demonstrate that the proposed biosimilar and reference product are highly similar. The similarity exercise was conducted to provide a comprehensive understanding of the physicochemical and functional characteristics of the reference product. The similarity study is consistent with the provisions of the EMA Guideline on 'Similar Biological Medicinal Products containing biotechnology-derived proteins as active substance: quality issues'3. In general, the biosimilarity assessment performed by the Applicant is considered adequate to confirm the analytical similarity between FKB238 and EU-approved Avastin The similarity ranges were established for quantitative key quality parameters using data from EU-licensed Avastin batches. The statistical approach involved tolerance intervals using mean ± 3SD based on the criticality of the quality attribute to demonstrating biosimilarity and the variability of the analytical methods. Similarity for the attributes were accepted when an individual value of 90% of the test product falls within the quality range of the reference product. The biosimilarity criteria for the quality range testing used by the applicant, where a positive conclusion on comparability will be made if more than 90 % of individual batches of FKB238 fall within the calculated range of mean ± 3 SD for reference product, was not considered to be acceptable. However, as data from the analysis of individual batches were provided, assessment could be performed independent of the statistical model used by the applicant. Attributes considered to have the lowest risk to clinical outcomes were assessed by graphical methods or raw data comparisons to confirm similarity and no statistical approach was used. In addition to comparisons between FKB238 to EU-licensed Avastin, comparisons for FKB238 vs US-licensed Avastin and EU-licensed Avastin vs US-licensed Avastin are also presented. Medicinal product no longer authorised

The Applicant presented a justification why the differences observed in glycan profiles do not impact clinical efficacy for bevacizumab, which is accepted.

Both Avastin and FKB238 finished product contain the active substance bevacizumab, the same dosage form, administration route and indication for use. The FKB238 finished product is supplied as a sterile and preservative-free solution. The formulation is designed to provide appropriate osmolality and pH and to prevent degradation.

<div style=\"page-break-after: always\"></div>

A comparability study was performed between active substance batches and finished product batches, in order to support the use of active substance in establishing biosimilarity between FKB238 and Avastin. The tests and analysis used for establishment of the comparability between active substance and finished product are considered sufficient.

An accelerated stability study is presented. Overall the tests included are acceptable including assessment of FKB238 potency, CEX-HPLC degradation rates, SE-HPLC degradation rates, CE-SDS-LIF degradation. However, the results indicate increased thermal stability of FKB238 in comparison to the reference medicinal product at both 25°C and 40°C, when compared to the reference medicinal product. A long-term stability protocol is presented. This is acceptable.

The similarity assessment indicates similar biological activity of both the Fab and Fc-based functionality of FKB238, EU-licensed Avastin and US-licensed Avastin. Overall, FKB238 is considered to be highly similar to EU-licensed Avastin with respect to the presented physicochemical and biological characteristics. Differences are identified with respect to glycosylation, charge/size heterogeneity and Fc γ R binding, for which the Applicant claims no clinical relevance or clinical impact, which can be accepted. It is noted that the data presented for process verification batches tends to represent the extreme values in several of the FKB238 data sets, trending towards or beyond the acceptance limits. However, taking in to account the mode of action and potential impact of the relevant datasets, the justification of highly unlikely meaningful clinical impact is accepted. 2.2.4. Discussion on chemical, pharmaceutical and biological aspects The active substance is well characterised with regard to its physicochemical and biological characteristics, using state-of-the-art methods, and appropriate specifications are set. The fermentation and purification of the active substance are adequately described, controlled and validated. The manufacturing process of the finished product has been satisfactorily described and validated. The quality of the finished product is controlled by adequate test methods and specifications. The chemical, pharmaceutical and biological documentation comply with existing guidelines. Viral safety and the safety concerning other adventitious agents including TSE have been sufficiently assured. From a quality point of view, biosimilarity with the reference product Avastin is considered demonstrated. The overall quality of Equidacent is considered acceptable when used in accordance with the conditions defined in the SmPC. 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects From a quality point view, the marketing authorisation application for Equidacent is considered approvable. Medicinal product no longer authorised

## 2.2.6. Recommendation(s) for future quality development

None.

<div style=\"page-break-after: always\"></div>

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

The FKB238 non-clinical programme consists of a number of in vitro assays, an in vivo study in SCID mice, a single dose toxicity study in rats and a 2-week repeat-dose toxicity study in Cynomolgus monkeys. All studies were done in comparison with EU and US-Avastin, except the mouse study, which only included US-Avastin. In addition, a 2-week repeat dose toxicity study with only FKB238 were performed in rats.

<!-- image -->

| Product                                                                                  | FKB238DS                           | Avastin (US)   | Avastin (EU)   |
|------------------------------------------------------------------------------------------|------------------------------------|----------------|----------------|
| VEGF-A165 binding by ELISA (%) a                                                         | 96.6 ± 2.8 (97.8 ±2.8)b product no | 99.8 ± 4.6     | 98.6 ± 3.5     |
| VEGF-A121 binding by ELISA (%) a                                                         | 106.0 ± 5.5                        | 97.6 ± 2.5     | 102.1 ± 1.0    |
| VEGF-A165 binding by SPR (× 10-10 M)                                                     | 4.2 ± 1.4                          | 3.9 ± 1.1      | 4.3 ± 1.4      |
| VEGF-A121 binding by SPR (× 10-10 M)                                                     | 6.6 ± 3.4                          | 6.7 ± 2.5      | 7.4 ± 2.7      |
| VEGF-A189 binding by SPR (× 10-10 M)                                                     | 4.9 ± 2.3                          | 5.1 ± 2.1      | 5.6 ± 2.5      |
| VEGF-B/C/D binding by SPR                                                                | No binding                         | No binding     | No binding     |
| Fc γ RI binding by SPR (× 10-10 M)                                                       | 8.3 ± 5.5                          | 5.4 ± 3.1      | 5.7 ± 3.8      |
| Fc γ RIIa binding by SPR (× 10-6 M)                                                      | 9.4 ± 0.7                          | 9.4 ± 0.5      | 9.4 ± 0.6      |
| Fc γ RIIb binding by SPR (× 10-6 M)                                                      | 13.0 ± 1.5                         | 13.9 ± 1.3     | 14.0 ± 1.1     |
| Fc γ RIIIa(F) binding by SPR (× 10-6 M)                                                  | 9.8 ± 0.8                          | 11.3 ± 0.5     | 11.4 ± 0.5     |
| Fc γ RIIIa(V) binding by SPR (× 10-6 M)                                                  | 5.9 ± 0.3                          | 6.8 ± 0.3      | 6.8 ± 0.3      |
| Fc γ RIIIbNA1 binding by SPR (× 10-6 M)                                                  | 9.6 ± 0.8                          | 13.3 ± 0.8     | 13.5 ± 1.1     |
| Fc γ RIIIbNA2 binding by SPR (× 10-6 M)                                                  | 9.3 ± 0.6                          | 11.8 ± 0.6     | 11.9 ± 0.5     |
| FcRn binding by SPR (× 10-8 M)                                                           | 13.1 ± 1.3                         | 12.6 ± 0.9     | 13.4 ± 1.1     |
| Neutralization of VEGF induced HUVEC cell proliferation (%) a                            | 106.3 ± 7.6 (108.0 ± 7.1) b        | 106.6 ± 6.4    | 104.0 ± 5.1    |
| Neutralization of VEGF induced signal transduction (Reporter gene assay) (%) a Medicinal | 97.5 ± 5.9                         | 97.8 ± 5.0     | 101.5 ± 3.7    |
| Binding to cell-associated VEGF in SKOV-3 cells (%) a                                    | 98.1 to 103.7                      | 78.5 to 105.4  | 93.7 to 108.0  |
| ADCC                                                                                     | No activity                        | No activity    | No activity    |
| CDC                                                                                      | No activity                        | No activity    | No activity    |
| C1q binding by ELISA (%) a                                                               | 99.4 ± 2.1                         | 99.9 ± 4.8     | 98.1 ± 3.1     |

2.3.2. Pharmacology Primary pharmacodynamic studies A number of in vitro functional assays were conducted to substantiate similarity between FKB238 and the European reference product Avastin. The assays included binding to VEGF isoforms, Fcγ receptors, FcRn and C1q, neutralisation of VEGF signal transduction (reporter gene assay) and neutralisation of VEGF induced cell proliferation of HUVEC. In addition, ADCC and CDC activities were investigated. Generally, the data presented by the applicant indicate similarity between FKB238 and Avastin. Table 1: Summary of in vitro pharmacology studies for FK238 and Avastin Medicinal product no longer authorised

Each value represents mean ± standard deviation. a, relative activity to reference standard. b, mean ± standard deviation from DS and DP

Anti-tumour activity of FKB238 and Avastin (US) against human colorectal adenocarcinoma DLD-1 cells, (study no. c-14-0133, non-GLP)

Anti-tumour activity of FKB238-DP and Avastin (US) was examined in severe combined immunodeficient (SCID) mice xenografted with human colorectal adenocarcinoma DLD-1 cells expressing VEGF. Seven

<div style=\"page-break-after: always\"></div>

days after cell inoculation, animals were administered intraperitoneally with FKB238 DP or 3 lots of US-Avastin at 1 mg/kg once weekly for 3 weeks (Days 0, 7 and 14). Remaining mice with cell inoculation were used for pharmacokinetic analysis. The tumour diameters were measured twice a week and the tumour volume (V) was estimated. Statistical analysis (Anova) indicated that there was comparable (p=0.127195) anti-tumour activity after once weekly dosing between FKB238 DP and US-Avastin in this mouse xenograft model (Figure 2).

<!-- image -->

| VEGF (pg/mL)   | VEGF (pg/mL)   | VEGF (pg/mL)   | VEGF (pg/mL)   | VEGF (pg/mL)   | VEGF (pg/mL)   |
|----------------|----------------|----------------|----------------|----------------|----------------|
| Sex            | Group          | Day 1          | Day 2          | Day 25         | Day 26         |
| Male           | P.Saline       | 20.45 ± 1.80   | 22.34 ± 3.50   | 18.56 ± 2.29   | 19.64 ± 4.28   |
|                | FKB238         | 20.19 ± 4.76   | 31.72 ± 7.97   | 59.60 ± 15.29  | 46.85 ± 15.87  |
|                | US-Avastin     | 20.31 ± 3.47   | 32.38 ± 5.97   | 47.13 ± 19.69  | 38.95 ± 14.86  |
|                | EU-Avastin     | 21.20 ± 2.86   | 31.42 ± 2.20   | 55.47 ± 9.27   | 45.16 ± 8.37   |

Each point represents mean ± standard error from 10 animals in tumour volume. Figure 2: Anti-tumor activity of FKB238 and US-Avastin against DLD-1 tumour xenografts in SCID mice Determination of biomarker concentrations in a 4-week repeat dose toxicity study in cynomolgus monkeys, (study no. SBL330-020, GLP) FKB238 DP, US-Avastin or EU-Avastin was intravenously administered to cynomolgus monkeys twice a week for 4 weeks at a dose level of 10 mg/kg (6 males and 6 females in each group). Concentrations of sVEGFR1 in serum and concentrations of VEGF in plasma were measured at Day 1 (before dosing), Day 2 (24 hours after the end of the first dose), Day 25 (before dosing) and Day 26 (24 hours after the end of the last dose) using validated analytical methods. sVEGFR1 concentrations in serum were below the lower limit of quantification (LLOQ; 2441.5 pg/mL) in all animals at all sampling time points. VEGF concentrations in plasma increased after dosing of FKB238, US-Avastin and EU-Avastin on Day 2 and Day 25, and decreased on Day 26 of dosing, see Table 2. Table 2: VEGF concentration in plasma in male and female cynomolgus monkeys (study no SBL330-020). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| Female   | P. Saline   | 18.80 ± 3.20   | 19.31 ± 3.55   | 17.19 ± 2.06   | 18.42 ± 1.18   |
|----------|-------------|----------------|----------------|----------------|----------------|
|          | FKB238      | 18.18 ± 2.14   | 31.24 ± 4.13   | 55.09 ± 10.37  | 43.92 ± 9.59   |
|          | US-Avastin  | 19.58 ± 3.11   | 30.47 ± 2.83   | 42.16 ± 21.59  | 34.92 ± 15.82  |
|          | EU-Avastin  | 20.96 ± 3.77   | 33.25 ± 4.30   | 57.11 ± 13.38  | 46.72 ± 11.09  |

Each value shows mean ± standard deviation from 6 animals.

P.Saline; physiological saline

## Secondary pharmacodynamic studies

No secondary pharmacodynamics studies were submitted (see discussion on non-clinical aspects). Safety pharmacology programme No safety pharmacodynamics studies were submitted (see discussion on non-clinical aspects). Pharmacodynamic drug interactions No pharmacodynamic drug interaction studies were submitted (see discussion on non-clinical aspects). 2.3.3. Pharmacokinetics Pharmacokinetic properties of FKB238 and bevacizumab (EU and US) were characterised in rats (single dose), SCID mice (US Avastin only) and in a GLP 4-week repeat dose toxicity study. A 2-week repeat dose toxicity study were also performed in rats, which only evaluated TK parameters of FKB238. Repeat-dose PK of FKB238 and Avastin (US) in SCID mice (study no. d-14-0207, non-GLP). FKB238 DP or US-Avastin (3 lots) was intraperitoneally administered to male SCID mice bearing human colorectal adenocarcinoma DLD-1 tumours at 1 mg/kg (8 males in each group) once weekly for three weeks. Serum samples were obtained prior to dosing, at 0.5, 4, and 24 hours and at 2, 4, and 7 days after the 1st and 3rd doses. Pharmacokinetic profiles of FKB238 and Avastin showed no clear differences between FKB238 and Avastin (US). The serum concentration of FKB238 and Avastin (US) increased with tmax of 4 to 48 h after intraperitoneally administration and no clear differences were observed in Cmax between FKB238 and Avastin (US). Single-dose PK of FKB238 and Avastin (US or EU) and anti-drug antibody evaluation in rats (study no. SBL330-009, non-GLP). Medicinal product no longer authorised

A single-dose PK study was conducted in male and female Crl:CD(SD) rats. FKB238 DP, US-Avastin or EU-Avastin was intravenously administered to rats at 10 mg/kg (6 males and 6 females in each group).

Serum samples were obtained prior to dosing, at 0.5, 2, 8 and 24 hours and at 2, 4, 7, 14, and 28 days after dosing. Serum concentrations of FKB238 and Avastin were analysed using a validated method with a lower limit of quantification of 0.1 μg/mL in serum. ADA production was assessed prior to dosing and on Day 14 and Day 28 after administration and samples were analysed using a bridging ECL format.

<div style=\"page-break-after: always\"></div>

The serum drug concentration-time curves and PK parameters were similar for FKB238, US-Avastin and EU-Avastin (Table 3: Single dose toxicokinetics of FKB238 in a 2-week rat study (study no. SBL330-009, non-GLP).). ADA was detected in pre-dose samples and post-dose sample at Day 28 after dosing. One female in the FKB238 group, 2 females in the US-Avastin group, and one male in the EU-Avastin group were ADA positive in pre-dose. One male in the EU-approved Avastin dosing group showed positive at 672 hours after dosing.

Table 3: Single dose toxicokinetics of FKB238 in a 2-week rat study (study no. SBL330-009, non-GLP).

| Dosing Article   | Sex    |   Cmax (µg/mL) |   AUC0-28d µg.day/mL |   AUC0- ∞ |   T1/2 (day) |   CL (mL/kg/day) authorised |   Vss mL/Kg |   MRT (day) |
|------------------|--------|----------------|----------------------|-----------|--------------|-----------------------------|-------------|-------------|
| FKB238           | Male   |            241 |                 1530 |      2010 |         14   |                        5.05 |        96.5 |        19.1 |
| FKB238           | Female |            207 |                 1560 |      2090 |         14.5 |                        4.83 |        96.7 |        20   |
| US-Avastin       | Male   |            284 |                 1620 |      2160 |         14.3 |                        4.72 |        90.4 |        19.4 |
| US-Avastin       | Female |            241 |                 1420 |      1800 |         13.1 |                        5.56 |        97.8 |        17.6 |
| EU-Avastin       | Male*  |            305 |                 1770 |      2330 |         14   |                        4.35 |        81.5 |        18.9 |
| EU-Avastin       | Female |            305 |                 1700 |      2240 |         14.1 |                        4.5  |        85.1 |        19.1 |

Systemic exposure to FKB238, US-Avastin and EU-Avastin and ADA production were assessed in a repeat-dose toxicity study in cynomolgus monkeys (8 males per group). The animals were administered intravenously at 10 mg/kg twice weekly for 4 weeks (8 doses), followed by a 4-week recovery period. Blood samples were collected at pre-dose, 0.5, 1, 2, 4, 8, 24, 48, 72 hours after Day 1 (1st dose) and Day 25 (8th dose) for TK measurements and on Day -7 and Days 1 and 28 during the recovery period for ADA assessment. There were no clear differences in TK parameters between the FKB238, US-Avastin, and EU-Avastin groups, and there were no clear sex differences in any parameters (Table 4).

* In 1 male in the EU-Avastin group, serum anti-FKB238 antibody was positive at 672 hours after dosing. Therefore, the group mean and S.D. was calculated except this animal. Repeat-dose PK of FKB238 in rats (study no. SBL330-008, non-GLP). The objective of the repeat-dose toxicity study in rats was to evaluate the toxicity of FKB238 when administered intravenously at 15 and 75 mg/kg, twice a week for 2 weeks. In addition, systemic exposure to FKB238 and ADA production was assessed in the satellite group (5 animals per group) with blood samples collected on Day 1 of dosing and after the final dose for TK (prior to dosing, at 0.5, 4, and 24 hours and at 2, and 3 days after dosing) and on Day -6 and at 72 hours after the final dose for ADA assessment. FKB238 concentrations and AUC levels increased with increasing dose levels and repeated dosing, without sex-related differences. The t1/2 was not affected by the dose level or repeated dosing. ADAs were not detected in any animals at 72 hours after FKB238 dosing. Repeat dose TK of FKB238 and Avastin in a 4-week monkey study (study no. SBL330-013, GLP). Medicinal product no longer authorised

ADAs were detected in one female in the US-Avastin group on Day 28 of recovery. This animal showed lower serum drug concentrations than the other animals in the same group from Day 25 of dosing, and this observation was considered to be related to ADA production.

<div style=\"page-break-after: always\"></div>

Table 4: Toxicokinetic parameters after the first and final dose of 10 mg/kg in the Cynomolgus Monkey toxicity study following twice-weekly administration for four weeks.

| Group                                                     |                                                           | FKB238                                                    | US-Avastin                                                | EU-Avastin                                                | FKB238                                                    | US-Avastin                                                | EU-Avastin                                                |
|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Sex                                                       |                                                           | Male                                                      | Male                                                      | Male                                                      | Female                                                    | Female                                                    | Female                                                    |
| Dose                                                      |                                                           | 10 mg/kg, twice a week, 4 weeks                           | 10 mg/kg, twice a week, 4 weeks                           | 10 mg/kg, twice a week, 4 weeks                           | 10 mg/kg, twice a week, 4 weeks                           | 10 mg/kg, twice a week, 4 weeks                           | 10 mg/kg, twice a week, 4 weeks                           |
| Toxicokinetics (mean ± standard deviation from 6 animals) | Toxicokinetics (mean ± standard deviation from 6 animals) | Toxicokinetics (mean ± standard deviation from 6 animals) | Toxicokinetics (mean ± standard deviation from 6 animals) | Toxicokinetics (mean ± standard deviation from 6 animals) | Toxicokinetics (mean ± standard deviation from 6 animals) | Toxicokinetics (mean ± standard deviation from 6 animals) | Toxicokinetics (mean ± standard deviation from 6 animals) |
| Cmax (μg/mL)                                              | 1st dose                                                  | 275 ± 38                                                  | 250 ± 25                                                  | 302 ± 29                                                  | 249 ± 17                                                  | 245 ± 21                                                  | 302 ± 32                                                  |
| Cmax (μg/mL)                                              | 8th dose                                                  | 712 ± 135                                                 | 650 ± 292                                                 | 768 ± 98                                                  | 764 ± 70                                                  | 751 ± 45 b                                                | 760 ± 79                                                  |
| AUC0-3d (μg·day/mL)                                       | 1st dose                                                  | 477 ± 53                                                  | 435 ± 54                                                  | 548 ± 45                                                  | 491 ± 64                                                  | 489 ± 35                                                  | 553 ± 74                                                  |
| AUC0-3d (μg·day/mL)                                       | 8th dose                                                  | 1650 ± 360                                                | 1390 ± 660                                                | 1730 ± 220                                                | 1900 ± 120                                                | 1880 ± 180 b                                              | 1910 ± 150                                                |
| AUC0- ∞ (μg·day/mL)                                       | 1st dose                                                  | 1140 ± 260                                                | 1070 ± 220                                                | 1490 ± 270                                                | 1200 ± 220                                                | 1290 ± 140                                                | 1460 ± 170                                                |
| AUC0- ∞ (μg·day/mL)                                       | 8th dose                                                  | 6970 ± 3430                                               | 6370 ± 4190                                               | 6730 ± 1160                                               | 9530 ± 2520                                               | 9610 ± 3010 b 10200 ±                                     | 3900                                                      |
| t1/2 (day) a                                              | 1st dose                                                  | 3.92 ± 0.72                                               | 4.12 ± 0.54                                               | 4.74 ± 1.02                                               | 4.07 ± 1.04                                               | 4.51 ± 0.82                                               | 4.58 ± 0.50                                               |
| t1/2 (day) a                                              | 8th dose                                                  | 7.47 ± 2.35                                               | 7.67 ± 4.07                                               | 7.21 ± 1.64                                               | 9.58 ± 3.16                                               | 9.55 ± 2.26 b                                             | 9.92 ± 3.84                                               |

There were no unscheduled deaths and no animal was euthanized. There were no treatment-related changes for clinical signs, body weight, food consumption, water consumption, ophthalmology, urinalysis, haematology, blood chemistry, bone marrow examination, organ weights, necropsy, and histopathology. Under the conditions of this study, no-observed-adverse-effect level (NOAEL) was considered to be 75 mg/kg.

a. t1/2 was calculated using 3 time points (from 24 to 72 hours after dosing). b. The values in an animal judged anti-drug antibody positive (no. 20) was excluded from the calculation for mean ± standard deviation. 2.3.4. Toxicology To support development of FKB238 for global registration, in vivo GLP repeat-dose toxicity studies in rats (FKB238) and cynomolgus monkeys (FKB238, US-Avastin, EU-Avastin) were conducted. Single dose toxicity No single-dose toxicity studies were submitted (see discussion on non-clinical aspects). Repeat dose toxicity FKB238: two-week repeat dose toxicity study in rats (study no. SBL330-008, GLP). The objective of this study was to investigate the toxicity of FKB238 when repeatedly administered intravenously to Crl:CD(SD) rats at 15 and 75 mg/kg, twice weekly for 2 weeks. Potential toxicity was evaluated by clinical signs, body weight, food consumption, water consumption, ophthalmology, urinalysis, haematology, blood chemistry, bone marrow examination, organ weights, necropsy, and histopathology. Systemic exposure to FKB238 and ADA production were also assessed, see section Pharmacokinetics. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## FKB238 and bevacizumab (EU and US): 4-week intermittent intravenous repeat dose toxicity study in cynomolgus monkeys (study no. SBL-013, GLP)

This study was conducted to evaluate and compare the toxicity of FKB238 with that of US-Avastin and EU-Avastin when administered intravenously (10 mg/kg) to cynomolgus monkeys (6 males and 6 females per group, 3-4 years old) twice weekly for 4 weeks (8 doses in total), and to assess the reversibility of toxicity during a 4-week recovery period. Systemic exposure and ADA were also assessed, see section 3.2 Absorption. Clinical signs, body weight, food consumption, ophthalmology, physical examination (including oxygen saturation and respiratory rate), body temperature, blood pressure, electrocardiography, urinalysis, haematology, blood chemistry, necropsy, organ weights, bone marrow examination and histopathology were evaluated. Biomarker concentrations were evaluated under non-GLP conditions and reported separately Increases in fibrinogen (treatment related) were noted in FKB238, US-Avastin and EU-Avastin groups, but were without corresponding inflammatory changes and no treatment-related changes were observed in prothrombin time or activated partial thromboplastin time. In blood chemistry, an increase in globulin and a decrease in albumin/globulin ratio (A/G) were noted in 1 male in FKB238 group and statistically significant differences were noted in A/G in males on Day 28 between FKB238 and US-Avastin, but not between FKB238 and EU-Avastin. Further, the findings were not related to histopathological lesions. Histopathology revealed hypertrophy of the chondrocytes in the epiphyseal plate of the femur in all males and in one to two females in the FKB238, US-Avastin, and EU-Avastin groups and thickening of the epiphyseal plate of the femur in one to three males in FKB238, US-Avastin, and EU-Avastin groups. The bevacizumab-related physeal changes were similar for all three groups. These treatment related changes recovered by the end of the 4-week recovery period. Genotoxicity No genotoxicity studies have been submitted (see discussion on non-clinical aspects). Carcinogenicity No genotoxicity studies have been submitted (see discussion on non-clinical aspects). Reproduction Toxicity No reproductive or developmental toxicity studies have been submitted (see discussion on non-clinical aspects). Medicinal product no longer authorised

## 2.3.5. Ecotoxicity/environmental risk assessment

The applicant has provided a justification for not conducting an environmental risk assessment (ERA) for FKB238. FKB238 is a monoclonal antibody not expected to pose a risk to the environment. ERA studies are therefore not required, in accordance with EMEA/CHMP/SWP/4447/00.

<div style=\"page-break-after: always\"></div>

## 2.3.6. Discussion on non-clinical aspects

A comprehensive number of in vitro functional assays has been conducted to substantiate similarity between FKB238 and the EU reference product Avastin.

Slightly higher binding affinities were observed for FKB238 on FcγRIIIa(F), IIIa(V), IIIbNA1 and IIIbNA2 as compared to Avastin that could be attributed to differences identified in the glycan profile. These differences can be considered acceptable from a non-clinical point of view, given that there were no ADCC activity of bevacizumab.

In line with EU guidance (Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues; EMEA/CHMP/BMWP/42832/2005 Rev1), in vivo studies are generally not considered necessary in terms of the non-clinical development. However, in order to support global development, the applicant conducted studies to compare anti-tumour effects in a mouse xenograft model (FKB238 and US-Avastin), and to evaluate effects on VEGF and sVEGFR in cynomolgus monkeys (FKB238, US-Avastin and EU-Avastin). The results showed that FKB238 and US-Avastin are able to inhibit tumour growth in a similar way. Further, there were no clear differences in VEGF concentrations in plasma between FKB238, US-Avastin and EU-Avastin. In the rat single dose PK study one male in the EU-Avastin group was ADA positive on Day 28 after administration. In the monkey study, one female cynomolgus monkey in the US-Avastin group was ADA positive on day 28 of recovery period. Both animals showed lower exposure to bevacizumab, suggesting that the ADA affected TK. In the single-dose PK study in rats, a total of four animals were ADA positive pre-dosing (1 FKB238 female, 2 US-Avastin females, 1 EU-Avastin male). The reason for these findings is not known, but the results are considered as false positives. Similar findings were not reported in other PK or TK studies. Ig in animal is generally not predictive for immunogenicity in human (see section on immunological events). A 2-week repeat dose toxicity study was conducted with FKB238 in rats. The formulation used was the same as intended formulation in the product to be marketed. As expected, due to lack of binding to rodent VEGF, no VEGF-related toxicity was observed. Further, no indication of systemic or local toxicity was observed, indicating that the formulation was well tolerated. A 4-week repeat dose toxicity study was conducted with FKB238 and Avastin (US and EU) in cynomolgus monkeys. Increased fibrinogen was noted in FKB238, US-Avastin and EU-Avastin groups. Histopathology revealed hypertrophy of the chondrocytes and thickening of the epiphyseal plate in the femur in the FKB238, US-Avastin, and EU-Avastin groups with a similar incidence. These reversible changes were considered to be pharmacologically related and were similar for all three groups. Medicinal product no longer authorised

Non-human primate toxicity studies are considered of limited value for biosimilarity evaluation and such studies are not generally recommended. It is however, acknowledged that these studies were conducted as part of a global development and may be considered supportive for the claimed biosimilarity.

Local toxicity studies were not performed per se, but local toxicity was evaluated as a part of the repeat dose toxicity studies. The intended formulation for FKB238 is different from Avastin with respect to excipients used. The excipients are however well known and did not trigger adverse effects at the site of administration in rats or monkeys.

Studies on secondary pharmacodynamics, safety pharmacology, pharmacodynamics drug interactions, genotoxicity, carcinogenicity, and reproduction and developmental toxicity were not conducted, in line with EMA/CHMP/BMWP/403543/2010.

<div style=\"page-break-after: always\"></div>

## 2.3.7. Conclusion on the non-clinical aspects

The data submitted are acceptable from a non-clinical point of view to support the approval of FKB238.

## 2.4. Clinical aspects

## 2.4.1. Introduction

GCP The Clinical trials were performed in accordance with GCP as claimed by the applicant The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC. · Tabular overview of clinical studies Table 5: Clinical studies of FKB238 AUC0∞=area under the concentration -time curve extrapolated to infinite time; AUC0-t=area under the concentration-time curve up to the last detectable value; BICR=blinded independent central review; CR=complete response; DCO=data cut-off; EU-Avastin=European Union-approved Avastin; NS-NSCLC=non-squamous non-small cell lung cancer; ORR=overall response rate; PK=pharmacokinetic(s); PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumours; US-Avastin=United States-licensed Avastin. Medicinal product no longer authorised

<!-- image -->

<!-- image -->

|            | longer   |
|------------|----------|
| product no |          |

a An Extended Treatment Period is ongoing (defined as the time after DCO to the end of study, in which patients could continue receiving IP if they were considered by the treating investigator to be gaining clinical benefit).

## 2.4.2. Pharmacokinetics

Three studies provided PK data:

- FKB238-001: PK similarity in healthy male individuals from the United Kingdom

<div style=\"page-break-after: always\"></div>

Study FKB238-001 was a randomised, double-blind, parallel, single-dose study in healthy male subjects aged 18 to 55 years. The primary objective of the study was to compare the safety and PK of FKB238 with EU-Avastin and US-Avastin after single 5 mg/kg doses, by iv infusion, in healthy male subjects, with a secondary objective of the assessment of tolerability and immunogenicity. A total of 99 healthy volunteers were randomised to receive FKB238 (n=33), EU-Avastin (n=34) and US-Avastin (n=32). Two subjects received wrong doses, and were not included in the PK similarity exercise.

The concentrations of FKB238, US-Avastin and EU-Avastin in human serum were quantitatively determined using ECL-based ligand binding assays.

· FKB238-003: PK similarity in healthy male individuals from Japan Study FKB238-003 was a randomised, double-blind, parallel, single-dose study in healthy male subjects aged 20 to 45 years. The PK objective of the study was to demonstrate the PK similarity of FKB238 with EU-Avastin after single 5 mg/kg doses, by iv infusion, in Japanese healthy male subjects, with a safety objective of the assessment of tolerability and immunogenicity. A total of 40 healthy volunteers were randomised to FKB238 (n=20) and EU-Avastin (n=20). The concentrations of FKB238 and EU-Avastin in human serum were quantitatively determined using enzyme linked immunosorbent assay (ELISA). · FKB238-002: Multicentre, comparative clinical study in patients with non-squamous, non-small cell lung cancer (NS-NSCLC). Study FKB238-002 was a randomised, double-blind, parallel study to compare the efficacy and safety of 15 mg/kg doses of FKB238 to EU-Avastin when used in combination with paclitaxel and carboplatin in the first-line treatment of patients aged 18 years or older with advanced/recurrent NS-NSCLC. The primary objective of the study was to demonstrate the efficacy equivalence of FKB238 and EU-Avastin when used in combination with paclitaxel/carboplatin as measured by overall response rate (ORR). Secondary objectives included the comparison of safety, anti-drug antibodies (ADAs) produced by FKB238 and EU-Avastin, and the comparison of the serum trough concentration (Ctrough) of FKB238 and EU-Avastin. A total of 728 patients with NS-NSCLC were randomised and received treatment with FKB238 (n=362) and EU-Avastin (n=366). Serum concentrations of FKB238 and EU-Avastin were determined with the same assay as in study FKB238-003. PK similarity · Phase I study FKB238-001 The terminal phase elimination rate constant (λ z) was estimated as the slope of a regression line fitted to the terminal phase logged concentration values over time. The goodness of fit statistic, r 2 , was high and greater than 0.80 in all subjects. In addition, %AUCext was less than 20% of AUC0-∞ in all subjects. The primary and secondary PK endpoints fell within the predefined similarity ranges (Table 6). Medicinal product no longer authorised

The serum concentration-time profiles of bevacizumab following a single iv infusion of FKB238, EU-Avastin, and US-Avastin are shown in Figure 3. No samples underwent intentional repeat analysis.

The non-compartmental PK parameters are presented in Table 7.

<div style=\"page-break-after: always\"></div>

|           |                           | Geometric LS mean   | Geometric LS mean   | Geometric LS mean   | Ratio of geometric LS means (90% CI)   | Ratio of geometric LS means (90% CI)   | Ratio of geometric LS means (90% CI)   |
|-----------|---------------------------|---------------------|---------------------|---------------------|----------------------------------------|----------------------------------------|----------------------------------------|
|           | Pharmacokinetic parameter | FKB238 (N=32)       | EU Avastin (N=33)   | US Avastin (N=32)   | FKB238/ EU Avastin                     | FKB238/ US Avastin                     | EU Avastin/ US Avastin                 |
| Primary   | AUCO-inf (h*ug/mL)        | 52500               | 50800               | 53500               | 1.03 (0.97， 1.10)                      | 0.98 (0.92, 1.04)                      | 0.95 (0.89, 1.01)                      |
|           | AUC0-t (h*ug/mL)          | 50800               | 49300               | 51800               | 1.03 (0.97， 1.09)                      | 0.98 (0.93， 1.04)                      | 0.95 (0.90, 1.01)                      |
| Secondary | Cmax (ug/mL)              | 139                 | 142                 | 138                 | 0.97 (0.91, 1.04)                      | 1.01 (0.94, 1.07)                      | 1.03 (0.97， 1.10)                      |
|           | t1/2 (h)                  | 456.13              | 438.06              | 462.56              | 1.04                                   | 66*0                                   | 0.95                                   |

Table 6: Summary of PK similarity of FKB238, EU-Avastin and US-Avastin in study FKB238-001

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 7: Pharmacokinetic parameters from study FKB238-001

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                        |        |        | (90%              |
|------------------------|--------|--------|-------------------|
| Secondary Cmax (ug/mL) | 116    | 118    | 0.99 (0.90,1.08)  |
| t1/2 (h)               | 388.77 | 418.65 | 0.93 (0.86, 1.00) |

Figure 3. Mean (SD) serum concentration-time profiles of bevacizumab by treatment in FKB238-001 Phase I study FKB238-003 The terminal phase λz was estimated as the slope of a regression line fitted to the terminal phase logged concentration values over time. The goodness of fit statistic, r2, was high and greater than 0.80 in all subjects. In addition, %AUCext was less than 20% of AUC0-∞ in all subjects. The primary and secondary PK endpoints fell within the predefined similarity ranges (Table 8). The noncompartmental PK parameters are presented in Table 9 while the serum concentration-time profiles of bevacizumab following a single iv infusion of FKB238 and EU-Avastin are shown in Figure 4. No samples underwent intentional repeat analysis. Table 8: Summary of PK similarity of FKB238 and EU-Avastin in study FKB238-003 Medicinal product no longer authorised

CI = Confidence interval; LS = Least squares.

PK parameters were logarithmically transformed prior to an analysis of variance (ANovA) including a term for treatment group.

Bioequivalence is concluded if the 90&amp; CI of the ratio Test:Reference is included within the range of 0.8 to 1.25 for

<div style=\"page-break-after: always\"></div>

Table 9: Pharmacokinetic parameters from study FKB238-003

<!-- image -->

ome ancl CHC not reported for tmax Values not Pr no

<div style=\"page-break-after: always\"></div>

Figure 4. Mean (SD) serum drug concentration-time profiles in study FKB238-003

<!-- image -->

## Phase III study FKB238-002

The mean serum concentrations from study FKB238-002 are presented in Table 10 and Figure 5. No samples underwent intentional repeat analysis.

<div style=\"page-break-after: always\"></div>

Table 10: Serum concentrations of FKB238 and EU-Avastin in patients with NS-NSCLC from study FKB238-002

<!-- image -->

|         |        | authorised   |
|---------|--------|--------------|
|         | longer |              |
|         | no     |              |
| product |        |              |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

Per request, the applicant resubmitted PK similarity analyses from study FKB238-001 and -003, where all subjects were included. The results demonstrated PK similarity between FKB238 and EU-Avastin both in the pivotal FKB238-001 study (Table 6), and in the supportive FKB238-003 study (Table 8).

Figure 5. Mean (SD) concentration-time plots of Ctrough in patients with NS-NSCLC from FKB238-002 2.4.3. Pharmacodynamics No clinical pharmacodynamic studies have been performed with FKB238. 2.4.4. Discussion on clinical pharmacology The pharmacokinetic properties of FKB238 were compared with both EU- and US-sourced bevacizumab (Avastin) in a pivotal phase I clinical trial in healthy male subjects (FKB238-001), following a 5 mg/kg body weight single iv injection. In addition, pharmacokinetics of FKB238 was compared with EU-Avastin in healthy Japanese males (FKB238-003). In the initial submission, the applicant omitted several subjects from analyses of PK similarity in the FKB238-001 and -003 trials. Eight subjects (3 subjects in the FKB238- and 5 in the EU-Avastin arm) in FKB238-001 and one subject in the EU-Avastin arm in FKB238-003 were omitted from the PK similarity analyses of AUC0-∞ and t1/2. Subjects were omitted due to what the applicant defined as 'unreliable' PK-data. The applicant had a predefined rule which stated that subjects should be omitted if the time period over which λ z was estimated was less than 2-fold the associated t1/2. In essence, the subjects were excluded due to long t1/2. Medicinal product no longer authorised P

In the pivotal phase III trial (FKB238-002), FKB238 was compared with EU-Avastin by side by side analyses of Ctrough and Cmax serum concentrations of FKB238 or EU-Avastin following repeat 15 mg/kg dose administration in patients with NS-NSCLC. The geometric mean pre-dose concentrations of FKB238 were slightly lower than that of EU-Avastin at some timepoints (Table 10). The differences in the pre-dose concentrations; however, are so small that they can be considered as clinically insignificant.

<div style=\"page-break-after: always\"></div>

Even though previous treatment with VEGF inhibitors was an exclusion criteria in study FKB238-002, the Ctrough sampled before the first cycle ranged from BLQ to 528.6 µg/mL for FKB238 and from BLQ to 410.3 µg/mL for EU-Avastin (Figure 5). The applicant presented all PK data from the 34 subjects that had quantifiable concentrations before infusion at C1D1 (data not shown). Of the 34 subjects, 33 also had quantifiable concentrations post-dose, ruling out the possibility of switching pre- and post-dose samples for these individual subjects. The applicant also mentioned that samples could have been contaminated with drug without elaborating on how this could happen. There could be many possible scenarios, but one possible explanation may be that several samples were pipetted with the same pipette. This could explain the samples with concentrations close to the LLoQ. Another explanation, which was not discussed by the applicant, is that some pre-dose samples may have been collected during the infusion of the investigational drug. The applicant concluded that the samples with quantifiable concentrations were due sample mislabelling, sample switching and/or drug contamination. It is unknown for which samples the applicant suspects the different scenarios may have happened. The matter was not pursued since it was not expected that the validity of samples collected from C2D1 and onwards would be affected to a relevant degree. This was supported by a routine GCP-inspection of two centres in Russia and Bosnia-Herzegovina that did not report any minor- or major findings with regards to PK sampling (GCP Inspection Report INS/GCP/2019/036). Validation reports of the bioanalysis/immunogenicity analyses for review were submitted and considered adequate. No new pharmacodynamic data have been submitted as part of this application. Validated PD markers considered relevant to predicting efficacy of bevacizumab in patients do not exist. Therefore, no PD markers were included in the PK study, and clinical endpoints were utilized in the phase III study in NSCLC patients. 2.4.5. Conclusions on clinical pharmacology PK similarity between FKB238 and EU-Avastin has been demonstrated in two Phase I 'bioequivalence' trials. 2.5. Clinical efficacy One phase 3 study in non-squamous non-small cell lung cancer (NS-NSCLC) patients for the efficacy and safety comparison of FKB238 with the reference product EU-Avastin, including monitoring of immunogenicity, was submitted by the applicant. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 11: Description of the comparative clinical phase 3 efficacy and safety study

| Study ID   | Number of centres                              | First patient consent Last patient consent   | Design       | Study&ctrl drugs                                     | Study objective                           | Patients by treatment          | Duration                                                               | Gender M/F                    | Diagnosis                                                  | Primary endpoint                              |
|------------|------------------------------------------------|----------------------------------------------|--------------|------------------------------------------------------|-------------------------------------------|--------------------------------|------------------------------------------------------------------------|-------------------------------|------------------------------------------------------------|-----------------------------------------------|
|            | Location(s)                                    | Randomisedl/ Treated                         |              | Dose,route &regimen                                  |                                           | Randomisedl/ Ongoing at DCO    |                                                                        | Mean age (range)              | Inclusion criteria                                         |                                               |
| FKB238-002 | 146/136 BA,BG,BY, DE,ES,GE, GR,HR,HU, IT,JP,KR | 21 Jun 2016 03 Jan 2018 731/728              | R, P, DB, MC | FKB238: 15 mg/kg IV every3weeks Avastin: 15 mg/kg IV | Efficacy equivalence ofFKB238 and Avastin | FKB238: 364/37 Avastin: 367/38 | Until disease progressionor othercriteriafor treatment discontinuation | 483/248 61.0 years (26 to 84) | Patients aged 18 years or older with advanced or recurrent | ORR (by RECIST v1.1), assessed as the rate of |

<!-- image -->

BA=Bosnia and Herzegovina; BG=Bulgaria; BY=Belarus; CR=complete response; Ctrl=control; DB=double blind; DCO=data cut-off; DE=Germany; ES=Spain; GE=Georgia; GR=Greece; HR=Croatia; HU=Hungary; IT=Italy; JP=Japan; KR=Republic of Korea; M=Male; MC=multicentre; ORR=overall response rate; P=parallel; PE=Peru; PH=Philippines; PO=Poland; PR=partial response; R=randomised; RECIST=Response Evaluation Criteria in Solid Tumours; RO=Romania; RS=Serbia; RU=Russia; TH=Thailand; TR=Turkey; TW=Taiwan; UA=Ukraine; US=United States; VN=Vietnam. aNumber of centres that screened/randomised patients. 2.5.1. Dose response study No dose response studies were performed and are not deemed necessary for a biosimilar medicinal product. 2.5.2. Main study FKB238-002 Study FKB238-002 is a global, multicentre, double-blind, parallel, randomised, comparative clinical study designed to compare the efficacy and safety of FKB238 and bevacizumab EU-reference product (EU-Avastin) when used in combination with paclitaxel and carboplatin in the first-line treatment of advanced or recurrent NS-NSCLC. Medicinal product no longer authorised

CBDCA=carboplatin; DCO=data cut-off; IP=investigational product (FKB238 or Avastin); NS-NSCLC=non squamous non-small cell lung cancer; PD=progression of disease; PS=performance status; PTX=paclitaxel.

Figure 6. Flow chart of study design

## Screening Period

Patients aged ≥18 years with advanced or recurrent NS -NSCLC were screened for participation in the study up to 28 days before randomisation.

## Study Treatment Period

<div style=\"page-break-after: always\"></div>

Upon randomisation, patients entered the Study Treatment Period. Following start of study treatment, patients were to return for study visits every 3 weeks as long as they were receiving study treatment. The combination drugs (paclitaxel + carboplatin) was administered on Day 1 of each 21-day cycle for at least four, and no more than six cycles. The number of cycles is determined by patients' need and the investigator's assessment. FKB238 or EU Avastin investigational product (IP) were also administrated on Day 1 of each 21-day cycle until objective PD or other criteria for treatment discontinuation are met.

## Data cut-off (DCO)

Data cut-off was defined as 12 months from randomisation of the last patient enrolled in the study. Up to the time of DCO, all data on systemic anti-cancer treatment, radiotherapy or cancer surgery conducted after discontinuation of study treatment were to be collected until death, loss to follow-up, withdrawal of consent or until end of study. Assessments for survival should be made every eight weeks (± 1 week) following objective PD. At data cut-off all patients previously discontinued from study treatment and continuing in follow-up will complete the study and no further study assessments will be performed. Extended treatment period (ETP) The Extended Treatment Period is the time after data cut-off to end of study in which patients may continue receiving IP if they are considered by the treating investigator to be gaining clinical benefit. Complete assessments for safety, efficacy, PK, and immunology will not be collected by the applicant during this period. End of study End of study is defined as the last patient's last visit. Methods Study Participants Key inclusion criteria 1. Patients aged 18 years or older 2. Newly diagnosed advanced (stage IV) /recurrent NS-NSCLC for which they had not received any systemic anti-cancer therapy for metastatic disease, including chemotherapy, biologic therapy, immunotherapy, or any investigational drug 3. Histologically or cytologically confirmed diagnosis of predominantly NS-NSCLC Medicinal product no longer authorised

4. Existence of at least one measurable lesion by response evaluation criteria (RECIST v1.1) defined as; at least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (excep t lymph nodes which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) which is suitable for accurate repeated measurements
5. ECOG PS 0 or 1
6. Adequate haematological function: absolute neutrophil count (ANC) ≥ 1.5 × 109/L; platelets ≥ 100 × 109/L; haemoglobin ≥ 9 g/dL
7. International normalised ratio (INR) ≤ 1.5 and partial thromboplastin time (PTT) ≤ 1.5 × the upper limit of normal (ULN) within 7 days prior to starting study treatment

<div style=\"page-break-after: always\"></div>

8. Adequate liver function: Serum bilirubin ≤ 1.5 × ULN (and in case of documented Gilbert's Syndrome [unconjugated hyperbilirubinaemia] ≤ 3 x ULN); transaminases ≤ 2.5 × ULN (and in case of liver metastases &lt; 5 × ULN)
9. Adequate renal function:
- Creatinine clearance, measured and/or calculated according to the formula of Cockroft and Gault ≥ 60 mL/min AND
- Urine dipstick or urinalysis for proteinuria &lt; 2+. If the urine dipstick or urinalysis is ≥ 2+, 24hour urine must demonstrate ≤ 1 g of protein in 24 hours.
13. Treatment with any other investigational agent for any reason within 28 days before the first dose of IP

Key exclusion criteria 1. Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumours and mixed adenosquamous carcinomas of predominantly squamous nature 2. Recurrence occurred within 12 months from the last dose of neoadjuvant/adjuvant therapy 3. Any unresolved toxicities from prior systemic therapy (e.g., adjuvant chemotherapy) greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study drug with the exception of alopecia 4. Evidence of a tumour that compresses or invades major blood vessels or tumour cavitation that in the opinion of the investigator is likely to bleed 5. Known sensitising EGFR mutations (e.g., deletion 19 or L858R) or EML4-ALK translocation positive mutations 6. Previous dosing with VEGF inhibitor 7. Brain metastasis or spinal cord compression (computed tomography [CT] or magnetic resonance imaging [MRI] of the head is required within 4 weeks prior to randomisation) 8. Non-healing wound, ulcer, or bone fracture 9. Patients with unstable angina, myocardial infarction, coronary artery bypass graft, angioplasty, vascular stenting, or cardiovascular event within 6 months before the first dose of IP; coagulopathy, any bleeding disorders, poorly controlled diabetes, or active gastrointestinal inflammation such as gastric or duodenal ulcer, diverticulitis, inflammatory bowel disease, or cholecystitis 10. History of fistulas or abdominal perforations 11. History of arterial or venous thromboembolic or ischemic events, or congestive heart failure (New York Heart Association class ≥ 2) withi n 6 months before the first dose of IP 12. History of haemoptysis of ≥ ½ teaspoon of red blood within 28 days before the first dose of IP Medicinal product no longer authorised

## Treatments

Doses and schedules of IPs and chemotherapy in the two treatment arms FKB238 group:

- FKB238 15 mg/kg on Day 1 of each 21-day cycle (IV infusion, 90-30 min, depending on tolerability) until objective PD or other criteria for treatment discontinuation are met

<div style=\"page-break-after: always\"></div>

- Paclitaxel 200 mg/m 2  on Day 1 of each 21-day cycle for at least four, and no more than six cycles (IV infusion over three hours)
- Carboplatin area under the curve (AUC) 6.0 on Day 1 of each 21-day cycle for at least four, and no more than six cycles (IV infusion over 15-60 min)

## EU-Avastin group:

- EU-Avastin 15 mg/kg on Day 1 of each 21-day cycle (IV infusion, 90-30 min, depending on tolerability) until objective PD or other criteria for treatment discontinuation are met

· Paclitaxel 200 mg/m 2  on Day 1 of each 21-day cycle for at least four, and no more than six cycles (IV infusion over three hours) · Carboplatin AUC 6.0 on Day 1 of each 21-day cycle for at least four, and no more than six cycles (IV infusion over 15-60 min) Objectives Primary objective · To demonstrate equivalent efficacy of FKB238 and EU-Avastin. Secondary objectives · Continuous measure of clinical efficacy, to compare safety, ADAs produced and serum trough concentrations (Ctrough) of FKB238 and EU-Avastin Outcomes/endpoints Primary efficacy endpoint · The primary efficacy endpoint of the study is overall response rate (ORR) defined as the proportion of patients with a best overall response (BOR) of complete response (CR) or partial response (PR) by RECIST v1.1, as assessed by blinded independent central review (BICR). Secondary endpoints Efficacy · ORR (by RECIST v1.1) at week 19, defined as the rate of the best response of CR or PR assessed at week 19 · Progression-free survival (PFS), defined as the time from randomisation to the first documented disease progression (progressive disease [PD]) or death, whichever occurs first · Overall survival (OS), defined as the time from randomisation to death from any cause Medicinal product no longer authorised

- Duration of response (DOR), defined as the time from the first documented PR or CR (by RECIST v1.1) to the first documented objective PD or death, whichever occurs first
- Disease control rate (DCR), defined as the rate of CR, PR, stable disease (SD) (≥ 6 weeks)

## Safety endpoints

- Safety as evaluated through AEs, vital signs, haematology, clinical chemistry, urinalysis, electrocardiogram (ECG), Eastern Collaborative Oncology Group Performance Status (ECOG PS), and physical examination

<div style=\"page-break-after: always\"></div>

## Sample size

Assuming a dropout rate of 10%, it was anticipated that approximately 730 patients would be randomised into the study in a 1:1 ratio (365 patients in the FKB238 group and 365 patients in the Avastin group), in order to have a total of 656 patients who complete study treatment.

To fulfil the EMA requirements, a meta-analysis of available randomised clinical studies of Avastin demonstrated that the risk-difference for the ORR for the control arm compared to the Avastin treatment arms was calculated to be 0.1938 (80% CI: [0.1564, 0.2312]). Based on the result of the meta-analysis, an equivalence margin for the risk difference was determined to be 0.1221, which preserves 22% of the treatment effect characterised by the lower 80% CI for the risk-difference of ORR.

This study was designed to test for equivalence. The Null hypothesis for the treatment comparison was that there is non-equivalence between EU-Avastin and FKB238 in ORR. The alternative hypothesis was that there is equivalence.

With the equivalence margin for the risk-difference of 0.1221, an expected response rate of 35% in both treatment arms, the study design employing a two one-sided test (TOST) procedure, and an overall Type I error rate of 2.5%, a sample size of 656 patients (328 per group) was calculated to provide 80% power to demonstrate that the 95% CI about the risk-difference comparing FKB238 and EU-Avastin falls completely within ± 0.1221. Randomisation Randomisation was stratified according to epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma receptor tyrosine kinase (ALK) gene arrangement status (both are tested and known negative versus status unknown for either), geographical region (North America, Western Europe, East Asia, All Other Regions), prior weight loss over the previous 6 months (&lt; 5% yes versus no) and disease stage (advanced or recurrent). Blinding (masking) Investigators, site staff including pharmacy staff, patients, CRO personnel, and Sponsor personnel (except for a specified investigational product (IP) distribution manager and unblinded site pharmacists located only at sites conducting the study under an amended protocol that specifies an unblinded pharmacist role.) were blinded to individual patient treatment assignment during the course of the study. The IP was packaged and labelled in such a way that visual inspection of the IP or packaging would not reveal the treatment assignment; however, each individual kit of IP was numbered so that, if necessary, the number could be used to break the treatment blind if this became necessary to protect the safety of the patient. Statistical methods Medicinal product no longer authorised

The following analysis populations were included for this study:

- ITT Population: all patients randomised to treatment. Patients included in the treatment group according to the randomisation assigned, regardless of the treatment actually given. All efficacy analyses to be performed on the ITT population. These analyses were to be treated as sensitivity analysis.

- Per Protocol Set: all patients randomised to treatment who received at least 1 dose of IP with no important protocol deviations. Patients were included in the treatment group according to the treatment

<div style=\"page-break-after: always\"></div>

actually given. All efficacy analyses were to be performed on the PPS. These analyses were to be treated as the primary analysis. The subjects to be included in the PPS were to be identified in a Data Review Meeting to be held prior to database lock for final analysis.

- Safety Population : all patients randomised to treatment who received at least 1 dose of IP.

Patients will be included in the treatment group according to the treatment actually given.

All safety analyses will be performed on the Safety Population. Treatment groups will be analysed according to the first IP actually received.

- PK Population : all PPS patients who have at least one serum drug concentration data, which is defined in the study protocol, after IP administration. Patients will be included in the treatment group according to the treatment actually given. A two one-sided test procedure was used to test this hypothesis. The analysis was performed using the per protocol set (PPS). A 95% CI for the ORR difference between FKB238 and EU-Avastin was estimated and compared to the margin [± 0.1221]. If the true CI was within the interval [± 0.1221], an equivalence between FKB238 and EU-Avastin, with respect to the ORR, was confirmed. Results Participant flow Medicinal product no longer authorised bAll patients still receiving IP at DCO who entered the Extended Treatment Period. The Extended Treatment Period is ongoing as of the DCO for this CSR and data from the Extended Treatment Period are not presented herein.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Figure 7: Study participant flow

## Recruitment

The first patient signed informed consent on 21 June 2016 and the last patient signed informed consent on 03 January 2018. The data cut-off, defined as 12 months from randomisation of the last patient enrolled in the study, was 24 January 2019 and all data up to and including this date were included in the study analyses.

<!-- image -->

Patients were screened at 146 centres in 24 countries, and of these 136 centres in 24 countries (patient numbers) randomised patients; Belarus (50), Bosnia and Herzegovina (23), Bulgaria (5), Croatia (8), Georgia (27), Germany (2), Greece (15), Hungary (52), Italy (5), Japan (5), South Korea (11), Peru (13), Philippines (13), Poland (31), Romania (13), Russia (184), Serbia (59), Spain (19), Taiwan (4), Thailand (36), Turkey (11), Ukraine (120), US (16) and Vietnam (9). Conduct of the study Amendments to the protocol The original clinical study protocol (CSP) was dated 04 February 2016. There were four amendments to the original protocol, for details see table below. In addition, several country specific amendments have been implemented locally. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 12: Changes to planned analyses

<!-- image -->

|                   | authorised   |
|-------------------|--------------|
|                   | longer       |
| no                |              |
| Medicinal product |              |

<div style=\"page-break-after: always\"></div>

| Exclusion criterion of treatment with any other investigational agent for any reason within 28 days before the first dose of IP updated to clarify that this treatment may be for any reason (Section 9.3.2).   | Updated to meet the Japan PMDA requirement                                    | Medical and Safety   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|----------------------|
| Introduction of the Coordinating Investigator (Section 6.1).                                                                                                                                                    | To introduce the Coordinating Investigator and his role as a signatory to the | Medical and Safety   |

| Medicinal   |
|-------------|

Changes to the statistical analysis plan The original SAP (version 1.0) was dated 08 June 2016. During the development of the SAP and prior to unblinding of the study data, changes were made to the planned analyses in SAP version 2.0 (dated 07 March 2019). The changes to the planned analyses made after unblinding of the data on 07 May 2019 concerned listing of data and removal of duplicated presented data and split of listing due to large size. Protocol deviations Important protocol deviations that led to exclusion from the per-protocol set (PPS) are listed below. Table 13: Important protocol deviations (ITT Population) Medicinal product no longer authorised

IP=investigational product (FKB238 or Avastin); ITT=Intent-to-Treat.

Study treatment=IP and/or any combination drugs (paclitaxel and carboplatin).

Note that the same patient may have had more than 1 important protocol deviation.

a Important deviations before the start of treatment and during treatment.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 14: Demographics and other baseline characteristics (ITT Population)

<!-- image -->

|    | authorised   |
|----|--------------|
|    | longer       |
| no |              |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

|            |        | authorised   |
|------------|--------|--------------|
|            | longer |              |
| product no |        |              |

<!-- image -->

BMI=body mass index; IWRS=interactive web response system; ITT=Intent-to-Treat; STD=standard deviation. aAs recorded at randomisation by IWRS. bOne patient was randomised in a further stratum, since at the time of randomisation it was not clear to which geographical region the patient should be assigned. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 15: Summary of disease characteristics at baseline (ITT Population)

<!-- image -->

|           |         | authorised   |
|-----------|---------|--------------|
|           | longer  |              |
|           | no      |              |
|           | product |              |
| Medicinal |         |              |

AJCC=American Joint Committee on Cancer; ALK=anaplastic lymphoma kinase; ECOG PS=Eastern Cooperative Oncology Group Performance Status; eCRF=electronic case report form; EGFR=epidermal growth factor receptor; ITT=Intent-to-Treat;

IWRS=interactive web response system; NOS=not otherwise specified; STD=standard deviation.

a Locally advanced=Stage II (A &amp; B) and III (A &amp; B). Metastatic=Stage IV.

b Disease stage recorded in eCRF.

c As recorded at randomisation by IWRS.

Fifteen (4.1%) patients in the FKB238 arm and seven (1.9%) patients in the Avastin arm received prior anti-cancer therapy, predominantly cytotoxic chemotherapy. 193 (53.0%) patients in the FKB238 arm versus 187 (51.0%) patients in the Avastin arm had undergone any previous surgery. The majority of

<div style=\"page-break-after: always\"></div>

patients (353 [97.0%] in the FKB238 arm and 355 [96.7%] in the Avastin arm) received concomitant medications during the study.

## Numbers analysed

Table 16: Analysis set

| Numberofpatients   | Numberofpatients   | Numberofpatients   |
|--------------------|--------------------|--------------------|
| FKB238             | Avastin            | Total              |

CSR=clinical study report; IP=investigational product (FKB238 or Avastin); ITT=Intent-to-Treat; PPS=Per Protocol Set.

|                   | no   |
|-------------------|------|
| Medicinal product |      |

a Includes all patients randomised. b Patients included in treatment arm as randomised. c Includes all patients randomised to treatment who received at least one dose of IP with no important protocol deviations. dPatients included in treatment arm as actually given. Outcomes and estimation Primary outcome Table 17: BOR and analysis of ORR - BICR assessment (PPS) Medicinal product no longer authorised

BICR=blinded independent central review; BOR=best overall response; CI=confidence interval; ORR=overall response rate; PPS=Per Protocol Set; RECIST=Response Evaluation Criteria in Solid Tumours. RECIST Version 1.1.

A Response does not require confirmation.

B Stable disease or no evidence of disease ≥6 weeks includes RECIST visit window (±7 days).

C Death due to any reason in the absence of RECIST progression.

D Defined as the proportion of patients with a BOR of complete response or partial response.

e95% Pearson-Clopper CI.

<div style=\"page-break-after: always\"></div>

F Wald asymptotic 95% CI.

G A 95% CI within ±0.1221 confirms equivalence between FKB238 and Avastin.

Table 18: Best Overall Response over Time - BICR Assessment (Per Protocol Set)

<!-- image -->

| authorised   |
|--------------|

Only tumour assessment performed up until 18 weeks (+/- 1 week) from randomisation are considered in this analysis.

a95% Pearson-Clopper confidence interval.

The median time to onset of objective response from randomisation was shorter in the FKB238 arm than in the Avastin arm (6.93 weeks versus 11.29 weeks, respectively). Secondary endpoints · ORR (by RECIST v1.1) at week 19 Table 19: Overall Response Rate at Week 19 - BICR Assessment (PPS) BICR = Blinded Independent Central Review. ORR = Overall Response Rate. RECIST version 1.1. bWald asymptotic 95% CI is used. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

- Duration of Objective Response - BICR Assessment (PPS)

Table 20: Duration of Objective Response - BICR Assessment (Per Protocol Set)

<!-- image -->

Avastin

FKB238

Figure 8: Kaplan-Meier Plot of Progression-Free Survival - BICR Assessment (Per Protocol Set)

<div style=\"page-break-after: always\"></div>

- Overall survival

The estimated OS rate at 12 months was 57.7% (95% CI: 52.1% to 62.9%) in the FKB238 arm and 63.5% (95% CI: 57.9% to 68.5%) in the EU-Avastin arm for the PPS population. The estimated median OS for the PPS was 14.13 months (95% CI: 12.62 to 16.56 months) and 16.95 months (95% CI: 14.55 to 19.02 months) in the FKB238 and Avastin arms, respectively. The estimated hazard ratio (HR) was 1.19 (95% CI: 0.97 to 1.47).

<!-- image -->

- PFS: in the ITT population, the proportion of patients having progressed or died was 67.6% vs. 69.5% in the FKB238 and Avastin groups, respectively, and the corresponding median PFS 7.72 months and 7.62 months by Kaplan-Meier analysis. The events of death in the absence of RECIST progression was slightly higher in the FKB238 group being 20.1% (73/364) vs. 16.1% (59/367) in the EU-Avastin group. The Kaplan-Meier survival curves overlapped between treatments in disease progression and the estimated hazard ratio (HR; FKB238: EU-Avastin) of 0.97 (95% CI: 0.82 to 1.16) was reached. The investigator-based sensitivity analyses and the analyses performed in the PPS population provided similar results.

Figure 9: Kaplan-Meier Plot of Overall Survival (Per Protocol Set) Ancillary analyses Sensitivity analyses in the ITT population: - ORR: in the ITT population (BIRC assessment) ORR was 51.6% (188 patients) for the FKB238 arm and 53.7% (197 patients) for the Avastin arm. - ORR at Week 19: in the ITT population, the ORR at Week 19 was 47.8% (174 patients) and 51.0% (187 patients) in the FKB238 and EU-Avastin arms, respectively. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 21: Progression status and analysis of PFS - BIRC assessment (ITT population)

<!-- image -->

| longer   |
|----------|
| no       |

- b
- P
- f
- g

Medicinal product no longer authorised

- Hazard ratio and its 95% CI are calculated using the cox regression model adjusting for the listed baseline characteristics (randomisation stratification factors, ECOG Performance status at baseline, gender, smoking history and age) with ties handled by the Efron method. Treatment hazard ratio &lt;1 favours FKB238.
- 95% Wald CI.

OS: in the ITT population, the proportion of patients with event was 195/364 (53.6%) and 178/367 (48.5%) in the FKB238 and EU-Avastin groups, respectively, and the estimated HR was 1.18 (95% CI: 0.96 to 1.45).

<div style=\"page-break-after: always\"></div>

Table 22: Survival status and analysis of OS (ITT population)

<!-- image -->

|        | authorised   |
|--------|--------------|
| longer |              |
| no     |              |

Subgroup analyses: Medicinal product no longer authorised a b p

<div style=\"page-break-after: always\"></div>

Subgroup analyses are shown for the ITT Population and PPS in Figure 10 and Figure 11 (for difference in ORR) and

<!-- image -->

Subgroups with less than 10 subjects in both treatment arms are not included in the analysis.

Figure 12 and Figure 13 (for difference in OS), respectively.

<div style=\"page-break-after: always\"></div>

Figure 10. Forest plot of overall response rate by subgroup (ITT Population)

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 11: Forest plot of overall response rate by subgroup (PPS)

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

Medicinal product no longer authorised

Figure 12: Forest plot of overall survival by subgroup (ITT Population)

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Summary of main study

The following table summarises the efficacy results from the main studies supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the biosimilarity assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 23: Summary of efficacy for trial FKB238-002

<!-- image -->

| Title: A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin in 1st Line Treatment for Patients with Advanced/Recurrent Non-Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin (AVANA)   | Title: A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin in 1st Line Treatment for Patients with Advanced/Recurrent Non-Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin (AVANA)   | Title: A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin in 1st Line Treatment for Patients with Advanced/Recurrent Non-Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin (AVANA)   | Title: A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin in 1st Line Treatment for Patients with Advanced/Recurrent Non-Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin (AVANA)                                                                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                      | FKB238-002 / EudraCT Number 2015-004104-33                                                                                                                                                                                                                            | FKB238-002 / EudraCT Number 2015-004104-33                                                                                                                                                                                                                            | FKB238-002 / EudraCT Number 2015-004104-33                                                                                                                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                                                                                | Double-blind, randomised, parallel group, multicenter                                                                                                                                                                                                                 | Double-blind, randomised, parallel group, multicenter                                                                                                                                                                                                                 | Double-blind, randomised, parallel group, multicenter                                                                                                                                                                                                                                                                                                          |
| Design                                                                                                                                                                                                                                                                | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                        | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                        | 21 June 2016 to 24 Jan 2019 not applicable 25 Jan 2019 - ongoing (but no further analyses of data)                                                                                                                                                                                                                                                             |
| Hypothesis                                                                                                                                                                                                                                                            | Equivalence                                                                                                                                                                                                                                                           | Equivalence                                                                                                                                                                                                                                                           | Equivalence                                                                                                                                                                                                                                                                                                                                                    |
| Treatments groups                                                                                                                                                                                                                                                     | FKB238                                                                                                                                                                                                                                                                | FKB238                                                                                                                                                                                                                                                                | Treatment : Paclitaxel 200 mg/m 2 on Day 1 for at least 4, and no more than 6 cycles, followed by Carboplatin AUC 6.0 on Day 1 for at least 4, and no more than 6 cycles followed by FKB238 15 mg/kg on Day 1 until objective PD or other criteria for treatment discontinuation are met. Duration : once every 21 [±3] days Number Randomised: 364 authorised |
| Treatments groups                                                                                                                                                                                                                                                     | Avastin no                                                                                                                                                                                                                                                            | Avastin no                                                                                                                                                                                                                                                            | Treatment : Paclitaxel 200 mg/m 2 on Day 1 for at least 4, and no more than 6 cycles, followed by Carboplatin AUC 6.0 on Day 1 for at least 4, and no more than 6 cycles, followed by Avastin 15 mg/kg on Day 1 until objective PD or other criteria for treatment discontinuation are met. Duration : once every 21 [±3] days Number Randomised: 367 longer   |
| Endpoints and definitions                                                                                                                                                                                                                                             | Primary: Overall Response Rate ORR                                                                                                                                                                                                                                    | Primary: Overall Response Rate ORR                                                                                                                                                                                                                                    | the proportion of subjects with a best overall response (BOR) of CR or PR (by RECIST v1.1)                                                                                                                                                                                                                                                                     |
| Endpoints and definitions                                                                                                                                                                                                                                             | Secondary: Overall Response Rate at Week 19 product                                                                                                                                                                                                                   | ORR at Week 19                                                                                                                                                                                                                                                        | the rate of the best response of CR or PR (by RECIST v1.1) assessed at Week 19                                                                                                                                                                                                                                                                                 |
| Endpoints and definitions                                                                                                                                                                                                                                             | Secondary: Progression-free Survival Medicinal                                                                                                                                                                                                                        | PFS                                                                                                                                                                                                                                                                   | the time from randomisation to the first documented disease progression (PD) or death, whichever occurred first                                                                                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                                             | Secondary: Overall Survival                                                                                                                                                                                                                                           | OS                                                                                                                                                                                                                                                                    | the time from randomisation to death due to any cause                                                                                                                                                                                                                                                                                                          |
| Endpoints and definitions                                                                                                                                                                                                                                             | Secondary: Duration of Response                                                                                                                                                                                                                                       | DOR                                                                                                                                                                                                                                                                   | the time from the first documented PR or CR (by RECIST v1.1) to the first documented objective PD or death, whichever occurred first                                                                                                                                                                                                                           |
| Endpoints and definitions                                                                                                                                                                                                                                             | Secondary: Disease Control Rate                                                                                                                                                                                                                                       | DCR                                                                                                                                                                                                                                                                   | the rate of CR, PR, SD (≥6 weeks)                                                                                                                                                                                                                                                                                                                              |
| Database lock                                                                                                                                                                                                                                                         | 02 May 2019                                                                                                                                                                                                                                                           | 02 May 2019                                                                                                                                                                                                                                                           | 02 May 2019                                                                                                                                                                                                                                                                                                                                                    |
| Results and Analysis                                                                                                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                                                                                                                                                           |
| Analysis description                                                                                                                                                                                                                                                  | Primary Analysis                                                                                                                                                                                                                                                      | Primary Analysis                                                                                                                                                                                                                                                      | Primary Analysis                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Analysis population and time point description   | Per protocol set (PPS), defined as all patients randomised to treatment who received at least 1 dose of IP with no important protocol deviations. Patients will be included in the treatment group according to the treatment actually given.   | Per protocol set (PPS), defined as all patients randomised to treatment who received at least 1 dose of IP with no important protocol deviations. Patients will be included in the treatment group according to the treatment actually given.   | Per protocol set (PPS), defined as all patients randomised to treatment who received at least 1 dose of IP with no important protocol deviations. Patients will be included in the treatment group according to the treatment actually given.   | Per protocol set (PPS), defined as all patients randomised to treatment who received at least 1 dose of IP with no important protocol deviations. Patients will be included in the treatment group according to the treatment actually given.   |
|--------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability  | Treatment group                                                                                                                                                                                                                                 | Treatment group                                                                                                                                                                                                                                 | FKB238                                                                                                                                                                                                                                          | Avastin                                                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability  | Number of subjects                                                                                                                                                                                                                              | Number of subjects                                                                                                                                                                                                                              | 352                                                                                                                                                                                                                                             | 354                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability  | ORR by blinded independent central review (BICR) Number (%) 95% Confidence Interval                                                                                                                                                             | ORR by blinded independent central review (BICR) Number (%) 95% Confidence Interval                                                                                                                                                             | 182(51.7) (46.35, 57.03)                                                                                                                                                                                                                        | 189(53.4) (48.04, 58.68)                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability  | ORR by investigator Number (%) 95% Confidence Interval                                                                                                                                                                                          | ORR by investigator Number (%) 95% Confidence Interval                                                                                                                                                                                          | 185(52.6) (47.20, 57.87)                                                                                                                                                                                                                        | 178(50.3) (44.95, 55.61) authorised                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability  | ORR at Week 19 (BICR) Number (%) 95% Confidence Interval                                                                                                                                                                                        | ORR at Week 19 (BICR) Number (%) 95% Confidence Interval                                                                                                                                                                                        | 168(47.7) (42.41, 53.09)                                                                                                                                                                                                                        | 180(50.8) (45.51, 56.17)                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability  | PFS (BICR) Median 95% Confidence Interval longer                                                                                                                                                                                                | PFS (BICR) Median 95% Confidence Interval longer                                                                                                                                                                                                | 7.72 (7.46, 8.15)                                                                                                                                                                                                                               | 7.62 (6.87, 7.82)                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability  | OS Median 95% Confidence Interval                                                                                                                                                                                                               | OS Median 95% Confidence Interval                                                                                                                                                                                                               | 14.13 (12.62, 16.56)                                                                                                                                                                                                                            | 16.95 (14.55, 19.02)                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability  | DOR Median 95% Confidence Interval no                                                                                                                                                                                                           | DOR Median 95% Confidence Interval no                                                                                                                                                                                                           | 6.47 (5.39, 7.69)                                                                                                                                                                                                                               | 6.28 (4.86, 7.16)                                                                                                                                                                                                                               |
| Effect estimate per comparison Medicinal         | Primary endpoint: ORR Primary analysis Sensitivity analysis product                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                                                               | FKB238 - Avastin                                                                                                                                                                                                                                |
| Effect estimate per comparison Medicinal         | Primary endpoint: ORR Primary analysis Sensitivity analysis product                                                                                                                                                                             | Difference in ORR (BICR)                                                                                                                                                                                                                        | Difference in ORR (BICR)                                                                                                                                                                                                                        | -0.02                                                                                                                                                                                                                                           |
| Effect estimate per comparison Medicinal         | Primary endpoint: ORR Primary analysis Sensitivity analysis product                                                                                                                                                                             | 95% Confidence Interval                                                                                                                                                                                                                         | 95% Confidence Interval                                                                                                                                                                                                                         | (-0.0905, 0.0568)                                                                                                                                                                                                                               |
| Effect estimate per comparison Medicinal         | Primary endpoint: ORR Primary analysis Sensitivity analysis product                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                                                               | FKB238 - Avastin                                                                                                                                                                                                                                |
| Effect estimate per comparison Medicinal         | Primary endpoint: ORR Primary analysis Sensitivity analysis product                                                                                                                                                                             | Difference in ORR (Investigator)                                                                                                                                                                                                                | Difference in ORR (Investigator)                                                                                                                                                                                                                | 0.02                                                                                                                                                                                                                                            |
| Effect estimate per comparison Medicinal         | Primary endpoint: ORR Primary analysis Sensitivity analysis product                                                                                                                                                                             | 95% Confidence Interval                                                                                                                                                                                                                         | 95% Confidence Interval                                                                                                                                                                                                                         | (-0.0510, 0.0965)                                                                                                                                                                                                                               |
| Effect estimate per comparison Medicinal         | Secondary endpoint: ORR (BICR) at Week 19                                                                                                                                                                                                       | Comparison groups                                                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                                                               | FKB238 - Avastin                                                                                                                                                                                                                                |
| Effect estimate per comparison Medicinal         | Secondary endpoint: ORR (BICR) at Week 19                                                                                                                                                                                                       | Difference in ORR (BICR) at Week 19                                                                                                                                                                                                             | Difference in ORR (BICR) at Week 19                                                                                                                                                                                                             | -0.03                                                                                                                                                                                                                                           |
| Effect estimate per comparison Medicinal         | Secondary endpoint: ORR (BICR) at Week 19                                                                                                                                                                                                       | 95% Confidence Interval                                                                                                                                                                                                                         | 95% Confidence Interval                                                                                                                                                                                                                         | -0.1049, 0.0425                                                                                                                                                                                                                                 |
| Effect estimate per comparison Medicinal         | Secondary endpoint: PFS                                                                                                                                                                                                                         | Comparison groups                                                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                                                               | FKB238/Avastin                                                                                                                                                                                                                                  |
| Effect estimate per comparison Medicinal         | Secondary endpoint: PFS                                                                                                                                                                                                                         | Hazard Ratio (HR) for PFS (BICR)                                                                                                                                                                                                                | Hazard Ratio (HR) for PFS (BICR)                                                                                                                                                                                                                | 0.96                                                                                                                                                                                                                                            |
| Effect estimate per comparison Medicinal         | Secondary endpoint: PFS                                                                                                                                                                                                                         | 95% Confidence Interval                                                                                                                                                                                                                         | 95% Confidence Interval                                                                                                                                                                                                                         | (0.81, 1.15)                                                                                                                                                                                                                                    |
| Effect estimate per comparison Medicinal         | Secondary endpoint:                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                                                               | FKB238/Avastin                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|       | OS                                                                                                                             | HR for OS                                                                                                                      | 1.19                                                                                                                           |
|-------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
|       |                                                                                                                                | 95% Confidence Interval                                                                                                        | (0.97, 1.47)                                                                                                                   |
| Notes | The primary analysis for EMA was based on the PPS. Analyses based on the Intent-to-treat (ITT) population were also performed. | The primary analysis for EMA was based on the PPS. Analyses based on the Intent-to-treat (ITT) population were also performed. | The primary analysis for EMA was based on the PPS. Analyses based on the Intent-to-treat (ITT) population were also performed. |

## Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable.

Clinical studies in special populations Not applicable for biosimilars. Supportive studies Not applicable. 2.5.3. Discussion on clinical efficacy Design and conduct of clinical studies The clinical development program to demonstrate biosimilarity between FKB238 and EU-Avastin (bevacizumab) in combination with paclitaxel and carboplatin is based on a randomised, double blind, comparative, multi-national (146 centres screened patients in 24 countries with 136 centres randomising patients), phase 3 study in first line patients with advanced or recurrent non-squamous NSCLC. A single pivotal phase 3 equivalence trial (FKB238-002) regarding similarity on efficacy and safety is considered adequate to support this application. The study design, study population, inclusion/exclusion criteria, dose regimen, study endpoints and sample size were in general in compliance with the given CHMP scientific advice. Indeed, non-squamous NSCLC is considered a relevant and sensitive population for detection of potential differences between the two products. Study protocol amendments 3 and 4 were conducted after the first patient signed informed consent. The amendment 3 concerned a change in the handling of subjects developing toxicity and allowed these patients to continue after a delay of more than 3 weeks. This change might have had an impact on efficacy analysis in the form of possible selection bias. However, the sensitivity analysis in the ITT population showed similar result to that seen in the PPS population. Medicinal product no longer authorised

<!-- image -->

The number of patients randomised to the study was consistent with the original sample size calculations. Based on the result of a meta-analysis of available randomised clinical studies of EU-Avastin, the equivalence margin for the risk difference of ORR was defined to be ± 0.1221 which is acceptable from a statistical and clinical point of view. Randomisation was stratified using a block randomisation scheme according to EGFR mutation and ALK gene arrangement status, geographical region, prior weight loss over the previous six months and disease stage.

The study was conducted in several geographic areas and countries possibly having divergent practices and bringing variability for the data evaluation. Overall, the difference between regions had no statistically significant impact on the outcome (data not shown). The Applicant repeated the interaction test with the inclusion of the geographic regions 'South America' and 'Eastern Europe' previously

<div style=\"page-break-after: always\"></div>

integrated in the 'All other regions' subgroup, which showed no statistical evidence of the heterogeneity among regions (interaction p-value = 0.5164).

Inclusion/exclusion criteria are based on those of the EU-Avastin pivotal trial supporting the NSCLC indication (EMEA/H/C/000582/II/0009). In the current study, a slightly different patient population was accepted (i.e. 10-12% of the patients were Stage I to IIIA, n=82) compared to the Avastin registration study (study E4599 also stage IIIB patients with malignant pleural effusion were eligible, n=44). Nevertheless, no significant differences were observed in the ORR between the patients having lower than Stage IV disease by initial staging vs. the overall patient population. This deviation in inclusion is thus not expected to affect the overall study outcome. Patients with known sensitising EGFR mutations and ALK gene arrangements were excluded from the study as current recommendation is to treat these patients with TKIs while EGFR/ALK negative patients were included. However, the majority of patients in both treatment arms had status unknown (EGFR mutation 73 %, ALK mutation 87 %) since testing was not mandatory for this trial. Nevertheless, status unknown is deemed not to preclude demonstration of biosimilarity, and importantly, randomisation has been stratified according to EGFR mutation and ALK gene arrangement status (known negative versus status unknown for either).

The primary efficacy endpoint of the study is overall response rate (ORR) defined as the proportion of patients with a best overall response (BOR) of complete response (CR) or partial response (PR) by RECIST v1.1, as assessed by blinded independent central review (BICR). The secondary endpoints included ORR (by RECIST v1.1) at week 19, PFS (defined as the time from randomisation to the first documented disease progression [PD]) or death, whichever occurs first), OS (defined as the time from randomisation to death from any cause), duration of response (DoR) and disease control rate (DCR). The choice of primary endpoint was not in line with the recommendation in the CHMP SA, which emphasised that ORR should be compared at a specific and sensitive time point and not as BOR of CR and PR. Nevertheless, ORR at Week 19 was included as a secondary endpoint and analysed using the same methods as for the primary endpoint, which is considered adequate. The other endpoints for this study are agreed. Endpoint analyses were conducted in both the PPS and the ITT populations. PPS was the primary analysis set and included all patients randomised to treatment who received at least one dose of IP and who had no important protocol deviations. Blinded independent central review assessment was used as the pivotal results of the study for both primary and secondary analyses. Efficacy data and additional analyses One thousand and twenty-three patients were screened, and of these, 731 were randomised to receive study treatment. The data cut-off (DCO), defined as 12 months from randomisation of the last patient enrolled in the study, was 24th of January 2019. All data up to and including this date were included in the study analyses. 89.7% (656) of patients had discontinued from study at DCO, the main reason was death, with a higher number of patients that had died in the FKB238 arm compared to the Avastin arm [195 patients [53.9%] vs. 177 patients [48.4%], respectively]). The majority of patients had no important protocol deviations (96.6% overall) with similar numbers across both arms. Medicinal product no longer authorised

There were some imbalances in demography and baseline characteristics in the overall ITT-population such as more current smokers, more patients with a past and current medical history of cardiovascular conditions, more patients with current respiratory conditions, and smaller number of patients who received subsequent anti-cancer therapy in the FKB238 arm (Refer to the Clinical Safety discussion for further details). During the study, a total of 36 patients had palliative radiotherapy. Of these, 6 patients (1 in the FKB238 arm and 5 in the Avastin arm) received it during the treatment period while the remaining received it post-treatment. In addition, 1 patient underwent surgery during study treatment (data not shown).

<div style=\"page-break-after: always\"></div>

For the primary endpoint ORR (PPS), similar outcomes were reported across the two arms (51.7% and 53.4% in the FKB238 and EU-Avastin arms, respectively). The difference in ORR was -0.02 (95% CI: -0.095, 0.568) and was well within the pre-defined equivalence margin, supporting similar efficacy between FKB238 and EU-Avastin.

In addition, outcomes of the following endpoint and sensitivity analyses support the above-mentioned conclusions: (i) The ORR risk difference (RD) primary endpoint (BICR and investigator evaluated), and (ii) the RD for the ORR at Week 19 secondary endpoint (BICR and investigator evaluated) in the ITT population, as well as (iii) the sensitivity analysis in the PP population for the DOR (HR) (data not shown).

The Applicant has provided the requested forest plots and subgroup analyses data for the ORR and OS endpoints for both ITT and PPS populations. The data showed similar response rate and survival in each subgroup except for the Western Europe region and the current smoking status. However, these subgroups are small in sample size, and hence it is impossible to draw robust conclusions based on these data. At week six, there was a slightly higher proportion of responders in the FKB238 arm than in the EU-Avastin arm (93 [26.4%] versus 81 [22.9%] patients). Clearly higher proportion of patients remained in response over 12 months of duration in the FKB238 group (16.5% vs. 8.6%). The median time to onset of objective response from randomisation was also shorter in the FKB238 arm than in the EU-Avastin arm (6.93 weeks versus 11.29 weeks, respectively). However, this might be due to a sampling artefact of the different response assessment timings (i.e. 6 weeks and 12 weeks). The mean time to response was 10.4 and 10.5 weeks for the FKB238 and Avastin arms, respectively. The estimated proportion of patients who were alive and progression-free at 12 months was 24.8% (95% CI: 19.8% to 30.2%) in the FKB238 arm and 24.8% (95% CI: 19.7% to 30.2%) in the EU-Avastin arm. The estimated median PFS was 7.72 months (95% CI: 7.46 to 8.15 months) and 7.62 months (95% CI: 6.87 to 7.82 months), respectively. The estimated OS rate at 12 months was 57.7% (95% CI: 52.1% to 62.9%) in the FKB238 arm and 63.5% (95% CI: 57.9% to 68.5%) in the EU-Avastin arm in the overall PPS. The Kaplan-Meyer (KM) survival curves in the overall PPS were overlapping until 3 months, at which time point the survival curves showed a slight separation between the treatment arms. However, the KM survival curves did not show any tendency of time-dependent increase in the death rate difference between the treatment groups, implying similarity in the progression of the disease by time. The estimated median OS for the PPS was 14.13 months (95% CI: 12.62 to 16.56 months) and 16.95 months (95% CI: 14.55 to 19.02 months) in the FKB238 and Avastin arms, respectively (HR 1.19 [95% CI: 0.97 to 1.47]). Nevertheless, the estimated HR was not significantly different from 1, and the 95% CI contained value 1 although the margins were skewed in favour of the reference product. Besides, the study FKB238-002 was not powered to draw any firm conclusions on the efficacy based on OS, and no type 1 error control was included. Furthermore, survival status of 14 subjects in the Avastin group is unknown due to withdrawal of consent and subsequently lost information on survival. Therefore, some deaths in the Avastin group might possibly not have been recorded (refer to Discussion on Clinical Safety). Medicinal product no longer authorised

According to the post-hoc subgroup analysis provided (data not shown), the events of deaths in the absence of RECIST progression were slightly higher in the FKB238 group being 20.1% (73/364) vs. 16.1% (59/367) in the EU-Avastin arm. Based on the KM curves in patients without PD (by BICR) who died in the ITT population, the survival curves were almost overlapping until 10 months, including at the 3-month time point. Therefore, the slightly lower survival in the overall FKB238 group cannot be explained by the difference in patients who discontinued without PD. Of note, the comparison and the causality evaluation of the deaths in this analysis (in patients who died without PD) is hampered due to the following: (i) After randomisation was broken, the comparisons did not include the initially randomised groups, and (ii) the treatment groups were no longer comparable in terms of anticancer

<div style=\"page-break-after: always\"></div>

treatments after the discontinuation or the completion of study. Although slightly more events of deaths were reported as a reason for discontinuation in the FKB238 group in the absence of RECIST progression by BICR, the large part of these were considered not necessarily due to AEs related to the treatment investigated.

As indicated in the Guideline on similar biological medicinal products containing monoclonal antibodies non-clinical and clinical issues (EMA/CHMP/BMWP/403543/2010) OS may not be sensitive enough for establishing comparability of a biosimilar mAb to a reference mAb, since they may be influenced by various factors not attributable to differences between the biosimilar mAb and the reference mAb, but by factors like tumour burden, performance status, previous lines of treatments, underlying clinical conditions, subsequent lines of treatment, etc. The observed imbalances in baseline characteristics (including patients with possibly worse prognosis due to several confounding factors) may likely be reflecting that the patients in the biosimilar arm might have been a more vulnerable patient group, potentially contributing to the noted difference. Importantly, the potential OS-difference is not reflected by an effect in PFS, DoR and DCR, hazard and odds ratios. In addition, the types of deaths were very variable including treatment-related and non-treatment-related deaths, with no clear pattern or accumulation of certain causes. Finally, one important factor potentially misbalancing the groups or their disease characteristics is the fact that EGFR and ALK status was unknown in 2/3 and 4/5 of patients, respectively. Therefore, it is difficult to compare the patient heterogeneity with regards to the type and severity of disease.

The applicant is seeking approval of FKB238 as a biosimilar bevacizumab product to the reference medicinal product European Union (EU)-approved, Avastin.

Overall, considering the totality of evidence, the OS-results should be interpreted with caution. It has to be taken into consideration that the study was neither adequately powered to demonstrate equivalence nor to detect differences in OS, and no type 1 error control was included. In addition, the 95% CI contained value 1 although the margins were skewed in favour of the reference product. The KM survival curves do not indicate any tendency of the time-dependent increase in the death rate difference, which speaks against the differences in disease progression between the study arms. The divergence seen early, only at 3-month time point in KM survival curve (being similar thereafter) might be due to patient heterogeneity and/or a random data variation rather than a real treatment effect. Taken together, several confounding and potentially contributing factors may have had an impact on the numerical OS-differences, and there is no indication of a difference in real treatment effect that may compromise biosimilarity. 2.5.4. Conclusions on the clinical efficacy The presented data on the primary endpoint from study FKB238-002 support similar efficacy between FKB238 and its reference product, EU-Avastin. 2.6. Clinical safety Medicinal product no longer authorised

Comparative safety data of FKB238 was derived from three clinical studies.The study designed to contribute key safety data was a randomised, double-blind, parallel study, conducted in 24 countries to compare the efficacy and safety of FKB238 to EU-Avastin when used in combination with paclitaxel and carboplatin in the first-line treatment of patients with advanced/recurrent non-squamous non-small cell lung cancer (NS-NSCLC; Study FKB238-002 ).

Prior to that, a single-dose PK study was conducted in the United Kingdom (UK) in healthy male subjects to compare the PK properties and safety of FKB238 with US-Avastin and EU-Avastin (Study

<div style=\"page-break-after: always\"></div>

FKB238-001 ). An additional PK study has been conducted, to meet the requirements of the Japanese Pharmaceuticals and Medical Devices Agency, to compare the PK characteristics and safety of FKB238 with those of EU-Avastin in Japanese healthy male subjects (Study FKB238-003 ).

Safety data are presented by study with no combined or integrated analyses of safety across studies planned or performed due to different treated study populations (NSCLC subjects versus healthy subjects) and different dosing regimens (single-dose versus multiple-dose).

## Patient exposure

Comparative clinical study FKB238-002 A summary of exposure, by study treatment, is presented for study FKB238-002 in Table 24. A total of 728 patients received at least 1 dose of IP (FKB238 or Avastin). Across both the FKB238 and Avastin arms, approximately half of patients had either an IP dose interruption or delay (184 [50.8%] and 198 [54.1%] patients, respectively. Most of these were IP delays, which were reported in 184 (50.8%) and 197 (53.8%) patients in the FKB238 and Avastin arms, respectively, with the majority of these having &lt;3 delays. Table 24: Extent of exposure: Safety Population (Study FKB238-002) AUC=area under the curve; CSR=clinical study report; SD=standard deviation. a Duration of exposure=(last dosing date - first dosing date + 21) / 7. For patients who died, were discontinued, or lost to follow-up prior to the end of the 21 days from last dose, duration was defined as (censoring date - first dosing date + 1) / 7, with censoring date as the earliest of the following dates (date of death, date of study discontinuation, date last known to be alive), as applicable. b Dose intensity=Cumulative dose level / ((last dosing date - first dosing date + 21) / 21). c Relative dose intensity was calculated as the dose intensity divided by the planned dose per cycle. Medicinal product no longer authorised

<!-- image -->

<!-- image -->

## Pharmacokinetic Studies FKB238-001 and FKB238-003

A total of 139 healthy male subjects received a single dose of FKB238 or Avastin, including 99 subjects in Study FKB238-001 (33 FKB238, 34 EU-Avastin, 32 US-Avastin) and 40 subjects in Study FKB238-003 (20 FKB238, 20 EU-Avastin).

## Baseline Demographics

Please refer to Table 14 and Table 15, Baseline section in the Clinical efficacy part for a tabular overview of Baseline demographics.

<div style=\"page-break-after: always\"></div>

The proportion of patients with any previous medical history was slightly higher in the FKB238 arm (27.2%) than in the Avastin arm (22.9%), with slight imbalances in the frequencies of previous medical history SOCs between the treatment arms. Slightly more patients in the FKB238 arm than in the Avastin arm had a previous medical history pertaining to cardiac disorders, (15 [4.1%] patients versus 9 [2.5%] patients, respectively). On the other hand, slightly fewer patients in the FKB238 arm than in the Avastin arm had a previous medical history of respiratory, thoracic and mediastinal disorders (9 [2.5%] patients versus 19 [5.2%] patients, respectively).

The proportion of patients with any current medical history was slightly higher in the FKB238 arm (89.8%) than in the Avastin arm (85.8%), with small imbalances in the frequencies of current medical history SOCs between the treatment arms. Of note, more patients in the FKB238 arm than in the Avastin arm had current medical histories in the SOC of respiratory, thoracic and mediastinal disorders (178 [48.9%] versus 139 [37.9%] patients, respectively). At the PT level, individual current medical histories were balanced across treatment arms, with the exceptions of cough (FKB238, 59 [16.2%]; Avastin, 31 [8.4%]) and dyspnoea (FKB238, 55 [15.1%]); Avastin, 31 [8.4%]).

<!-- image -->

Adverse events Comparative clinical Study FKB238-002 An overall summary of AEs for Study FKB238-002 is presented in Table 25. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 25: Overall summary of adverse events: Safety Population (Study FKB238-002)

<!-- image -->

|        | authorised   |
|--------|--------------|
| longer |              |
| no     |              |

<!-- image -->

CSR=clinical study report; CTCAE=Common Terminology Criteria for Adverse Events; IP=investigational product; TEAE=treatment-emergent adverse event; TESAE=treatment-emergent serious adverse event. a Patients with multiple events in the same category are counted only once in that category. Patients with events in ≥1 category are counted once in each of those categories. b As assessed by the investigator. An overall summary of AEs for Studies FKB238-001 and FKB238-003 is presented in the table below. Table 26: Overall summary of adverse events: Safety Population (Studies FKB238-001 and FKB238-003) Medicinal product no longer authorised

CSR=clinical study report; EU=European Union; SAE=serious adverse event; TEADR=treatment-emergent adverse drug reaction;

TEAE=treatment-emergent adverse event; US=United States.

TEADRs are defined as TEAEs where the relationship to study medication was recorded as 'related' or 'possibly related'.

<div style=\"page-break-after: always\"></div>

## Common adverse events

## Comparative clinical Study FKB238-002

A summary of TEAEs, by SOC and PT, is presented for Study FKB238-002 in Table 27.

Table 27: Treatment-emergent adverse events reported for ≥ 5% of patients in either treatment group: Safety Population (Study FKB238-002)

<!-- image -->

|           |        | authorised   |
|-----------|--------|--------------|
|           | longer |              |
|           | no     |              |
| product   |        |              |
| Medicinal |        |              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| authorised   |
|--------------|

<!-- image -->

CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities; PT=preferred term; SOC=system organ class; TEAE=treatment-emergent adverse event. TEAEs were coded using MedDRA Version 21.1. A summary of TEAEs, by SOC and PT, is presented for Studies FKB238-001 and FKB238-003 in Table 28. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 28: Treatment-emergent adverse events reported for ≥ 5% of subjects in any treatment group/study Safety Population (Studies FKB238-001 and FKB238-003)

<!-- image -->

CSR=clinical study report; EU=European Union; MedDRA=Medical Dictionary for Regulatory Activities; PT=preferred term; SOC=system organ class; TEAE=treatment-emergent adverse event; US=United States. Events ordered per overall SOC and PT frequency in Study FKB238-001. Source: Table 10 and Table 14.3.1.2.2.1, Study FKB238-001 CSR (Module 5.3.3.1); Table 10 and Errata Table 14.3.1.2.2.1, Study

TEAEs were coded using MedDRA Version 17.1 and Version 21.1 in Studies FKB238-001 and FKB238-003, respectively. FKB238-003 CSR (Module 5.3.5.4).

There was an imbalance in reported TEAEs between treatment arms in both PK-studies. Headache was a commonly reported TEAE and with highest frequency in the FKB238 arm (48.5% compared to 17.6% in

<div style=\"page-break-after: always\"></div>

the EU-Avastin arm and 31.3% in the US-Avastin arm). Headache was also the most common reported TEADR although with less prominent difference between the treatment arms. Regarding to the frequency of headache, elevations in the diastolic blood pressure were observed in the morning and in the evening across all treatment arms without a pattern. Other measurements (laboratory values, ECG, vital signs) were well balanced as well.

## Treatment-related adverse events

## Comparative clinical Study FKB238-002

A summary of TEADRs (considered causally related to IP, FKB238 or Avastin, by the investigator), by SOC and PT, is presented for Study FKB238-002 in Table 29.

<!-- image -->

Table 29: Treatment-emergent adverse drug reactions reported for ≥ 5% of patients in either treatment group: Safety Population (Study FKB238-002) CSR=clinical study report; IP=investigational product; MedDRA=Medical Dictionary for Regulatory Activities; PT=preferred term; SOC=system organ class; TEADR=treatment-emergent adverse drug reaction; TEAE=treatment-emergent adverse event. Events ordered per frequency in the FKB238 arm. TEADRs are defined as TEAEs considered causally related to IP (FKB238 or Avastin), as assessed by the investigator. TEAEs were coded using MedDRA Version 21.1. Source: Table 14.3.2.7, Study FKB238-002 CSR (Module 5.3.5.1). Medicinal product no longer authorised

A summary of TEADRs by SOC and PT, is presented for Studies FKB238-001 and FKB238-003 in Table 30.

<div style=\"page-break-after: always\"></div>

Table 30: Treatment-emergent adverse drug reactions reported for ≥ 5% of subjects in any treatment group in either study: Safety Population (Studies FKB238-001 and FKB238-003)

<!-- image -->

CSR=clinical study report; EU=European Union; MedDRA=Medical Dictionary for Regulatory Activities; PT=preferred term; SOC=system organ class; TEADR=treatment-emergent adverse drug reaction; TEAE=treatment-emergent adverse event; US=United States. Events ordered per overall SOC frequency in Study FKB238-001. TEADRs are defined as TEAEs where the relationship to study medication was recorded as 'related' or 'possibly related'. TEADRs were coded using MedDRA Version 17.1 and Version 21.1 in Studies FKB238-001 and FKB238-003, respectively. Source: Table 11 and Table 14.3.1.2.2.2, Study FKB238-001 CSR (Module 5.3.3.1); Table 12 and Table 14.3.1.2.2.2, Study FKB238-003 CSR (Module 5.3.5.4). Adverse events of special interest AEs of special interest were identified using a prospectively compiled list of medical concepts aligned with the list of important identified risks in the Avastin EU Risk Management Plan (RMP; Version 28.1), in order to reflect the expected class-related toxicities for an Avastin biosimilar. Comparative clinical Study FKB238-002: Analysis of adverse events by organ system or syndrome: Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 31: Summary of TEAEs of special interest: Safety Population (Study FKB238-002)

<!-- image -->

|        | authorised   |
|--------|--------------|
| longer |              |
| no     |              |

CTCAE ≥ grade 3 TEAEs were experienced by 3 (0.8%) patients in the FKB238 arm and 2 (0.5%) patients in the Avastin arm, respectively. TEAEs considered related to IP were experienced by 3 (0.8%) and 1 (0.3%) patients, respectively, and TEAEs considered related to study treatment (IP and/or any combination drugs) were experienced by 3 (0.8%) and 1 (0.3%) patients, respectively. One (0.3%) patient in each of the treatment arms discontinued IP due to arterial thromboembolic events, and 1 (0.3%) patient in each of treatment arms discontinued study treatment due to arterial thromboembolic events. One (0.3%) patient in each of the treatment arms experienced arterial thromboembolic events leading to death.

AE=adverse event; ATE=arterial thromboembolic events; CHF=congestive heart failure; CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities; TEAE=treatment-emergent adverse event. MedDRA version 21.1. Number (%) of patients are sorted alphabetically by TEAE of special interest. a Patients with multiple AEs are counted once for each medical concept. Source: Table 14.3.6.1, Study FKB238-002 CSR (Module 5.3.5.1). Arterial thromboembolic events TEAEs pertaining to the medical concept of arterial thromboembolic events are shown in Table 32. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 32: Summary of TEAEs pertaining to the medical concept of arterial thromboembolic events: Study FKB238-002 (Safety Population)

| Mledicalconcept               | Number(%o)ofpatients   | Number(%o)ofpatients   |
|-------------------------------|------------------------|------------------------|
| MedDRApreferred term          | FKB238 (N=362)         | Avastin (N=366)        |
| Arterial thromboembolicevents | 5(1.4)                 | 2 (0.5)                |
| Acute myocardial infarction   | 1 (0.3)                | 0                      |
| Amaurosis fugax               | 1(0.3)                 | 0                      |

<!-- image -->

AE=adverse event; CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities; TEAE=treatment-emergent adverse event. MedDRA version 21.1. Number (%) of patients with AEs are sorted alphabetically by preferred term. a Patients with multiple AEs are counted once for each medical concept and for each preferred term within each medical concept. Source: Table 14.3.6.1, Study FKB238-002 CSR (Module 5.3.5.1). Bleeding/haemorrhage CTCAE ≥ grade 3 bleeding/haemorrhage TEAEs were experienced by 6 (1.7%) patients in the FKB238 arm and 3 (0.8%) patients in the Avastin arm, respectively. TEAEs considered related to IP were experienced by 26 (7.2%) and 33 (9.0%) patients, respectively, and TEAEs considered related to study treatment (IP and/or any combination drugs) were experienced by 29 (8.0%) and 37 (10.1%) patients, respectively. Four (1.1%) patients in each of the treatment arms discontinued IP due to TEAEs pertaining to the medical concept of bleeding/haemorrhage, with 4 (1.1%) patients in each of the treatment arms also discontinuing study treatment due to bleeding/haemorrhage TEAEs. Two (0.6%) and 1 (0.3%) patients in the FKB238 and Avastin arms, respectively, experienced bleeding/haemorrhage TEAEs leading to death. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 33: Summary of TEAEs pertaining to the medical concept of bleeding/haemorrhage: Study FKB238-002 (Safety Population)

<!-- image -->

|           | longer   |
|-----------|----------|
|           | no       |
| product   |          |
| Medicinal |          |

AE=adverse event; CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities;

TEAE=treatment-emergent adverse event.

MedDRA version 21.1.

Number (%) of patients with AEs are sorted alphabetically by preferred term.

a Patients with multiple AEs are counted once for each medical concept and for each preferred term within each medical concept.

Source: Table 14.3.6.1, Study FKB238-002 CSR (Module 5.3.5.1).

Coagulation laboratory data were similar in both treatment arms.

<div style=\"page-break-after: always\"></div>

## Cardiac disorders (excluding congestive heart failure and arterial thromboembolic events)

CTCAE ≥ grade 3 TEAEs were experienced by 1 (0.3%) patient in the FKB238 arm and 3 (0.8%) patients in the Avastin arm, respectively. TEAEs considered related to IP were experienced by 2 (0.6%) and 9 (2.5%) patients, respectively, with TEAEs considered related to study treatment (IP and/or any combination drugs) experienced by 5 (1.4%) and 13 (3.6%) patients, respectively. One (0.3%) patient in each of the treatment arms discontinued IP due to TEAEs pertaining to the medical concept of cardiac disorders, with 1 (0.3%) patient in each of the treatment arms also discontinuing study treatment due to such events. No patients in the FKB238 arm and 1 (0.3%) patient in the Avastin arm experienced cardiac disorder TEAEs leading to death.

<!-- image -->

Table 34: Summary of TEAEs pertaining to the medical concept of cardiac disorders (excluding congestive heart failure and arterial thromboembolic events): Study FKB238-002 (Safety Population) AE=adverse event; CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities; TEAE=treatment-emergent adverse event. MedDRA version 21.1. Number (%) of patients with AEs are sorted alphabetically by preferred term. Medicinal product no longer authorised a Patients with multiple AEs are counted once for each medical concept and for each preferred term within each medical concept.

## Fistula (excluding gastrointestinal)

Two patients in the FKB238 arm experienced serious CTCAE grade 2 events of oesophagobronchial fistula that were considered related to IP and combination drugs and led to permanent discontinuation of both IP and combination drugs. The events were reported as not resolved in 1 patient and recovered/resolved with sequelae in the other patient. One patient in the Avastin arm experienced a non-serious CTCAE grade 1 event of tracheo-oesophageal fistula that was not considered related to IP or combination drugs, but led to dose delay for both IP and combination drugs. The event was reported as not recovered/resolved.

<div style=\"page-break-after: always\"></div>

Table 35: Summary of TEAEs pertaining to the medical concept of fistula (excluding gastrointestinal): Study FKB238-002 (Safety Population)

| Mledicalconcept                      | Number(%o)ofpatients   | Number(%o)ofpatients   |
|--------------------------------------|------------------------|------------------------|
| MedDRAprefenred tenm                 | FKB238 (N=362)         | Avastin (N=366)        |
| Fistula (excluding gastrointestinal) | 2(0.6)                 | 1(0.3)                 |
| Oesophagobronchial fistula           | 2(0.6)                 | 0                      |
| Tracheo-oesophageal fistula          |                        | 1(0.3)                 |

<!-- image -->

| Medicinal   |
|-------------|

AE=adverse event; ; CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities; TEAE=treatment-emergent adverse event. MedDRA version 21.1. Number (%) of patients with AEs are sorted alphabetically by preferred term. a Patients with multiple AEs are counted once for each medical concept and for each preferred term within each medical concept. Source: Table 14.3.6.1, Study FKB238-002 CSR (Module 5.3.5.1). Gallbladder perforation The only reported event relating to gallbladder perforation was a non-serious CTCAE grade 3 event of gallbladder abscess in the Avastin arm, which was not considered related to IP or combination drugs, but led to permanent discontinuation of IP. The outcome for the event was recovered/resolved. Gastrointestinal perforation CTCAE ≥ grade 3 gastrointestinal perforation TEAEs were experienced by 1 (0.3%) patient in the FKB238 arm and 3 (0.8%) patients in the Avastin arm, respectively. TEAEs considered related to IP were experienced by 2 patients in each of the treatment arms (0.6% and 0.5%, respectively), and TEAEs considered related to study treatment (IP and/or any combination drugs) were experienced by 2 patients in each of the treatment arms (0.6% and 0.5%, respectively). Three (0.8%) and 4 (1.1%) patients, respectively, discontinued IP due to TEAEs pertaining to the medical concept of gastrointestinal perforation, with 3 (0.8%) and 4 (1.1%) patients also discontinuing study treatment due to such events. One patient (0.3%) in each of the treatment arms experienced gastrointestinal perforation TEAEs leading to death. Table 36: Summary of TEAEs pertaining to the medical concept of gastrointestinal perforation: Study FKB238-002 (Safety Population) Medicinal product no longer authorised

AE=adverse event; CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities;

TEAE=treatment-emergent adverse event.

MedDRA version 21.1.

Number (%) of patients with AEs are sorted alphabetically by preferred term.

a Patients with multiple AEs are counted once for each medical concept and for each preferred term within each medical concept.

<div style=\"page-break-after: always\"></div>

Source: Table 14.3.6.1, Study FKB238-002 CSR (Module 5.3.5.1).

## Hypersensitivity reactions/infusion reactions

CTCAE ≥ grade 3 TEAEs were experienced by 7 (1.9%) patients in the FKB238 arm and 5 (1.4%) patients in the Avastin arm, respectively. TEAEs considered related to IP were experienced by 12 (3.3%) and 10 (2.7%) patients, respectively, and TEAEs considered related to study treatment (IP and/or any combination drugs) were experienced by 37 (10.2%) and 28 (7.7%) patients, respectively. Two (0.6%) and 1 (0.3%) patients, respectively, discontinued IP due to TEAEs pertaining to the medical concept of hypersensitivity reactions/infusion reactions, with 3 (0.8%) and 1 (0.3%) patients also discontinuing study treatment due to such TEAEs. Two (0.6%) and 3 (0.8%) patients in the FKB238 and Avastin arms, respectively, experienced hypersensitivity reactions/infusion reactions TEAEs leading to death.

<!-- image -->

|           | longer     |
|-----------|------------|
|           | product no |
| Medicinal |            |

<div style=\"page-break-after: always\"></div>

| Respiratory failure   | 2 (0.6)   | 3 (0.8)   |
|-----------------------|-----------|-----------|
| Rhinitis allergic     | 1 (0.3)   | 1 (0.3)   |
| Skin erosion          | 1 (0.3)   | 0         |
| Stomatitis            | 8 (2.2)   | 10 (2.7)  |
| Urticaria             | 2 (0.6)   | 2 (0.5)   |
| Wheezing              | 1 (0.3)   | 0         |

AE=adverse event; CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities; TEAE=treatment-emergent adverse event.

<!-- image -->

MedDRA version 21.1. Number (%) of patients with AEs are sorted alphabetically by preferred term. a Patients with multiple AEs are counted once for each medical concept and for each preferred term within each medical concept. Source: Table 14.3.6.1, Study FKB238-002 CSR (Module 5.3.5.1). There were slightly more patients in the FKB238 arm compared to Avastin arm that experienced hypersensitivity/IRR events (48 vs 43 patients respectively). Hypertension CTCAE ≥ grade 3 TEAEs were experienced by 14 (3.9%) patients in the FKB238 arm and 21 (5.7%) patients in the Avastin arm, respectively. TEAEs considered related to IP were experienced by 24 (6.6%) and 27 (7.4%) patients, respectively, and TEAEs considered related to study treatment (IP and/or any combination drugs) were experienced by 24 (6.6%) and 27 (7.4%) patients, respectively. One (0.3%) and 4 (1.1%) patients, respectively, discontinued IP due to TEAEs pertaining to the medical concept of hypertension, with 1 (0.3%) and 4 (1.1%) patients also discontinuing study treatment due to such TEAEs. No patients in either treatment arm experienced TEAEs pertaining to the medical concept of hypertension that led to death. Table 38: Summary of TEAEs pertaining to the medical concept of hypertension: Study FKB238-002 (Safety Population) AE=adverse event; CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities; TEAE=treatment-emergent adverse event. MedDRA version 21.1. Number (%) of patients with AEs are sorted alphabetically by preferred term. Medicinal product no longer authorised a Patients with multiple AEs are counted once for each medical concept and for each preferred term within each medical concept.

Source: Table 14.3.6.1, Study FKB238-002 CSR (Module 5.3.5.1).

Vital signs evaluations, which included assessments of blood pressure, were similar in both treatment arms. Thus, the slight imbalance in the reporting of hypertension events between the treatment arms was not supported by the objective data.

## Necrotising fasciitis

No TEAEs were retrieved using this search.

<div style=\"page-break-after: always\"></div>

## Neutropenia

CTCAE ≥ grade 3 TEAEs were experienced by 80 (22.1%) patients in the FKB238 arm and 93 (25.4%) in the Avastin arm, respectively. TEAEs considered related to IP were experienced by 23 (6.4%) and 41 (11.2%) patients, respectively, and TEAEs considered related to study treatment (IP and/or any combination drugs) were experienced by 135 (37.3%) and 165 (45.1%) patients, respectively. One (0.3%) and 0 patients, respectively, discontinued IP due to TEAEs pertaining to the medical concept of neutropenia, with 6 (1.7%) and 1 (0.3%) patients discontinuing study treatment due to such TEAEs. No patients in either treatment arm experienced TEAEs pertaining to the medical concept of neutropenia leading to death.

| longer   |
|----------|

Source: Table 14.3.6.1, Study FKB238-002 CSR (Module 5.3.5.1).

CTCAE ≥ grade 3 TEAEs were experienced by 10 (2.8%) patients in the FKB238 arm and 3 (0.8%) patients in the Avastin arm, respectively. TEAEs considered related to IP were experienced by 13 (3.6%) and 14 (3.8%) patients, respectively, with TEAEs considered related to study treatment (IP and/or any combination drugs) experienced by 125 (34.5%) and 124 (33.9%) patients, respectively. One (0.3%) and 0 patients, respectively, discontinued IP due to TEAEs pertaining to the medical concept of peripheral sensory neuropathy, with 10 (2.8%) and 12 (3.3%) patients also discontinuing study treatment due to such events. No patients in either treatment arm experienced TEAEs pertaining to the medical concept of peripheral sensory neuropathy that led to death.

Table 39: Summary of TEAEs pertaining to the medical concept of neutropenia: Study FKB238 002 (Safety Population) AE=adverse event; CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities; TEAE=treatment-emergent adverse event. MedDRA version 21.1. Number (%) of patients with AEs are sorted alphabetically by preferred term. a Patients with multiple AEs are counted once for each medical concept and for each preferred term within each medical concept. Osteonecrosis of the jaw TEAEs pertaining to the medical concept of osteonecrosis of the jaw were experienced by 1 (0.3%) patient (PT: pain in jaw) in the FKB238 arm and 5 (1.4%) patients in the Avastin arm. All of the events were non-serious and of CTCAE grade 1 or 2, and none led to discontinuation of study treatment. None of these events are considered to be consistent with the medical concept of osteonecrosis of the jaw. Ovarian failure Of the pre-specified PTs for this medical concept, none was reported in Study FKB238-002. Peripheral sensory neuropathy Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 40: Summary of TEAEs pertaining to the medical concept of peripheral sensory neuropathy: Study FKB238-002 (Safety Population)

| authorised   |
|--------------|

CTCAE ≥ grade 3 TEAEs were experienced by 1 (0.3%) patient in the FKB238 arm and 6 (1.6%) patients in the Avastin arm, respectively. TEAEs considered related to IP were experienced by 17 (4.7%) and 28 (7.7%) patients, respectively, with TEAEs considered related to study treatment (IP and/or any combination drugs) experienced by 17 (4.7%) and 30 (8.2%) patients, respectively. One (0.3%) and 2 (0.5%) patients, respectively, discontinued IP due to proteinuria TEAEs, with 1 (0.3%) and 2 (0.5%) patients discontinuing study treatment due to such events. No patients in either treatment arm experienced TEAEs pertaining to the medical concept of proteinuria that led to death.

AE=adverse event; CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities; TEAE=treatment-emergent adverse event. MedDRA version 21.1. Number (%) of patients with AEs are sorted alphabetically by preferred term. a Patients with multiple AEs are counted once for each medical concept and for each preferred term within each medical concept. Source: Table 14.3.6.1, Study FKB238-002 CSR (Module 5.3.5.1). Posterior reversible encephalopathy syndrome Only 1 patient in the FKB238 arm experienced a TEAE pertaining to the medical concept of PRES. This was a serious CTCAE grade 3 event which was considered related to IP but not to combination drugs and led to permanent discontinuation of IP. The event started 107 days from the first dose of IP and had an outcome of recovered/resolved with sequelae. This patient had clinically relevant high blood pressure 85 days prior to the event, but not on the day prior to the event. Vital signs assessments were not recorded for this patient during the event. Proteinuria Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 41: Summary of TEAEs pertaining to the medical concept of proteinuria: Study FKB238 002 (Safety Population)

| Mledicalconcept     | Number(o%o)ofpatients   | Number(o%o)ofpatients   |
|---------------------|-------------------------|-------------------------|
| MedDRAprefenredterm | FKB238 (N=362)          | Avastin (N=366)         |
| Proteinuria         | 27 (7.5)                | 41 (11.2)               |
| Albuminunia         | 1(0.3)                  | 0                       |
| Haemoglobinuria     | 1(0.3)                  | 0                       |

| Corpulmonale           | 1 (0.3)   | 0        |
|------------------------|-----------|----------|
| Diastolic dysfunction  | 1 (0.3)   | 0        |
| Dyspnoea               | 18 (5.0)  | 29 (7.9) |
| Dyspnoea exertional    | 1(0.3)    | 0        |
| Hypoxia                | 0         | 1(0.3)   |
| Pulmonary hypertension | 1 (0.3)   | 1(0.3)   |

AE=adverse event; CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities; TEAE=treatment-emergent adverse event. MedDRA version 21.1. Number (%) of patients with AEs are sorted alphabetically by preferred term. a Patients with multiple AEs are counted once for each medical concept and for each preferred term within each medical concept. Source: Table 14.3.6.1, Study FKB238-002 CSR (Module 5.3.5.1). Pulmonary haemorrhage TEAEs pertaining to the medical concept of pulmonary haemorrhage were experienced by 3 (0.8%) patients in the FKB238 arm and 2 (0.5%) patients in the Avastin arm (all reported under the PT of pulmonary haemorrhage). Four of the patients experienced serious events of CTCAE grade 5, with the remaining patient (Avastin arm) experiencing a non-serious CTCAE grade 1 event which led to permanent discontinuation of IP. Pulmonary hypertension CTCAE ≥ grade 3 TEAEs were experienced by 4 (1.1%) patients in the FKB238 arm and 6 (1.6%) patients in the Avastin arm, respectively. TEAEs considered related to IP were experienced by 1 (0.3%) and 4 (1.1%) patients, respectively, with TEAEs considered related to study treatment (IP and/or any combination drugs) experienced by 6 patients in each treatment arm (1.7% and 1.6% of patients, respectively). No patients in either treatment arm discontinued IP or study treatment due to TEAEs pertaining to the medical concept of pulmonary hypertension. Three (0.8%) and 1 (0.3%) patients in the FKB238 and Avastin arms, respectively, experienced TEAEs pertaining to the medical concept of pulmonary hypertension that led to death. Table 42: Summary of TEAEs pertaining to the medical concept of pulmonary hypertension: Study FKB238-002 (Safety Population) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

AE=adverse event; CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities; TEAE=treatment-emergent adverse event.

MedDRA version 21.1.

Number (%) of patients with AEs are sorted alphabetically by preferred term.

a Patients with multiple AEs are counted once for each medical concept and for each preferred term within each medical concept. Source: Table 14.3.6.1, Study FKB238-002 CSR (Module 5.3.5.1).

## Surgery and wound healing complications

Only 2 patients (in the Avastin arm) experienced TEAEs pertaining to the medical concept of surgery and wound healing complications. Both patients experienced non-serious CTCAE grade 2 events of impaired healing. One of the events was considered related to IP and led to a dose delay of IP.

<!-- image -->

<!-- image -->

| product   |
|-----------|

## Serious adverse event/deaths/other significant events

Thrombotic microangiopathy This pre-specified PT was not reported in this study. Venous thromboembolic events CTCAE ≥ grade 3 TEAEs were experienced by 10 (2.8%) patients in the FKB238 arm and 8 (2.2%) patients in the Avastin arm, respectively. TEAEs considered related to IP were experienced by 6 (1.7%) and 2 (0.5%) patients, respectively, with TEAEs considered related to study treatment (IP and/or any combination drugs) experienced by 8 (2.2%) and 2 (0.5%) patients, respectively. Three (0.8%) and 1 (0.3%) patients, respectively, discontinued IP due to venous thromboembolic events, with 3 (0.8%) and 1 (0.3%) patients, discontinuing study treatment due to such events. Two (0.6%) and 3 (0.8%) patients in the FKB238 and Avastin arms experienced venous thromboembolic events leading to death. Table 43: Summary of TEAEs pertaining to the medical concept of venous thromboembolic events: Study FKB238-002 (Safety Population) AE=adverse event; CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities; TEAE=treatment-emergent adverse event. MedDRA version 21.1. Number (%) of patients with AEs are sorted alphabetically by preferred term. a Patients with multiple AEs are counted once for each medical concept and for each preferred term within each medical concept. Source: Table 14.3.6.1, Study FKB238-002 CSR (Module 5.3.5.1). Medicinal product no longer authorised

## Deaths

Pharmacokinetic Studies FKB238-001 and FKB238-003

There were no deaths during Studies FKB238-001 and FKB238-003.

<div style=\"page-break-after: always\"></div>

## Comparative clinical Study FKB238-002

## Overall summary of deaths

All deaths in Study FKB238-002 are presented for the Safety Population in Table 44, and TEAEs leading to death are summarised by SOC and PT in Table 45.

As of data cut-off, there was a numeric imbalance in the number of deaths observed between the FKB238 arm (195 [53.9%] patients) and the Avastin arm (177 [48.4%] patients).

Several factors contributed to the imbalance in deaths between the treatment arms.

Baseline data for the ITT-population show some imbalances in demography and baseline characteristics (more current smokers, more patients with a past and current medical history of cardiovascular conditions, more patients with current respiratory conditions, and smaller number of patients who received subsequent anti-cancer therapy in the FKB238 arm), indicating that patients in the FKB238 arm had a higher background risk of death than those in the Avastin arm. Fewer patients withdrew consent to follow-up in the FKB238 arm compared to the Avastin arm, 36 [9.9%] patients versus 49 [13.4%] patients, respectively. TEAEs leading to discontinuation of study treatment were reported for a higher proportion of withdrawal of consent (WoC)-patients in the Avastin arm than in the FKB238 arm (8 [16.3%] versus 2 [5.7%] patients, respectively), as were TEAEs with Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher (24 [49.0%] versus 14 [40.0%] patients, respectively) and treatment-emergent SAEs (11 [22.4%] versus 5 [14.3%] patients, respectively). Baseline characteristics for the 85 patients who discontinued due to WoC (FKB238, 36; Avastin, 49) showed that a higher proportion of patients had AJCC stage IV disease at diagnosis in the Avastin arm than in the FKB238 arm (47 [95.9%] versus 31 [86.1%] patients, respectively). Additionally, a higher proportion of patients were aged ≥ 65 years in the Avastin arm than in the FKB238 arm (18 [36.7%] versus 10 [27.8%] patients, respectively), with 6 (12.2%) patients in the Avastin arm aged between 75 and 84 years compared to no patients in the FKB238 arm. The proportion of current smokers for this group of patients was also slightly higher in the Avastin arm than in the FKB238 arm (19 [38.8%] versus 12 [33.3%] patients, respectively), as was the proportion of patients with an ECOG PS of 1 (24 [49.0%] versus 17 [47.2%] patients, respectively). More patients in the Avastin arm than the FKB238 arm withdrew following AEs and PD. Overall, patients in the Avastin arm who withdrew consent to the study had a worse AE profile and worse prognostic factors than those in the FKB238 arm. In order to investigate the impact of the missing survival data on the reliability of the OS estimation, the MAH performed a post-hoc sensitivity analysis in which discontinuation from the study due to WoC was considered as a death event. The results of this sensitivity analysis are shown in the KM plot below. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

| no      |
|---------|
| product |

Source: Table 34, Study FKB238-002 CSR (Module 5.3.5.1).

Figure 14: Kaplan-Meier plot of OS considering patients who discontinued study due to WoC as event (ITT Population) Table 44: All deaths: Safety Population (Study FKB238-002) AE=adverse event; CSR=clinical study report; IP=investigational product. Study treatment=IP and/or any combination drugs (paclitaxel and carboplatin). a As assessed by the investigator. b Deaths not related to the disease under investigation for which no AE with an outcome of death was recorded and deaths with an unknown relationship to the disease under investigation. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## TEAEs with a fatal outcome

<!-- image -->

Table 45: Treatment-emergent adverse events leading to death: Safety Population (Study FKB238-002)

<!-- image -->

|           | longer   |
|-----------|----------|
|           | no       |
| product   |          |
| Medicinal |          |

CSR=clinical study report; MedDRA=Medical Dictionary for Regulatory Activities; PT=preferred term; SOC=system organ class; TEAE=treatment-emergent adverse event.

TEAEs were coded using MedDRA Version 21.1.

Source: Table 35, Study FKB238-002 CSR (Module 5.3.5.1).

The PTs reported in the cardiac disorders SOC are consistent with the expected safety profile of Avastin (acute coronary syndrome, acute myocardial infarction) or were found to represent terminal events in patients with lung cancer (cardio-respiratory arrest, cor pulmonale).

Fatal events in the SOC of general disorders and administration site conditions were mainly driven by deaths that were reported conservatively as AEs by the investigator because the patient died unattended

<div style=\"page-break-after: always\"></div>

at home without any preceding AEs or objective evidence of disease progression. Autopsies were not performed in any of these cases. The Study FKB238-002 protocol states 'Events, which are unequivocally due to disease progression, should not be reported as an AE during the study'. In each case where death was reported as a SAE due to underlying disease the investigator was asked if they considered the event to be unequivocally due to disease progression. If the event was due to underlying disease but there was no objective evidence of progression the event was to be reported as an SAE according to the protocol. It is acknowledged that there are challenges in assessing the cause of death and the causality to the given study treatment in the absence of autopsies, and especially in the cases of sudden death at home.

The fatal PTs reported in the respiratory, thoracic and mediastinal disorders SOC are mainly consistent with the expected safety profile of Avastin (pulmonary embolism, pulmonary haemorrhage, haemoptysis), or the underlying lung cancer can cause the events (acute respiratory failure, dyspnoea, respiratory failure). The 53 patients who experienced TEAEs leading to death were analysed in detail for any factors that could support interpretation of the event and grouped into mutually exclusive categories accordingly. In 6 cases, the report describes death of unknown cause (e.g. AE of 'Death' or 'Sudden death') where no further information is available. A further 6 case reports describe death due to NSCLC only, and in 16 cases the report describes an event that is consistent with a terminal event in advanced NSCLC (e.g., respiratory failure, general deterioration, dyspnoea, cor pulmonale, pneumonia aspiration, cardio-respiratory arrest, pulmonary haemorrhage). In 17 reports, the event is completely consistent with the known safety profile of Avastin. For the 8 remaining case reports (4 FKB238, 4 Avastin), no clear alternative causal factors were identified and they described events that were not contained in the SmPC for Avastin. Narratives for these 8 cases were provided. TEAEs with a fatal outcome: overall conclusions Due to the fact that 18 more deaths overall were observed in the FKB238 arm during the study, the TEAEs with a fatal outcome were thoroughly reviewed to identify any potential safety concerns. The baseline and disease characteristics of the patients who experienced a TEAE with a fatal outcome were fairly balanced between study arms with observed differences in both directions. Compared to the overall study population, there is a trend that patients experiencing TEAE with fatal outcome included more current smokers, more patients with a past and current medical history of cardiovascular conditions, more patients with current respiratory conditions, and smaller number of patients who received subsequent anti-cancer therapy in the FKB238 arm, indicating that patients in the FKB238 arm had a higher background risk of death than those in the Avastin arm. It is common that the performance status declines faster during anticancer treatments in patients with advanced cancer and with overall poor performance status at baseline. A summary of narratives for all fatal TEAEs was submitted and the Applicant did not amend (upgrade or downgrade) the investigator's causality assessment for any event. Also individual summary narratives were provided. Medicinal product no longer authorised

Of the 6 patients with death of unknown cause, none had progressive disease and none were considered related to IP. Two patients in the FKB238 arm had a current respiratory medical history, and no patient had a current or past cardiovascular medical history or past respiratory medical history. Of the 16 patients categorized to terminal events in the context of advanced non-small cell lung cancer, all the reported PT were in accordance with the symptoms and conditions belonging to terminal phase. Most of the patients had current cardiovascular and/or respiratory conditions. In 15 of the 16 patients, fatal TEAE was considered causally not to be related to IP. The cases were accordingly reported as TEAEs.

<div style=\"page-break-after: always\"></div>

Of the 6 patients categorized as death due to underlying NSCLC, all 6 had Stage IV disease at original diagnosis. Of them only 2 patients in the FKB238 arm had PD prior to death. Most of the patients had current cardiovascular and/or respiratory conditions. In 4 of the 6 cases, fatal TEAE was considered causally not to be related to IP.

Of the 17 patients categorized as fatal TEAEs consistent with safety profile of bevacizumab, two patients had PD prior to death and 15 patients experienced fatal TEAEs considered not to be related to IP. Most of the patients had current cardiovascular and/or respiratory conditions. The reported PTs (Acute coronary syndrome, Acute myocardial infarction, Cerebrovascular accident, Haemorrhagic stroke, Ischemic stroke and Pulmonary embolism) were balanced between the study arms. Even though some of the TEAEs with fatal outcome labelled as 'death due to underlying NSCLC' and terminal events in advanced NSCLC' are also possibly events consistent with known safety profile of Avastin, such as 'dyspnoea' and pulmonary haemorrhage', the distribution over treatment arms remain relatively similar

<!-- image -->

Of the 8 patients with fatal TEAEs with no clear alternative causal factors, 2 patients had PD prior to death and all cases were considered not to be related to IP. Most of the patients had current cardiovascular and/or respiratory conditions. The FKB238-002 was a multi-centre study conducted in several geographic areas in 146 centres in 24 countries, of which 136 centres randomised patients. The distribution of TEAEs, TESAEs and fatal TEAEs were balanced across the study sites and by region and centre. Serious adverse events Pharmacokinetic Studies FKB238-001 and FKB238-003 No SAEs were reported in Studies FKB238-001 and FKB238-003. Comparative clinical Study FKB238-002 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 46: Treatment-emergent serious adverse events reported in at least 3 patients in either treatment group: Safety Population (Study FKB238-002)

<!-- image -->

|         |           | authorised   |
|---------|-----------|--------------|
|         | no longer |              |
| product |           |              |

The incidence of individual TEAEs was similar between the treatment arms, although slightly more patients experienced TEAEs of neutropenia in the Avastin arm (18 [4.9%] patients) than in the FKB238 arm (7 [1.9%] patients).

<div style=\"page-break-after: always\"></div>

## Laboratory findings

## Comparative clinical Study FKB238-002

## Haematology

Across both the FKB238 and Avastin treatment arms, there were minor fluctuations in mean haematology values over time, particularly in the first cycles when chemotherapy was administered concomitantly. Values for each haematological parameter were generally similar across both treatment arms.

For most haematology parameters, only small proportions (&lt;10%) of patients with CTCAE grade 0 or 1 at baseline worsened to CTCAE grade 3 or 4 on treatment in both treatment arms. A notable exception was for decreased neutrophil count, in which 19 (5.3%) and 42 (11.7%) patients in the FKB238 and Avastin arms, respectively, with CTCAE grade 0 at baseline shifted to CTCAE grade 4 on treatment. A total of 68 (19.0%) and 61 (17.0%) patients, respectively, with CTCAE grade 0 at baseline shifted to CTCAE grade 3 on treatment. Clinically relevant abnormal haematology values were common during the study in both treatment arms, with a similar incidence of TEAEs pertaining to abnormal haematology values reported in both treatment arms, with the exception of neutropenia (reported for 109 [30.1%] and 145 [39.6%] patients, the FKB238 and Avastin arms, respectively) and thrombocytopenia (44 [12.2%] and 66 [18.0%] patients, respectively). Other common abnormal haematology values with similar distribution between treatment arms were anaemia (reported for 105 [29.0%] and 119 [32.5%] patients, respectively) and leukopenia (reported for 43 [11.9%] and 50 [13.7%] patients, respectively). Clinical chemistry Across both the FKB238 and Avastin treatment arms, generally minor fluctuations in mean clinical chemistry values over time were observed. For all clinical chemistry parameters, only small proportions (&lt;10%) of patients with CTCAE grade 0 or 1 at baseline worsened to CTCAE grade 3 or 4 on treatment in both treatment arms. Clinically relevant abnormal clinical chemistry values were common during the study, with a similar incidence of TEAEs pertaining to abnormal clinical chemistry values reported in both treatment arms, with the exception of blood lactate dehydrogenase increased, which was reported for fewer patients in the FKB238 arm than in the Avastin arm (6 [1.7%] versus 18 [4.9%] patients, respectively). Other common abnormal clinical chemistry values with similar distribution between treatment arms were alanine aminotransferase increased (reported for 38 [10.5%] and 35 [9.6%] patients, respectively) and gamma glutamyltransferase increased (reported for 38 [10.5%] and 31 [8.5%] patients, respectively). In each of the FKB238 and Avastin treatment arms, 1 SAE of potential Hy's Law was identified based on reported AE verbatim terms of 'Hys law' (PTs of drug-induced liver injury were reported). Laboratory results of 2 additional patients fulfilled Hy's law criteria on 1 or more occasions (one in each treatment arm); however, AEs of Hy's law were not reported for either of these patients. Medicinal product no longer authorised

## Vital signs

In Study FKB238-002, across both the FKB238 and Avastin treatment arms, there were only minor changes in vital signs parameters over time. The incidence of clinically relevant vital signs values was low in both treatment arms, with a similar incidence of TEAEs pertaining to abnormal vital sign values reported in both treatment arms.

<div style=\"page-break-after: always\"></div>

## Electrocardiogram

In Study FKB238-002, there were no notable differences between the treatment arms in ECG findings. Only small proportions of patients in the FKB238 and Avastin treatment arms with a normal ECG at baseline had an ECG that worsened to an abnormal, clinically relevant finding at the end of treatment (6/223 [2.7%] and 4/193 [2.1%] patients, respectively). The incidence of clinically relevant ECG values was low in both treatment arms, with a similar incidence of TEAEs pertaining to abnormal ECG values reported in both treatment arms. These included TEAEs of electrocardiogram QT prolonged (0.6% and 0.8% of patients in the FKB238 and Avastin arms, respectively), electrocardiogram QT shortened (0.3% and 0%), and electrocardiogram repolarisation abnormality (0.8% and 1.1%). Additional reported TEAEs within the SOC of cardiac disorders are discussed under the TEAE of special interest medical concepts.

The extent of the evaluation of relative immunogenicity was based on the following considerations:

Physical examination In Study FKB238-002, the majority of patients in both treatment arms had normal findings on physical examination at baseline. The only notable exception was for the respiratory system, for which approximately half of patients had an abnormal baseline assessment in both treatment arms. In both treatment arms, only small numbers of patients (&lt;16%) with a normal baseline physical examination had an abnormal finding during treatment. Of note, per the protocol any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment was to be reported as an AE. Left ventricular ejection fraction In Study FKB238-002, there were no notable differences between the treatment arms in LVEF findings. Of the patients with a post-baseline LVEF assessment, only 1 patient (in the Avastin arm) had an LVEF decrease of ≥ 10 percentage points and an absolute value of &lt;50%, and across both treatment arms, small numbers of patients had an LVEF decrease of ≥ 15 percentage points and an absolute value of ≥ 50% (7 [1.9%] and 3 [0.8%] patients, respectively). Pharmacokinetic Studies FKB238-001 No notable trends were observed in clinical laboratory data in Study FKB238-001. There were a few variations in the mean values for the haematology, biochemistry, and urinalysis parameters when compared to baseline evaluations, but no notable trends were observed across the 3 treatment groups. Safety in special populations The effect of intrinsic factors on the safety of FKB238 has not been formally investigated. Immunogenicity The applicant submitted an Integrated Summary of Immunogenicity (ISI). Medicinal product no longer authorised

· Nature of risks identified for the reference medicinal product bevacizumab (Avastin) in different populations.

· Sensitivity of methodology to detect clinically relevant differences in immunogenicity between the biosimilar and reference medical product, particularly in terms of the need to apply suitably drug and target tolerant ADA (anti-drug antibodies) and Nab (neutralising Anti-drug antibody) assays.

- Scale of product quality differences and the associated uncertainty about impact on immunogenicity-related risks.

• Responses received from concerned regulatory agencies during clinical development of FKB238.

<div style=\"page-break-after: always\"></div>

## FKB238-002 study in NS-NSCLC patients

Table 47: ADA sampling time-points in study FKB238-002

<!-- image -->

| Day   | Study Treatment Period (all visits within ± 3 days of schedule)   | Study Treatment Period (all visits within ± 3 days of schedule)   | Study Treatment Period (all visits within ± 3 days of schedule)   | Study Treatment Period (all visits within ± 3 days of schedule)   | Study Treatment Period (all visits within ± 3 days of schedule)   | Study Treatment Period (all visits within ± 3 days of schedule)   | Study Treatment Period (all visits within ± 3 days of schedule)   | Study Treatment Period (all visits within ± 3 days of schedule)   | Study Treatment Period (all visits within ± 3 days of schedule)   | Study treatment disconti- nuation (±7 days)   | Follow-up   |
|-------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-----------------------------------------------|-------------|
| Day   | Cycle 1                                                           | Cycle 1                                                           | Cycle 1                                                           | Cycle 2 Day 1                                                     | Cycle 3 Day 1                                                     | Cycle 4 Day 1                                                     | Cycle 5 Day 1                                                     | Cycle 6 Day 1                                                     | Cycle 7 & sub- sequent cycles Day 1                               | Study treatment disconti- nuation (±7 days)   | Follow-up   |
| Day   | Day 1                                                             | Day 8                                                             | Day 15                                                            | Cycle 2 Day 1                                                     | Cycle 3 Day 1                                                     | Cycle 4 Day 1                                                     | Cycle 5 Day 1                                                     | Cycle 6 Day 1                                                     | Cycle 7 & sub- sequent cycles Day 1                               | Study treatment disconti- nuation (±7 days)   | Follow-up   |
|       |                                                                   | 3                                                                 | 4                                                                 | 5                                                                 | 6                                                                 | 7                                                                 | 8                                                                 | 9                                                                 | Visit 10                                                          |                                               |             |

|           | product   |
|-----------|-----------|
| Medicinal |           |

A total of 731 eligible patients were randomly assigned in a 1:1 ratio to receive either: · FKB238 group: paclitaxel + carboplatin (combination drugs) + FKB238; or · Avastin group: paclitaxel + carboplatin (combination drugs) + EU-Avastin Number of subjects for whom ADA samples were available (table below). Table 48: ADA test results for study FKB238-002 as proportion of number of patients treated Medicinal product no longer authorised 1 2 3 4

Source: Quality issue report 174758, Table 14.1.1 Patient Disposition, CSR Study FKB238-002, Module 5.3.5.1,

adis,sas7bdat.

## Proportion of false positives in ADA sample testing

Based on the assay cut points shown, the overall (i.e. including pre- and post-treatment samples) False Positive Error Rate (FPER) was 60.5% in the FKB238 treatment group and 61.3% in the EU-Avastin treatment group respectively (as shown in the table below).

<div style=\"page-break-after: always\"></div>

Table 49: False positive rate for ADA test results in study FKB238-002

|                                      | Treatment group   | Treatment group   | Overall   |
|--------------------------------------|-------------------|-------------------|-----------|
| Statistics                           | FKB238            | EU-Avastin        |           |
| Total number of samples screened     | 1442              | 1457              | 2899      |
| Number of samples screened Positive  | 884               | 906               | 1790      |
| Number of samples confirmed Positive | 11                | 13                | 24        |
| Number samples confirmed Negative    | 871               | 891               | 1762      |

<!-- image -->

a Screening False Positive rate = (No. of samples confirmed negative / No. of samples screened positive) x 100 b FPER = [(# of samples screened positive - # of samples confirmed positive) / Total sample #] x 100 c Confirmatory cut point was based on a 1% false positive rate with modified outlier exclusion approach Source: CSR Study FKB238-002, Module 5.3.5.1, adis,sas7bdat. Samples with no reportable value are removed from this calculation; 6 samples for screening assay, 4 samples for confirmatory assay due to insufficient volume. The false positive error rate (FPER) was much lower for the pre-dose samples (5.6%) compared with the post-dose samples (approx. 60%), consistent with the putative VEGF interference effect only in the post-dose samples. A modified outlier approach was used to calculate a confirmatory cut point using a 1% false positive rate applied to the pre-study validation cut point dataset. Based on application of the confirmatory cut point of 50.9% inhibition to the results for the 656 pre-dose samples tested in the ADA assay, of which 41 samples screened positive, 4 pre-dose samples (0.6% of total) were confirmed as positive. ADA results Confirmed ADA positive signals were detected in nine subjects (3.0% of the ADA Evaluable Population) in both the FKB238 and EU-Avastin treatment groups. Treatment-emergent ADA was detected in seven subjects (2.3% of the ADA evaluable population) in each group. Only one (0.3% of the ADA evaluable population) of these confirmed positive samples in the FKB238 treatment group, and three (1.0% of the ADA evaluable population) samples in the EU-Avastin treatment group, met the criteria of 'persistent positive'. The highest treatment-emergent ADA titer was 16, and ADA titer distribution was similar for the FKB238 and EU-Avastin treatment groups. The table below provides a summary of the results from ADA and NAb testing of clinical samples from study FKB238-002. The results are from the clinical analyses dataset and are based on the assay cut points using the modified approach for outlier exclusion. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 50: Summary of ADA and NAb responses during study FKB238-002 by treatment group (ADA Evaluable Population )

<!-- image -->

|         | authorised   |        |
|---------|--------------|--------|
| longer  | longer       | longer |
| product |              |        |
| no      | no           | no     |

last positive) or positive at last post-baseline assessment. Transient positive is defined as having at least on postbaseline ADA positive assessment and not fulfilling the conditions of persistent positive. [e] Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to a 4-fold or higher level following drug administration. [d] Treatment-emergent ADA positive is defined as either treatment-induced ADA or treatmentthe number of ADA evaluable subjects in the treatment group.

## Impact of ADA on systemic drug concentration

The number of subjects with confirmed ADA positive results was low in each treatment group. The results are summarised in the table below.

<div style=\"page-break-after: always\"></div>

Table 51: Summary of serum concentrations (μg/mL) of FKB238 and Avastin by ADA Category - Subgroup - ADA Evaluable Population (Pharmacokinetics Population)

|         |         |         | authorised   |         |         |         |
|---------|---------|---------|--------------|---------|---------|---------|
|         | no      | longer  |              |         |         |         |
| product | product | product | product      | product | product | product |

Abbreviations: ADA=Anti-Drug Antibody; BLQ=Below Lower Limit of Quantification; NC=Not Calculable; SD=Standard Deviation; min=Minimum; max=Maximum Note: n = number of subjects in ADA evaluable population with at least one serum drug concentration value, excluding pre-dose values after cycle 1 without IP dose in previous cycle, excluding post-dose values without IP dose in this cycle. ADA positive population includes subjects who do have any ADA positive results at baseline or post-baseline. Treatment-emergent ADA positive is defined as either treatment-induced ADA (post-baseline ADA positive only) or treatment-boosted ADA. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to a 4-fold or higher level following drug administration. ADA negative population includes subjects who do not have any ADA positive results at baseline or post-baseline. Medicinal product no longer authorised

## Study FKB238-001

The chosen dose level of FKB238 and Avastin (5 mg/kg given intravenously) was the lowest recommended therapeutic dose for the licensed indications. This dose has a well-established safety profile in patients and according to the applicant was appropriate to give to healthy subjects (in accordance with EMA Guideline EMA/CHMP/BMWP/403543/2010).

Confirmed ADA positive samples were detected in only four subjects: in pre-treatment samples from one subject in the FKB238 treatment group and from two subjects in the EU-Avastin treatment group; and in the Day 15 post-treatment samples from one subject in the US-Avastin treatment group (Table 52).

<div style=\"page-break-after: always\"></div>

Table 52: Summary of subjects with confirmed ADA positive results in at least one of the ADA assay formats used for study FKB238-001 sample analysis

<!-- image -->

|                       |                       | Confirmatory ADA assay   | Confirmatory ADA assay   | Confirmatory ADA assay   | ADA titer assay       | ADA titer assay       | ADA titer assay       | NAb assay             | NAb assay             | NAb assay             |
|-----------------------|-----------------------|--------------------------|--------------------------|--------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Subject No.           | Day                   | FKB238                   | EU- Avastin              | US- Avastin              | FKB238                | EU- Avastin           | US- Avastin           | FKB238                | EU- Avastin           | US- Avastin           |
| Treatment=FKB238      | Treatment=FKB238      | Treatment=FKB238         | Treatment=FKB238         | Treatment=FKB238         | Treatment=FKB238      | Treatment=FKB238      | Treatment=FKB238      | Treatment=FKB238      | Treatment=FKB238      | Treatment=FKB238      |
| 043                   | Pre-dose              | P                        | P                        | P                        | 1                     | 4                     | 1                     | P                     | N                     | N                     |
| Treatment =EU-Avastin | Treatment =EU-Avastin | Treatment =EU-Avastin    | Treatment =EU-Avastin    | Treatment =EU-Avastin    | Treatment =EU-Avastin | Treatment =EU-Avastin | Treatment =EU-Avastin | Treatment =EU-Avastin | Treatment =EU-Avastin | Treatment =EU-Avastin |

Abbreviations: ADA=Anti-Drug Antibody; NAb=Neutralising Antibody; P=Positive; N=Negative Source: Tables 1, 2 and 3 in Bioanalytical Study Report, No. 238-CA14-008, Appendix 16.1.10 of CSR Module 5.3.3.1 Study FKB238-003 The bioanalytical study in Japanese healthy volunteers, FKB238-003, where the PK-profile of FKB238 were compared to EU-Avastin, confirmed the low immunogenicity potential of FKB 238. Safety related to drug-drug interactions and other interactions Not applicable. Discontinuation due to adverse events No TEAEs led to the premature discontinuation of subjects from Studies FKB238-001 and FKB238-003. In Study FKB238-002, similar proportions of patients in the FKB238 and Avastin arms experienced TEAEs leading to discontinuation of IP (9.9% and 11.2%, respectively), discontinuation of any combination drugs (11.6% and 10.1%), and discontinuation of study treatment overall (IP and/or any combination drugs) (15.2% and 15.8%). Likewise, similar proportions of patients in the FKB238 and Avastin arms experienced TEAEs leading to discontinuation of IP that were considered related to IP (3.9% and 4.9%, respectively), TEAEs leading to discontinuation of any combination drugs considered related to any combination drugs (9.4% and 6.8%), and TEAEs leading to discontinuation of study treatment considered related to study treatment (11.3% and 11.2%). Of the 20 patients with an IP dose interruption, 13 patients interrupted IP due to an AE. Of the 381 patients with an IP cycle delay, 219 patients delayed due to an AE and 43 patients delayed due to delayed haematological recovery. The incidence of patients who interrupted or delayed IP due to an AE or due to delayed haematological recovery was similar between the treatment arms. Medicinal product no longer authorised

Of the patients who had a dose interruption, reduction, or delay for any combination drugs (248 and 232 patients for paclitaxel and carboplatin, respectively), the majority did so due to an AE. The incidence of patients who had any combination drug dose interruption, reduction, or delay due to an AE was similar between the treatment arms.

The  number of  discontinuations  due  to  AEs  causally  related  to  treatment  was  slightly  higher  in  the EU-Avastin arm, and the number of fatal TEAEs was higher in the FKB238 arm.

<div style=\"page-break-after: always\"></div>

## Post marketing experience

FKB238 is not yet approved in any country worldwide in any indication. Thus, there are no post-marketing data available for the use of FKB238.

## 2.6.1. Discussion on clinical safety

Comparative safety data of FKB238 was derived from two PK studies in healthy volunteers (study FKB238-001 and study FKB238-003) and one phase III study in 1st line treatment for patients with advanced/recurrent non-squamous non-small cell lung cancer in combination of paclitaxel and carboplatin (FKB238-002)

The two PK-studies are small studies not primarily designed for safety evaluations, and the observed differences between treatment groups are most likely chance findings.

Overall, these studies constitute a total safety database for FKB238 of 415 subjects, including 33 healthy male subjects who received a single dose of FKB238 in Study FKB238-001, 20 Japanese healthy male subjects who received a single dose of FKB238 in Study FKB238-003 and 362 patients treated for advanced/recurrent NS-NSCLC. In study FKB238-002, four protocol amendments were conducted of which the third protocol amendment was conducted on 12th April 2017 after the enrolment of the study participants. The amendments were justified and did not interfere with the safety assessment. The overall duration of exposure to investigational product [IP; FKB238 or Avastin] in Study FKB238-002 was mean 35.61 weeks, range 0.3 to 111.4 weeks. Adverse events: In the PK- study FKB238-001, more subjects experienced TEAEs in the FKB238 arm (32; 97.0 %) compared to the Avastin arms (26; 76.5 % EU-Avastin and 23; 71.9 % US-Avastin). The TEAE PT reported for the highest proportion of subjects was headache (32.3% of subjects overall). There was a rather large imbalance in the incidence of headache events across the treatment arms, which were reported for 16 (48.5%), 6 (17.6%), and 10 (31.3%) subjects in the FKB238, Avastin, and US-Avastin arms, respectively.  The safety concerns regarding the relatively high proportion of reported AEs of headache have been addressed adequately. The reported AEs of headache were transient and non-serious, and no connection or clinical pattern could be detected to any serious development of a medical condition. Of note, in Study FKB238-002, the PT of headache was reported for a similar proportion between treatment arms; 18 (5.0%) and 23 (6.3%) in the FKB238 and Avastin arms, respectively. The number of subjects reporting TEAEs in PK-study FKB238-003 was also higher in the FKB238-arm compared to the Avastin-arm (12; 60% vs. 6; 30%, respectively).  A thorough examination of reported TEAEs and TEADRs for studies FKB238-001 and -003 have been provided. Considering the small numbers of subjects in each treatment arm of this study, a small number of events can make a large apparent difference in reporting rate, and in particular when multiple events are reported by the same patient. Medicinal product no longer authorised

Overall in the main study FKB238-002, similar proportion of patients experienced at least 1 TEAE between the FKB238 and Avastin treatment arms (94.2% and 95.1% of patients, respectively).

TEAEs considered causally related to IP (FKB238 or Avastin) were most frequently reported in the SOCs of blood and lymphatic system disorders (13.7% of patients overall), investigations (13.0%), skin and subcutaneous tissue disorders (9.3%), and general disorders and administration site conditions (9.1%). The incidence of any TEAEs causally related to IP was somewhat lower in the FKB238 arm than in the

<div style=\"page-break-after: always\"></div>

Avastin arm (40.9% versus 47.5% of patients, respectively), as was the incidence of TEAEs causally related to any combination drugs (82.3% versus 84.4% of patients, respectively). Overall, the incidence of TEAEs causally related to study treatment (IP and/or any combination drugs) was balanced between the treatment arms (85.4% and 86.1% of patients, respectively) and no clinically meaningful differences were seen.

A clearly higher frequency of anaemia and neutropenia was reported in the EU-Avastin arm compared to the FKB238 arm. Also, asthenia and proteinuria were more commonly seen in this EU-Avastin arm.

No TEADRs were reported with a difference in incidence between the treatment arms of &gt;5%. The greatest difference between the treatment arms was seen for TEADRs of neutropenia, which were reported as IP-related for more patients in the Avastin arm than in the FKB238 arm (29 [7.9%] versus 14 [3.9%] patients, respectively). The proportion of patients receiving combination chemotherapy at each cycle was higher in the Avastin arm compared to the FKB238 arm and concomitant chemotherapy might influence both neutrophil count and reduce renal function (leading to proteinuria). The proportions of patients with CTCAE ≥ grade 3 TEAEs (53.6% and 55.5% of patients, respectively) and CTCAE ≥ grade 3 TEAEs considered related to IP (11.0% and 13.7% of patients, respectively) were also similar between the treatment arms. TEAEs leading to discontinuation of IP were reported for 36 (9.9%) and 41 (11.2%) patients in the FKB238 and Avastin arms, respectively, with TEAEs leading to discontinuation of IP considered related to IP for 14 (3.9%) and 18 (4.9%) patients, respectively. Overall, in the pivotal study FKB238-002, only slight numeric imbalances in reporting of individual TEAEs were observed. For example, the incidence of TEAEs in the SOC of blood and lymphatic disorders was lower in the FKB238 arm (55.2%) than in the Avastin arm (59.0%), whereas the incidence of TEAEs in the SOC of gastrointestinal disorders was higher in the FKB238 arm than in the Avastin arm (31.8% versus 29.5%, respectively). For most SOCs, there seem to be slightly more patients reporting TEAEs in the Avastin-arm compared to the FKB238-arm. However, there was no clear pattern in the most commonly reported TEAEs ( ≥ 5%) to suggest any difference in the safety profile between FKB238 and Avastin. Adverse events of special interest derived from the Avastin SmPC were investigated. The overall incidence of TEAEs of special interest was generally similar between the FKB238 and Avastin treatment arms (266 [73.5%] and 280 [76.5%] patients, respectively), and in line with frequency stated for Avastin SmPC, but some differences were observed. Slightly more patients in the FKB238 arm compared to Avastin arm experienced hypersensitivity/IRR events (48 vs 43 patients respectively). The events that were reported within a relevant timeframe for a hypersensitivity/IRR had a similar distribution over treatment arms (17 in the FKB238-arm and 13 in the Avastin-arm). None of the events was serious AEs. Deaths and serious adverse events: There were no SAEs, including deaths, during Studies FKB238-001 and FKB238-003. Medicinal product no longer authorised

Overall, the frequency of SAEs in study FKB238-002 is similar between treatment arms. Small differences are seen on the SOC/PT level but are considered not to be clinically meaningful.

As of data cut-off, there were 18 more deaths observed in the FKB238 arm (195 [53.9%] patients) compared to the Avastin arm (177 [48.4%] patients). Approximately 40% of patients' deaths in both the FKB238 and Avastin arms occurred more than 30 days after the last study treatment (IP and/or any combination drugs) (151 [41.7%] and 137 [37.4%] patients, respectively). The majority of deaths were related to the disease under investigation: 156 and 148 patients in the FKB238 and Avastin arms,

<div style=\"page-break-after: always\"></div>

respectively. The number of TEAEs with a fatal outcome was 30 (8.3%) versus 23 (6.3%) for FKB238 and Avastin, respectively.

Due to the difference in deaths between study arms, the applicant has performed a thorough evaluation of all deaths in study FKB238-002.

Baseline data for the ITT-population show imbalances in demography and baseline characteristics ( Δ ≈ 3-11% with regards to more current smokers, more patients with a past and current medical history of cardiovascular conditions, more patients with current respiratory conditions, and smaller number of patients who received subsequent anti-cancer therapy in the FKB238 arm) indicating that patients in the FKB238 arm had a higher background risk of death than those in the Avastin arm.

The estimated hazard ratio (HR) from this sensitivity analysis is 1.09 (95% confidence interval [CI]: 0.90 to 1.31), which is lower than the value obtained in the pre-specified analysis (1.18 [95% CI: 0.96 to 1.45]). Median OS in the FKB238 and Avastin treatment arms using the sensitivity analysis were 12.25 months and 13.40 months, respectively. This sensitivity analysis shows that the higher numbers of WoC in the Avastin arm relative to the FKB238 arm could have introduced non-negligible bias into the pre-specified OS analysis, thereby resulting in an overestimated HR.

Fewer patients withdrew consent to follow-up in the FKB238 arm compared to the Avastin arm, 36 [9.9%] patients versus 49 [13.4%] patients, respectively. The survival status of 13 more subjects in the Avastin arm as compared to the FKB238 arm is unknown due to withdrawal of consent and subsequently lost information on survival. Therefore, some deaths in the Avastin group might possibly not have been recorded. TEAEs leading to discontinuation of study treatment were reported for a higher proportion of withdrawal of consent (WoC)-patients in the Avastin arm than in the FKB238 arm (8 [16.3%] versus 2 [5.7%] patients, respectively), as were TEAEs with CTCAE grade 3 or higher (24 [49.0%] versus 14 [40.0%] patients, respectively) and treatment-emergent SAEs (11 [22.4%] versus 5 [14.3%] patients, respectively). Baseline characteristics for the 85 patients who discontinued due to WoC (FKB238, 36; Avastin, 49) showed that a higher proportion of patients had AJCC stage IV disease at diagnosis in the Avastin arm than in the FKB238 arm (47 [95.9%] versus 31 [86.1%] patients, respectively). Additionally, a higher proportion of patients were aged ≥ 65 years in the Avastin arm than in the FKB238 arm (18 [36.7%] versus 10 [27.8%] patients, respectively), with 6 (12.2%) patients in the Avastin arm aged between 75 and 84 years compared to no patients in the FKB238 arm. The proportion of current smokers for this group of patients was also slightly higher in the Avastin arm than in the FKB238 arm (19 [38.8%] versus 12 [33.3%] patients, respectively), as was the proportion of patients with an ECOG PS of 1 (24 [49.0%] versus 17 [47.2%] patients, respectively). Overall, patients in the Avastin arm who withdrew consent to the study had a worse AE profile, worse prognostic factors and thereby a higher risk of death, than those in the FKB238 arm. More patients in the Avastin arm than the FKB238 arm withdrew following AEs and PD.  Thus, some deaths might not have been recorded. In order to investigate the impact of the missing survival data on the reliability of the OS estimation, the MAH performed a post-hoc sensitivity analysis in which discontinuation from the study due to WoC was considered as a death event. Medicinal product no longer authorised

## Immunogenicity:

The bioanalytical methods regarding ADAs are considered of good quality and appropriately validated.

Immunogenicity of FKB-238 versus EU-Avastin was low with a similar number of ADA positives in each arm. No ADA positive samples were detected after cycle six (or EoT), with most treatment-emergent ADA being transient in both groups.

<div style=\"page-break-after: always\"></div>

A substantial number of patients with missing ADA results at different time points conferred uncertainty to the similarity between arms regarding immunogenicity. The applicant has adequately justified that the missing ADA samples would not have had any impact on the biosimilarity assessment, and that ADA measurements were balanced between treatment arms.

## 2.6.2. Conclusions on the clinical safety

Overall, the safety profile of FKB238 is comparable to EU-Avastin and is in line with the safety profile for bevacizumab (SmPC Avastin).

<!-- image -->

| Summary of Safety Concerns   | Summary of Safety Concerns   |
|------------------------------|------------------------------|
| Important identified risks   | None                         |
| Important potential risks    | None                         |
| Missing information          | None                         |

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

2.7. Risk Management Plan Safety concerns Summary of safety concerns Summary of Safety Concerns None None Pharmacovigilance plan Not applicable as there are no safety concerns Risk minimisation measures Not applicable as there are no safety concerns Conclusion The CHMP and PRAC considered that the risk management plan version 0.3 is acceptable. 2.8. Pharmacovigilance Pharmacovigilance system Medicinal product no longer authorised

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.9.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Equidacent (bevacizumab) is included in the additional monitoring list as: · It is a biological product authorised after 1 January 2011; Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle. 3. Biosimilarity assessment 3.1. Comparability exercise and indications claimed Equidacent, FKB238 (bevacizumab), has been developed as a biosimilar to the reference product Avastin. The administration and posology are according to the reference product, as described in the Avastin SmPC. FKB238 is claiming the same indications as authorised for the reference product Avastin, except for one indication concerning platinum-resistant ovarian cancer, which was excluded due to patent restrictions: · Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. · Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor (HER2) status. · Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Avastin in combination with capecitabine. Medicinal product no longer authorised

- Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.
- Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.

<div style=\"page-break-after: always\"></div>

- Bevacizumab in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.
- Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynaecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.

The clinical efficacy and safety program to demonstrate equivalence between FKB238 and the reference product EU-Avastin (bevacizumab) in combination with paclitaxel and carboplatin is based on a single randomised, double blind, comparative, phase 3 study in first line patients with advanced or recurrent non-squamous NSCLC, FKB238-002.

· Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. Summary of analytical comparability (quality data) Both FKB238 active substance lots and FKB238 finished product lots were used for similarity studies, which is considered acceptable as high comparability between the active substance and the finished product has been demonstrated. Furthermore, the same formulation is used for both active substance and finished product, only the concentrations and the containers differ. FKB238 was compared to both EU-approved Avastin lots and US-licensed Avastin lots at 100 mg and 400 mg concentrations. The analytical comparability studies included comparisons of primary, secondary and higher order structures, post-translational modifications (charge variants and glycan profiles), purity and impurities, quantity, biological activity for Fab and Fc related functions, and comparative stability studies. Summary of non-clinical data The FKB238 non-clinical programme consisted of a number of in vitro assays, an in vivo study in SCID mice, a single dose toxicity study in mice and a 2-week repeat-dose toxicity study in Cynomolgus monkeys. All studies were done in comparison with Avastin. In addition, a 2-week repeat dose toxicity study with only FKB238 were performed in rats. Summary of clinical comparability data The PK similarity between FKB238 and both EU- and US-sourced bevacizumab (Avastin) was investigated in a pivotal phase I clinical trial in healthy male subjects (FKB238-001). In addition, PK similarity of FKB238 and EU-Avastin was also investigated in a phase I trial in healthy Japanese males (FKB238-003). A total of 99 healthy males were randomised to receive FKB238, EU-Avastin and US-Avastin in FKB238-001, and 40 healthy Japanese males were randomised to FKB238 or EU-Avastin in FKB238-003. The co-primary endpoints were that 90% CIs of log ratio test/reference of AUC0∞ and AUC0 -t were between 80-125%. Medicinal product no longer authorised

731 patients were randomised to receive FKB238 or EU-Avastin in combination with 4-6 cycles of chemotherapy (paclitaxel/carboplatin). After chemotherapy was completed the investigational product was continued as monotherapy until PD or other criteria for treatment discontinuation are met. At data cut-off, all patients had been followed for at least 12 months. The primary endpoint was ORR defined as BOR. The equivalence margin for the risk difference of ORR was defined to be ± 0.1221. Other endpoints were secondary efficacy outcomes, safety, immunogenicity and pharmacokinetics.

<div style=\"page-break-after: always\"></div>

The design of the phase 1 and phase 3 studies has been discussed in two CHMP scientific advice (SA) from 2015 (EMA/CHMP/SAWP/169264/2015 and EMA/CHMP/SAWP/819725/2015). From a PK, efficacy and safety point of view the applicant mostly followed the CHMP SA.

## 3.2. Results supporting biosimilarity

## Quality data

Both FKB238 active substance lots and FKB238 finished product lots were used for similarity studies and high comparability between the active substance and the finished product has been demonstrated. Furthermore, the same formulation is used for both active substance and finished product, only the concentrations and the containers differ. FKB238 was compared to both EU-approved Avastin lots and US-licensed Avastin lots at 100 mg and 400 mg concentrations. The analytical comparability studies included comparisons of primary, secondary and higher order structures, post-translational modifications (charge variants and glycan profiles), purity and impurities, quantity, biological activity for Fab and Fc related functions, and comparative stability studies. FKB238 is considered to be highly similar to EU-licensed Avastin with respect to the presented physicochemical and biological characteristics. Non-clinical data A number of in vitro functional assays were conducted to substantiate similarity between FKB238 and the European reference product Avastin. The assays included binding to VEGF isoforms, Fcγ receptors, FcRn and C1q, neutralisation of VEGF signal transduction (reporter gene assay) and neutralisation of VEGF induced cell proliferation of HUVEC. In addition, ADCC and CDC activities were investigated. Further, pharmacokinetic and toxicological properties of FKB238 and bevacizumab (EU and US) were characterised in rats (single dose), SCID mice (US Avastin only) and in a GLP 4-week repeat dose toxicity study in cynomolgus monkey. A 2-week repeat dose toxicity study were also performed in rats, which only evaluated TK parameters of FKB238. Generally, the data presented by the applicant indicate similarity between FKB238 and Avastin. Clinical data Pharmacokinetics In the two PK similarity trials, the PK ratios of the co-primary endpoints (AUC0-∞ and AUC0-T) and secondary endpoints (Cmax and t1/2) were within the predefined 90% CI of the log ratio FKB238/EU-Avastin within 80 to 125%. Efficacy Medicinal product no longer authorised

For the primary endpoint ORR (BIRC assessment of PPS), similar outcomes were reported across the two arms (51.7 % [95% CI: 46.35 to 57.03] and 53.4% [95% CI: 48.04 to 58.68] in the FKB238 and EU-Avastin arms, respectively). The difference in ORR was -0.02 and inside the pre-defined equivalence margin of ±0.1221.

The ORR by BICR assessment for the ITT population and ORR by investigator assessment (PPS) showed similar outcome as the primary analysis.

Secondary endpoints ORR at week 19, PFS, DOR and DCR (BIRC assessment of PPS) were all in line with the outcome of the primary analysis.

<div style=\"page-break-after: always\"></div>

## Safety

For the pivotal study FKB238-002, some slight numeric imbalances in reporting of individual TEAEs were observed. The incidence of TEAEs in the SOC of blood and lymphatic disorders was lower in the FKB238 arm (55.2%) than in the Avastin arm (59.0%), whereas the incidence of TEAEs in the SOC of gastrointestinal disorders was higher in the FKB238 arm than in the Avastin arm (31.8% versus 29.5%, respectively). For the other SOCs, small differences were observed. In conclusion, there was no clear pattern in the most commonly reported TEAEs ( ≥ 5%) to suggest any difference in the safety profile between FKB238 and Avastin.

As of data cut-off, there were 18 more deaths observed in the FKB238 arm (195 [53.9%] patients) compared to the Avastin arm (177 [48.4%] patients). Baseline data for the ITT-population show imbalances in demography and baseline characteristics ( Δ ≈ 3-11% with regards to more current smokers, more patients with a past and current medical history of cardiovascular conditions, more patients with current respiratory conditions, and smaller number of patients who received subsequent anti-cancer therapy in the FKB238 arm). Immunogenicity The ADA prevalence was 3.0% in both treatment arms (9 out of 305 ADA evaluable patients in each arm tested positive for ADA at any visit). The detected ADA incidence (FKB238-001,-002, -003) seems to correspond to what was reported by the originator company for EU-Avastin in earlier clinical studies, and the titres measured in confirmed ADA positive samples in the phase 3 patient study (FKB238-002), seem relatively low (maximum titre value = 64). Overall, there were no apparent differences in any of the immunogenicity-related parameters that were evaluated in study FKB238-002. 3.3. Uncertainties and limitations about biosimilarity There are no remaining uncertainties and limitations that have an impact on the conclusion of biosimilarity. 3.4. Discussion on biosimilarity The Applicant has analysed the similarity between FKB238 and EU-approved Avastin in a comprehensive comparability exercise. High similarity was demonstrated for most of the physicochemical parameters. Some minor differences were detected for some of the parameters, which were appropriately discussed and justified by the applicant not to have a clinical impact. High similarity was demonstrated for most of the in vitro functional parameters, including for critical parameters such as binding to target VEGF-A and neutralisation of VEGF activities. Differences were noted in binding affinity of FKB238 to FcγRIIIa (F, V) and FcγRIIIb (NA1, NA2) in comparison to EU -approved Avastin. These binding differences are likely caused by the different levels of afucosylated glycan species, and the applicant conducted a risk analysis for the differences in binding activity against FcγRIIIa. The lack of ADCC and CDC effector functions was demonstrated in FKB238, similar to EU-approved Avastin. Taking into consideration the mode of action for bevacizumab and similar PK profile, the observed differences in binding affinity are not considered clinically meaningful. Medicinal product no longer authorised

PK similarity between FKB238 and EU-Avastin has been demonstrated in two PK similarity ('bioequivalence') trials.

<div style=\"page-break-after: always\"></div>

The pivotal phase 3 clinical efficacy and safety study was adequately designed and the primary and secondary efficacy outcomes and equivalence criteria are deemed acceptable. The primary efficacy data was supportive of biosimilarity between FKB238 and EU-Avastin and sustained by the majority of secondary endpoints. Furthermore, the safety data pivotal study of the most commonly reported TEAEs ( ≥ 5%) was not suggestive of any difference in the safety profile between FKB238 and Avastin. There was an imbalance in the number of deaths between treatment arms FKB238 arm (n=195 [53.9%] FKB238 arm, n=177 [48.4%] Avastin arm). At the same time the baseline data for the ITT-population showed imbalances in demography and baseline characteristics and a smaller number of patients who received subsequent anti-cancer therapy in the FKB238 arm which could indicate that patients in the FKB238 arm had a higher background risk of death than those in the Avastin arm.

Fewer patients withdrew consent to follow-up in the FKB238 arm compared to the Avastin arm, 36 [9.9%] patients versus 49 [13.4%] patients, respectively. Patients in the Avastin arm who withdrew consent to the study had a worse AE profile, worse prognostic factors and thereby a higher risk of death, than those in the FKB238 arm. Thus, some deaths might not have been recorded and the risk of this was higher in the Avastin arm. Post-hoc sensitivity analyses to investigate the impact of the withdrawal of consent (WoC) patients on OS were presented, and the resulting HR is brought closer to 1. This sensitivity analysis indicates that the higher numbers of WoC in the Avastin arm relative to the FKB238 arm could have introduced non-negligible bias into the pre-specified OS analysis, thereby resulting in an overestimated HR. Also, separation of the OS-Kaplan-Meier curves in these patients who withdrew consent seemed to occur approximately at the same time point (at 3-4 months) as seen in the Kaplan-Meier curve for the OS in the overall ITT population, hence being a possible contributing factor for the numerical OS-difference. In conclusion, the numerical difference in deaths between study arms might be explained by several confounding factors and is not considered a real difference in biosimilarity. Overall, the Applicant has provided a thorough comparative exercise in terms of quality, non-clinical, and clinical parameters in line with the EU guidance to demonstrate biosimilarity between FKB238 and Avastin. Biosimilarity has been demonstrated in quality, non-clinical and clinical (PK, efficacy and safety, including immunogenicity) data. 3.5. Extrapolation of safety and efficacy The indications granted for the reference product Avastin were applied for Equidacent, except for one indication concerning platinum-resistant ovarian cancer, which was excluded due to patent restrictions. All indications that are applied for share the same mechanism of action. In addition, posology and route of administration are the same across all indications. Based on this, extrapolation to all EU-Avastin approved indications can be supported. 3.6. Additional considerations Medicinal product no longer authorised

Not applicable.

## 3.7. Conclusions on biosimilarity and benefit risk balance

Based on the review of the submitted data, Equidacent is considered biosimilar to Avastin. Therefore, a benefit/risk balance comparable to the reference product can be concluded.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Equidacent is not similar to Zejula within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix 1

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Equidacent is favourable in the following indications: Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Equidacent in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations. Bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. Medicinal product no longer authorised

Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

<!-- image -->

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. Conditions or restrictions with regard to the safe and effective use of the medicinal product Risk Management Plan (RMP) The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP. An updated RMP should be submitted: · At the request of the European Medicines Agency; · Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States Not applicable. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Appendix

1. CHMP AR on similarity dated 23 July 2020

<!-- image -->